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1 
1 INTRODUCTION  
1.1 Natural products 
1.1.1 Definition 
Natural products are a huge and diverse group of chemical compounds produced by living creatures 
from nature (Porter, 1913) (http://www.thefreedictionary.com/natural+product). They can be extracted 
from plants and animals, from cells or tissues, from microorganisms (bacteria, fungi) or their excreted 
metabolites (Strobel and Daisy, 2003) and may have notable biological activity for using as 
phamaceuticals. 
Natural products include flavonoids, alkaloids (quinine, ephedrine, chelerythrine etc.), polysaccharides, 
volatiles oils, quinonoids, terpenoids, waxes, coumarins, saponins, cardiac glycosides from plants, but 
also monosaccharides, oligosaccharides, polysaccharides, phenylpropanoids, amino acids (L-glutamic 
acid, L-lysine), antibiotics (streptomycin), pigments (cytochrome C), polypeptides, vitamins, organic 
acids, phenols, lactones, steroids, tannins, and other naturally occurring chemicals from 
microorganisms and their fermentation broths. About 50% of the drugs introduced into the market in 
the last 20 years were traced back to natural products or derivatives thereof. Several reviews and 
reports have discussed this significant role of natural products in drug discovery (Newman et al., 2000; 
Newman et al., 2003; Chin et al., 2006; Koehn and Carter, 2005; Paterson and Anderson, 2005). 
1.1.2 Category 
In the field of organic chemistry, natural products can be defined into primary metabolites and 
secondary metabolites. Primary metabolites are deemed essential to the survival of organism in 
maintaining basic metabolic pathways that are required for life. They are associated with significant 
cellular functions such as nutrient assimilation, energy production, and growth/development and 
propagation. Primary metabolites include carbohydrates, lipids, amino acids (Kliebenstein, 2004; 
Karlovsky, 2008), and nucleic acids which are typically produced during the active growth phase. 
Many primary metabolites and fermentation products are used in industrial microbiology for large-
scale fermentation production like beer and wine, amino acids including L-glutamate and L-lysine, 
citric acid that are used in mass marketing production as ingredients in food production and 
pharmaceutical and cosmetic industries. 
Secondary metabolites have an extrinsic function that in particular affects other organisms. Secondary 
metabolites are organic compounds in many cases formed at the end of stationary phase of growth. In 
contrast to primary metabolites, secondary metabolites are small molecules that are dispensable and 
not required for sustaining life. However, they increase the competitiveness of the producer within its 
environment with the ability of biochemical and signal transduction pathways modulations. Secondary 
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metabolites have a broad range of functions. These include pheromones (act as social signalling 
molecules), communication molecules, and competitive biological weapons (repellents, venoms, 
toxins etc.). 
A restrictive definition limiting natural products to secondary metabolites is commonly used within the 
fields of medicinal chemistry and pharmacognosy. These metabolites can be used in industrial 
microbiology to obtain amino acids, develop vaccines and antibiotics, and isolate chemicals necessary 
for organic synthesis. General structural classes of secondary metabolites include alkaloids, 
phenylpropanoids, polyketides, and terpenoids. Examples of important secondary metabolites are 
antibiotics such as the antibiotic bacitracin (Figure 1-1), which is synthesized in nature by a 
nonribosomal peptide synthetase and the antimicrobial erythromycin (Figure 1-2), which derived from 
Saccharopolyspora erythraea. 
 
 
Figure 1-1. Structure of bacitracin. 
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Figure 1-2. Structure of erythromycin. 
 
Until the early 20
th
 century, treatments of infections were based primarily on traditional folklore 
medicine. Such mixtures with antimicrobial properties that were used in treatments of infections were 
described over 2000 years ago. In the ancient Egyptian and ancient Greek cultures (Lindblad, 2008), 
specially selected molds and plant materials and their extracts were used to treat infections 
(Wainwright, 1989; Shah, 2011; Forrest, 1982). 
In 1928, Alexander Fleming, a Scottish microbiologist, identified a compound derived from the fungus 
Penicillium chrysogenum and demonstrated its antibacterial activity (Newman et al., 2000). He named 
the compound penicillin. Later in 1942, Howard Florey and Ernst Boris Chain succeeded in purifying 
the first antibiotic of the penicillin class, penicillin G (Figure 1-3 and Figure 1-4). Penicillin displayed 
potent antibacterial activity against a wide range of bacteria and had low toxicity in humans. Further, 
Dorothy Crowfoot Hodgkin determined the chemical structure in 1945. For the successful 
development of penicillin, as a therapeutic drug in clinic application, Ernst Chain and Howard Florey 
and Alexander Fleming shared the 1945 Nobel Prize in Medicine. 
 
Figure 1-3. Structure of penicillin. 
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Figure 1-4. Structure of penicillin G. 
 
Another example of a successful antibiotic drug is streptomycin which is derived from Actinomyces 
griseus (later changed the name to Streptomyces griseus in 1943) isolated by Selman Waksman’s 
group from soil and water samples (Schatz et al., 1944). It is an important antibiotic agent to treat a 
variety of infectious diseases. Selman Waksman was awarded the 1952 Nobel Prize in physiology or 
medicine for the discovery of streptomycin as the first antibiotic effective against tuberculosis. 
 
From: http://amrls.cvm.msu.edu/pharmacology/historical-perspectives/the-golden-age-of-antibacterials 
Figure 1-5. The history of the golden age of antibiotics. 
 
The serendipitous discovery and subsequent clinical successes of penicillin and streptomycin 
prompted a large-scale search for other microorganisms that might produce pharmacologically active 
natural products with anti-infective properties. The following decade are known as the ‘Golden Age of 
Antibiotics’ (Figure 1-5), the time period from the 1940s to the 1970s in which most of the modern 
drugs were discovered. 
About 200,000 natural compounds are currently known until 2005 (Tulp and Bohlin, 2005). The 
chemical diversity of natural compounds represents a basis for their use in drug therapy. Some show 
antibacterial activities (β-lactams, aminoglycosides), antifungal activities (lipopeptides, non-
lipoeptides), antimalarial (nucleoside analogues, HIV protease inhibitors), and some are enzyme 
inhibitors which can be used to treat cardiovascular (the β-adrenergic amines, cholesterol lowering 
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agents, angiotensin converting enzyme inhibitors (ACE inhibitors), pain and central nervous system 
(the opiates, the conotoxins, the epibatidines). 
 
 
Figure 1-6. The structure of streptomycin. 
 
About 50% of the drugs introduced into the market during the last 20 years are derived directly or 
indirectly from natural products (Vuorela et al., 2004). Even a high percentage of pharmaceuticals are 
products of synthetic chemistry, natural products have by no means forfeited their importance as a 
source of new drugs. During the period from 1981 to 2006, 68% of anti-infectives and 63% of drugs 
used in cancer treatment were derived from natural products (Newman and Cragg, 2007). 
1.2 Marine natural products 
Secondary metabolites, in limited consideration, are thought to have specific functions in 
interrelationships between microorganisms and are produced under specific environmental conditions. 
Throughout the long time period of human history, traditional pharmacognosy mainly focused on the 
investigation and identification of medically important plants and animals in the terrestrial 
environment. Due to the increasing infectious resistance, available treatments for many diseases 
became limited. In addition, diseases caused by viral pathogens have demonstrated the need for new 
medicines. Today, many scientists focus the research for new drugs to the oceans. The oceans cover 
more than 70% of the earth’s surface and have more biological and chemical diversity and higher 
probability of yielding natural products with unprecedented carbon skeletons than that in terrestrial 
environments. 
Marine sources may contain over 80% of the world’s animal species (Chakraborty et al., 2009) and 
account for 90% of biomass of the earth’s total biomass. Since the organisms first appeared in the sea 
over 3.5 billion years ago, they developed numerous mechanisms to survive various harsh conditions 
in marine environments such as high salinity, extreme high or low temperatures, high pressure, 
INTRODUCTION 
 
 
 
6 
different levels of aeration and radiation in layers and harsh conditions in the depth of the ocean 
(Jimeno et al., 2004; Skropeta, 2008). Therefore, the diversity of marine microorganism is very high 
and the ocean is considered as a treasure box containing lots of hidden biological, pharmacological 
active natural products. This consideration has initiated great interest in the marine organisms and in 
particular in marine natural products recently. Our current understanding on marine life in general and 
marine microbial life in special is rather limited (less 1% of marine microorganisms are known to date) 
and marine natural products chemistry is still young, dating back only to the 1950s. In the early days, 
marine natural products discovery mainly focussed on most conspicuous and easily collected 
organisms. Chemists turned to the marine microorganisms with the development of open circuit self-
contained underwater breathing apparatus (SCUBA) in the 1940s. Today, more than 22,000 marine 
metabolites have been isolated and structurally characterized (Gerwick and Fenner, 2013). 
In the early 1950s arabinose nucleosides (spongouridine and spongothymidine) from a Caribbean 
sponge were discovered and later due to their potent activities used for the development of anticancer 
drugs by Bergmann (Buss and Butler, 2010). The drug discovery starts its focus to marine natural 
products chemistry in the 1970s. By 1974, two marine-derived natural products (cytarabin, Ara-C and 
vidarabine, Ara-A) were part of the pharmacopeia used to treat human disease (Mayer et al., 2010b). 
Almost 30 years later, another novel marine-derived natural product, ziconotide (Prialt®) gained 
approval and become part of the pharmacopeia for the treatment of severe pain. In 2007, Yondelis® 
has received European approval for the treatment of soft tissue sarcoma (STS) and for ovarian 
carcinoma (in 2009). 
At present, most marine natural products are either sterols, terpenes, saponins, unsaturated fatty acids, 
polysaccharides and glycosides, macrolides, polyether compounds, enzymes or peptides which have 
shown promise in treating cancer, pain, inflammation, allergies, and viral infections (Newman and 
Cragg, 2004; Newman and Cragg, 2012). 
In the last 60 years, marine natural products have become fascinating targets for searching lead 
compounds in the purpose of clinical development (Cooper, 2004; Bhadury et al., 2006; Bull and 
Stach, 2007; Williams, 2009; Jones et al., 2009; Gulder and Moore, 2009; Mayer et al., 2011; Mayer 
et al., 2010a; Villa and Gerwick, 2010; Waters et al., 2010). There are several databases of natural 
compounds from marine sources. For example, 42 950 natural products were identified from marine 
microorganisms which possess highly interesting pharmaceutical properties by September of 2014 
from the database of AntiBase 2014 (Laatsch, 2014). 35 000 natural compounds were selected in 
marine chemistry of the Chapman & Hall/CRC Dictionary of Marine Natural Products database (untill 
November 2015). 
However, only few marine natural products have been advanced to pharmaceuticals and achieved full 
commercial application. From 2003-2013, 10 599 natural products were isolated and identified from 
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marine environment and hundreds of new natural compounds are found from marine organisms per 
year, especially over 1 000 new compounds are discovered every year since 2008 (Hu et al., 2015) 
(http://marinepharmacology.midwestern.edu/clinPipeline.htm). Nevertheless, only 39 compounds 
(until August 2015) account for a small percentage of these have been tested for pharmaceutical 
potential as following (in clinical used or in preclinical phases).  
There are now six drugs approved by the Food and Drug Administration (FDA), namely cephalosporin 
C (brentuximab vedotin, SGN-35, Adcetris
®
), cytarabine (Ara-C, Cytosar-U
®
, Depocyt
®
), eribulin 
mesylate (E7389, Halaven
®
), omega-3-acid ethyl esters (Lovaza
®
), ziconotide (Prialt
®
), and vidarabine 
(Vira-A
®
), one EU registered drug trabectedin (ET-743, Yondelis
®
), and 32 natural products or 
derivatives in different phases of the clinical pipeline. In addition, a large number of marine natural 
products (http://marinepharmacology.midwestern.edu/clinPipeline.htm) are in the preclinical pipeline. 
More detailed information of marine natural compounds is shown in Table 1-1. From a global 
perspective the marine pharmaceutical pipeline remains very active, and now has sufficient momentum 
to deliver several additional compounds to the marketplace in the near future (Mayer et al., 2010a). 
Although the percentage of marine natural products that can be expected to be promoted into a drug is 
very low (1 out of 331), it is highly likely that an increasing number of marine bioactive compounds 
will be approved for the treatment of human diseases (Haefner, 2003; Nastrucci et al., 2012; Liu et al., 
2012). 
Many different marine organisms have been explored for bioactive compounds such as vertebrate 
animals (e.g. fish, sharks and snakes), invertebrates (e.g. sponges, coelenterates, tunicates, 
echinoderms, corals, algae, mollusks and bryozoans), as well as microorganisms (bacteria and fungi) 
(Chakraborty et al., 2009). 
In symbiotic relationship with e.g. sponges and tunicates, bacteria could be the actual producers of 
some of the metabolic products (Piel, 2004). Recently, attention turned to marine microorganisms that 
had previously escaped cultivation and examination, such as marine cyanobacteria, actinobacteria and 
fungi. Marine microorganisms will certainly be of particular interest in the future especially due to 
their ability to produce new valuable bioactive compounds with different pharmacological activities 
(Salomon et al., 2004). 
There are many compounds produced by marine bacteria, mostly come from cyanobacteira, however, 
salinosporamide A (NPI-0052, marizomib) with cytotoxic activity trials was isolated from the marine 
actinobacterium Salinispora tropica (Feling et al., 2003; Niewerth et al., 2014). 
Reports on marine natural products with anticancer, antibacterial activities, and effects against other 
infectious diseases are discussed in various reviews (Molinski et al., 2009; Newman et al., 2000; 
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Newman and Cragg, 2012; Newman and Cragg, 2014; Munro et al., 1999; Haefner, 2003; Gerwick 
and Moore, 2012; Mayer et al., 2010a; Mayer et al., 2013). 
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Table 1-1. Some marine natural products isolated from microorganisms. 
Compound name 
Trade-
mark 
Marine organism Activity 
Chemical 
class 
Molecular 
targets 
Reference 
Clinical 
status 
Brentuximab 
vedotin (SGN-35) 
Adcetris
®
 Mollusk/cyanobacterium anticancer ADC(MMAE) CD30 & microtubules Katz et al. (2011) 
FDA-
approved 
ABT-414 
EGFRvIII-MMAF 
NA Mollusk/cyanobacterium anticancer ADC(MMAF) EGFR & microtubules Phillips et al. (2013) II 
Glembatumumab 
Vedotin (CDX-011) 
NA Mollusk/cyanobacterium anticancer ADC (MMAE) GPNMB & microtubules 
Naumovski and Junutula 
(2010) 
II 
PSMA-ADC NA Mollusk/cyanobacterium anticancer ADC (MMAE) PSMA & microtubules Petrylak et al. (2014) II 
DNIB0600A NA Mollusk/cyanobacterium anticancer ADC (MMAE) NaPi2b & microtubules Lin et al. (2014) I/II 
Pinatuzumab 
vedotin 
(DCDT-2980S) 
NA Mollusk/cyanobacterium anticancer ADC (MMAE) CD22 & microtubules Pfeifer et al. (2015) I/II 
Polatuzumab 
vedotin 
(DCDS-4501A) 
NA Mollusk/cyanobacterium anticancer ADC (MMAE) CD79b & microtubules Pfeifer et al. (2015) I/II 
AGS-16C3F NA Mollusk/cyanobacterium anticancer ADC (MMAE) ENPP3 & microtubules Thompson et al. (2015) I 
ASG-67E NA Mollusk/cyanobacterium anticancer ADC (MMAE) CD37 & microtubules Pereira et al. (2015) I 
ASG-15ME NA Mollusk/cyanobacterium anticancer ADC (MMAE) SLITRK6 & microtubules Jain et al. (2015) I 
ASG-22ME NA Mollusk/cyanobacterium anticancer ADC (MMAE) Nectin-4 & microtubules Jain et al. (2015) I 
DEDN6526A NA Mollusk/cyanobacterium anticancer ADC (MMAE) ETBR & microtubules Infante et al. (2014) I 
DMUC5754A NA Mollusk/cyanobacterium anticancer ADC (MMAE) Mucin 16 & microtubules Liu et al. (2013) I 
DSTP3086S NA Mollusk/cyanobacterium anticancer ADC (MMAE) STEAP1 & microtubules Danila et al. (2014) I 
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HuMax
®
-TF-ADC NA Mollusk/cyanobacterium anticancer ADC (MMAE) 
Tissue Factor & 
microtubules 
Newman and Cragg (2014) I 
Marizomib 
(NPI-0052; 
Salinosporamide A) 
NA Bacterium anticancer 
Beta-lactone-
gamma lactam 
20S proteasome Feling et al. (2003) I 
MLN-0264 NA Mollusk/cyanobacterium anticancer ADC (MMAE) GCC & microtubules Jain et al. (2015) I 
SGN-CD19A NA Mollusk/cyanobacterium anticancer ADC (MMAE) CD19 & microtubules Jain et al. (2015) I 
SGN-LIV1A NA Mollusk/cyanobacterium anticancer ADC (MMAE) LIV-1 & microtubules Jain et al. (2015) I 
PM00104 Zalypsis
®
 Mollusk anticancer Alkaloid DNA-binding 
Guirouilh-Barbat et al. 
(2009) 
II 
Soblidotin  
(TZT 1027) 
NA Bacterium anticancer peptide 
microtubule & monosodium 
glutamate-induced tubulin 
polymerization 
Natsume et al. (2000) III 
 
ADC: Antibody Drug Conjugate; CD: Cluster of Differentiation; EGFR: Epidermal Growth Factor Receptor; ENPP3: Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3; 
ETBR: Endothelin B Receptor; FDA: Food and Drug Administration; GCC: Guanylyl Cyclase C; GPNMB: Glycoprotein nonmetastatic B; LIV-1: Zinc transporter SLC39A6; NA: Not 
Available; NaPi2b: Sodium-Dependent Phosphate Transport Protein 2b; PSMA: Prostate-Specific Membrane Antigen; SLITRK6: SLIT and NTRK-like protein 6; STEAP1: Anti-Six 
Transmembrane Epithelial Antigen of the Prostate 1 
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1.3 Methods of natural products screening 
Natural products become one of the most important sources for lead compounds in drug discovery. 
Most biologically active natural compounds are secondary metabolites with very complex structures. 
The compounds usually have to be extracted from the natural source by complex processes including 
the isolation, identification, structure elucidation and characterization of the chemical substances 
produced by living organisms. 
In traditional drug discovery, if the lead compound or active compound is present in a mixture of other 
compounds from a natural source, it has to be purified and isolated. The elucidation of the chemical 
structure is critical to identify the compounds. Potential bioactive compounds were extracted by 
different solvents and structure elucidated with the help of the technologies that have become widely 
used in the pharmaceutical industry, such as high-performance liquid chromatography coupled with 
diode array detection and mass spectrometry (HPLC-DAD/MS) for the analytical screening. Semi-
preparative high-performance liquid chromatography (semi-preparative HPLC) is often used to 
separate the individual chemicals, and nuclear magnetic resonance (NMR) spectra are used to obtain 
structural information of novel compounds showing interesting bioactivity. These methods allow 
purification and characterization of secondary metabolites from natural sources. 
For detecting the secondary metabolite pathways for natural products synthesis, genetic approaches are 
promising tools. The genome analysis of marine microorganisms facilitates the use of specific genes 
for biotechnological applications such as the production of new drugs. Part of known natural products 
are derived from nonribosomal peptides and polyketides (Donadio et al., 2007) which are 
biosynthesized by nonribosomal peptide synthetase (NRPSs) and polyketide synthases (PKSs), 
respectively. PKs and NRPs are the key enzymes in the regulation of secondary metabolite 
biosynthesis of polyketides and nonribosomal peptides, respectively. 
1.3.1 Polyketides 
Polyketides (PKs) are produced by bacteria, fungi, plants and animals and represent a large and 
important class of secondary metabolites with diverse biological activities and pharmacological 
properties They are an important source of naturally occurring small molecules used for chemotherapy 
(Koehn and Carter, 2005) and structurally classified into four major groups: aromatics (e.g., 
doxorubicin and tetracycline), macrolides (e.g., erythromycin and rapamycin), polyethers (e.g., 
monensin and salinomycin), and polyenes (e.g., amphotericin and candicidin) (Shen, 2000). For 
example, rapamycin (immunosuppressant), erythromycin (antibiotic), lovastatin (anticholesterol drug), 
and epothilone B (anticancer drug), avermectin (antihelmintic agent) can be produced industrially 
(Wawrik et al., 2005).  
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The common feature of polyketides natural products is that they are biosynthesized by repeated 
addition of small building blocks to form a linear chain. The polyketide chains, which are catalyzed by 
large enzyme complexes, polyketide synthases (PKSs), are frequently further modified into bioactive 
natural products.  
PKSs are a family of large multienzyme protein complexes that consists of multiple active domains 
organized into modules. PKSs are divided into three classes: type I PKSs are multifunctional proteins 
consisting of processive or iterative multidomains for individual enzyme activities and have been 
found in bacteria, fungi and plants; type II PKSs are aggregates of mono-functional discrete proteins 
which are involved in the biosynthesis of aromatic natural products (e. g., actinorhodin, 
tetracenomycin and doxorubicin) only in bacteria so far; and type III PKSs are always responsible for 
the synthesis of small aromatic molecules in plants and bacteria without having a phosphopantetheinyl 
(P-pant) arm. 
Many of the polyketide synthase pathways have not yet been characterized (Castoe et al., 2007; Ridley 
et al., 2008). However, the key chain-building step of polyketide biosynthesis is a decarboxylative 
condensation of extender units with the growing polyketide chain that is analogous to the well-
understood chain elongation process (a Claisen condensation) of fatty acid biosynthesis (catalyzed by 
fatty acid synthases, FASs) (Khosla et al., 1999; Jenke-Kodama et al., 2005). 
The synthesis of a polyketide requires multidomains that can be organized in modules. Each module is 
responsible for the construction of a carbon-carbon bond. There is a loading module in most PKSs for 
obtaining the starter unit at the front of module 1. The loading module of type I PKS normally starts 
with the acyltransferase (AT) domain. The AT-domain is responsible for loading of starter, extender 
and intermediates bound to the enzymatic machinery. 
Acyl carrier protein (ACP) domains are dependent on a post-translational modification to function. 
This modification is the attachment of a 4’-phosphopantetheine cofactor to a conserved serine residue. 
Therefore the substrates are covalently attached to the growing polyketide via a thioester bond with an 
SH group on the 4’-phosphopantetheine (4’PP) cofactor. The extension of polyketide is catalyzed by 
β-keto-acyl-synthase (KS) between the growing poly-β-ketone intermediates and ACP. The growing 
acyl chain can be further modified with β-keto reductase (KR, responsible for the first reduction to 
alcohol functionality), enoyl reductase (ER, catalyzes the final reduction to full saturation) or 
dehydratase (DH, responsible for eliminating water to give an unsaturated thioester) domains before 
finally being released from the enzyme complex via a thioesterase domain (TE, responsible for 
unloading the product at the end of the last module). These type I and II polyketides are synthesized 
via the step-wise condensation. In the case of modular type I PKSs, it includes iterative PKSs, which 
reuse domains in a cyclic fashion, and modular PKSs, which contain a sequence of discrete modules 
and do not repeat domains. This type I PKSs include non-reducing PKSs (NR-PKS), the products of 
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which are true polyketides, the practically reducing PKSs (PR-PKS), and fully reducing PKSs (FR-
PKSs) which are fatty acid derivatives.  
 
An individual domains in a full type I polyketide synthase extension module. Homodimeric contacts are made in the N-
terminal docking, ketosynghase, dehydratase, enoyl recuctase, and C-terminal docking domains (Tonia J. Buchholz et al., 
2009).  
Figure 1-7. Conventional modular type I PKS paradigm. 
 
 
 
Figure from Siezen and Khayatt (2008) 
Figure 1-8. Basic steps during polyketide synthesis.  
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Type II PKS systems are aggregates of monofunctional proteins. They produce a linear polypeptide by 
the action of an iteratively used keto-synthase (KS) domain with an SH group on a cysteine side-chain, 
and make the unmodified aromatic polyketide together with chain length factor (CLF), aromatase 
(ARO), cyclase (CYC). 
Type III polyketide synthases (PKSs) have been found in bacteria, fungi and plant. Type III PKS 
systems which do not use ACP domains are simple homodimers of KSs which catalyze the 
condensation of two β-keto fatty acyl CoAs to several molecules of extender substrate onto a starter 
substrate via iterative decarboxylative Claisen condensation reactions (Katsuyama and Ohnishi, 2012; 
Hashimoto et al., 2014). Many compounds produced by microbial type III PKSs have significant 
biological functions or important pharmaceutical activities.  
Several polyketide antibiotics, antifungals, cytostatics, anticholesteremic, antiparasitics, coccidiostats, 
animal growth promoters and natural insecticides are now in commercial use. 
1.3.2 Nonribosomal peptides  
Many microorganisms have evolved an unusual way of producing secondary peptide metabolites, 
using a nonribosomal peptides biosynthesis, which is differ from the ribosomal pathway. Non-
ribosomal peptides (NRPs) are produced by a large number of bacteria, fungi, and lower eukaryotes.  
The biological functions of most nonribosomal peptides are unknown; however, for some of them an 
essential function has been identified. For example, the well-studied penicillin produced by Penicillum 
notatum is a weapon against nutrient competitors, and the siderophore bacillibactin helps its producer 
Bacillus subtilis to acquire iron and thereby prevent iron starvation (Schoenafinger and Marahiel, 
2009).Nonribosomal peptides (NRPs) are a diverse class of cyclic and branched linear peptide 
secondary metabolites. They are synthesized by mega-enzymes nonribosomal peptide synthetases 
(NRPSs) which compose a unique class of multidomain enzymes capable of producing peptides with 
various functions, such as cytostatic, immunosuppressive, antibacterial, or antitumor properties. The 
mechanisms of NRPSs are a kind of assembly line of template-directed, nucleic-acid-independent 
modules. Each module takes up one specific amino acid and each one of NRPS can produce only one 
type of nonribosomal peptide (Weber and Marahiel, 2001). 
Modules can be subdivided into initiation and elongation modules (Finking and Marahiel, 2004). 
These modules catalyse at least the steps of substrate activation, covalent binding, and peptide bond 
formation of nonribosomal peptide synthesis. 
Before peptide formation occur, the building blocks (amino acids) to be condensed need to be 
recognized and activated. The adenylation (A) domain is capable of substrate recognition and 
formation of the corresponding acyl-adenylate-monophosphate by consumption of ATP. Thus, the 
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peptidyl carrier protein (PCP) domain (∼90 amino acid residues, counterpart to the ACP in PKS and 
FAS) acts as a thioester through covalent fixation to keeping the reaction intermediates bound to the 
enzymatic machinery. PCP domains are post-translational modified to function via the attachment of a 
4’-phosphopantetheine cofactor to a conserved serine residue. Thus, amino acids are covalently 
attached to PCP domains via a thioester. After such an acylation, the PCP domain directs the substrate 
toward the next processing condensation (C) domain (∼450 aa). The C domain catalyses the formation 
of peptide bonds between an activated aminoacyl bound intermediate and a peptidyl-bound 
intermediates of two adjacent module. The growing peptide chain is handed over from one module to 
the next until it reaches the PCP-domain of the final module, in which a transesterification (TE) 
domain (∼250 aa) promotes the liberation of the assembled peptide from the synthetase.  
The basic set of domains within a module can be edited and/or extended by optional modification 
domains, including domains for substrate epimerization, N-methylation, and oxidation, methylation, 
reduction domains, and heterocyclic ring formation. Cyclization of amino acids against the peptide 
"backbone" is often performed, resulting in further oxidized or reduced oxazolines and thiazolines. In 
addition to the essential domains, a number of tailoring enzymes act in the maturation of the NRPS-
products.  
 
Figure modified from Siezen and Khayatt (2008). 
Figure 1-9. Basic steps during nonribosomal peptide synthesis.  
 
Although NRPSs, PKSs, and fatty acid synthases (FASs) are related in their biosynthetic logic, the 
existence of NRPS-PKS hybrids led to the assumption that at least the PKS part of the protein should 
dimerize. The NRPS part of the protein, however, was thought to retain a monomeric architecture. 
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NRPs are a very diverse family of natural products with an extremely broad range of biological 
activities and pharmacological properties. They are often toxins, siderophores, or pigments. Non-
ribosomal peptide antibiotics, cytostatics, and immunosuppressants are in commercial use. 
1.3.3 Phenanzines 
Another important compound class are the phenazines, which have been paid attention and which 
represent promising secondary metabolites and possible drug candidates (Arbiser and Moschella, 
1995). More than 100 biologically active (antibacterial, antifungal, antiviral, antitumor) phenazines 
from natural origin are known till now, and they are synthesized mainly by Pseudomonas and 
Streptomyces species (McDonald et al., 2001). 
Phenazine (C12H8N2 or C6H4N2C6H4, structure is seen in Figure 1-10) is a dibenzo annulated pyrazine 
and has been used as the original substance of many dyestuffs (e.g. toluene red, indulines and 
safranines). 
 
Figure 1-10. The structure of phenazine. 
 
Bacteria such as Pseudomonas spp. and Streptomyces spp. can produce phenazine products, which can 
be implicated in the virulence and competitive fitness of the producing organism. For instance, the 
phenazine pyocyanin produced by Pseudomonas aeruginosa contributes to its ability to colonize the 
lungs of cystic fibrosis patients (McDonald et al., 2001). 
At the point subsequent to chorismic acid in the shikimic acid biosynthesis pathway, the specific 
biosynthesis of phenazines starts. Two molecules of chorismate-derived intermediates are then brought 
together to form the basic phenazine scaffold. Sequential modifications then lead to a variety of 
phenazines with different biological activities. 
The genetic ability of phenazine biosynthesis was verified by analyzing the metabolite pattern of PCR-
positive strains via HPLC-UV/MS (Schneemann et al., 2011). The PCR based screening approach for 
the identification of phenazine producing bacteria was demonstrated by the transformation from 
chorismate to 2-amino-2-deoxyisochorismic acid (ADIC), which is necessary for the formation of the 
core structure of phenazines and is catalyzed by the enzyme PhzE. Sequences of phzE were used to 
design one universal primer system and to analyze the ability of bacteria to produce phenazine. The 
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application of the phzE primer system is a promising tool to indicate the presence of the phenazine 
biosynthetic pathway in various groups of bacteria including marine Actinobacteria. 
1.3.4 Terpenes 
Terpenes are a large and diverse class of organic compounds, produced mainly by a variety of plants, 
particularly conifers (Webster, 2006). They are often strong-smelling and may protect the plants that 
produce them by deterring herbivores and by attracting predators and parasites of herbivores (Martin et 
al., 2003). Many terpenes are aromatic hydrocarbons and thus may have had a protective function 
(Pichersky et al., 2006). They are the major components of resins, and of turpentine produced from the 
resins. In addition to their roles as end-products in many organisms, terpenes are major biosynthetic 
building blocks within nearly every living creature. Steroids, for example, are derivatives of the 
triterpene squalene. 
Terpenes and terpenoids are the primary constituents of the essential oils of many types of plants and 
flowers. Essential oils are used widely as natural flavour additives for food, as fragrances in perfumery, 
and in medicine and alternative medicines such as aromatherapy. Synthetic variations and derivatives 
of natural terpenes and terpenoids also greatly expand the variety of aromas used in perfumery and 
flavours used in food additives. Vitamin A is a terpene. 
Isoprene (C5H8, Figure 1-11) is the basic unit from which terpenes derive biosynthetically. The 
molecular formulae of terpenes are multiples of isoprene, (C5H8)n, and the value of n is the number of 
linked isoprene units. They may be linked together ‘head to tail’ to form linear chains or arranged to 
form rings. 
 
Figure 1-11. The structure of isoprene. 
 
Isopentenyl pyrophosphate (IPP, Figure 1-12) and dimethylallyl pyrophosphate (DMAPP, Figure 1-13) 
are the components in activated forms in the biosynthetic pathway while isoprene itself does not 
undergo the process. IPP can be formed by HMG-CoA reductase pathway and 2-Methyl-D-Erythritol-
4-phosphate pathway (MEP pathway) which start from acetyl-CoA and C5-sugars, respectively. In 
both pathways, IPP is isomerized to DMAPP by the enzyme isopentenyl pyrophosphate isomerase. 
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Figure 1-12. The structure of isopentenyl pyrophosphate (IPP). 
 
 
Figure 1-13. The structure of dimethylallyl pyrophosphate (DMAPP). 
 
Isoprene units are synthesized by terpene synthase to chains and the resulting terpenes are classified by 
the number of basic units in the molecule, such as hemiterpenes, moniterpenes (C5H8)2, sesquiterpenes 
(C5H8)3, diterpenes (C5H8)4, sesterterpenes(C5H8)5, triterpenes (C5H8)6, and sesquarterpenes (C5H8)7, 
tetraterpenes (C5H8)8, and polyterpenes (C5H8)n. 
A range of terpenes have been identified as high-value chemicals in food, cosmetic, pharmaceutical 
and biotechnology industries (Thimmappa et al., 2014; Augustin et al., 2011). 
Chemical synthesis of terpenes can be problematic because of their complex structure, and plants 
produce very small amounts of these valuable chemicals, making it difficult, time consuming and 
expensive to extract them directly from plants. Scientists are working to identify the key enzymes and 
pathways that produce terpenes in plants. 
Once genes for the synthetic pathway of a specific terpene have been identified, synthetic biology 
techniques could be used to make high levels of this terpene, using plants or microorganisms (e.g. 
yeast) as “factories”. This could mean cheaper and more sustainable production of economically and 
medicinally important terpenes. For example, the effective anti-malarial terpene artemisinin, from the 
plant Artemisia annual, can now be produced in yeast (Paddon and Keasling, 2014). 
1.3.5 Updating tools for exploration of diversities of natural compounds 
Various genome-based strategies together with traditional bioassay-based methods promote the 
exploration of natural compounds. However, Glöckner and Joint (2010) pointed out that the success of 
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the genome-based methods is largely dependent on the accuracy of bioinformatic analysis. Researchers 
are now developing various bioinformatic tools such as antiSMASH 3.0 (Weber et al., 2015), 
ClustScan (Starcevic et al., 2008), NP searcher (Li et al., 2009), SBSPKS (Anand et al., 2010) for the 
analysis of PKS or NRPS modular sequences and structure predictions. 
On the other hand, new tools in the detection of natural products are continuously being developed to 
explore the chemical diversity of microbial natural products, such as the imaging mass spectrometry 
(IMS) tools (Esquenazi et al., 2008), the PrISM (Proteomic Investigation of Secondary Metabolism) 
approach (Bumpus et al., 2009) and single-cell genomics approaches (Siegl et al., 2011). All these 
updated bioinformatics tools and detection tools can be combined to facilitate new marine natural 
products in the future. 
1.4 Anoxygenic phototrophic bacteria 
Anoxygenic phototrophic bacteria (APB) that are capable of anaerobic anoxygenic photosynthesis are 
referred to as anaerobic anoxygenic phototrophic bacteria, in contrast to those that are aerobic bacteria 
contain Bchl and perform anoxygenic photosynthesis under aerobic conditions which are called the 
aerobic anoxygenic phototrophic bacteria (AAPBs) (Yurkov and Beatty, 1998). 
APBs perform anoxygenic photosynthesis without oxygen production and convert the light energy to 
ATP. APBs are widely distributed in nature and play an important role in carbon dioxide assimilation 
and nitrogen fixation. Anoxic conditions are required for photosynthesis, and these bacteria cannot 
thrive in oxygenated environments (Proctor, 1997). 
Most characteristically, they can oxidize sulfide and other reducing agent as electron donor (Imhoff, 
2008) that is different from the mechanisms in plants (Bryant and Frigaard, 2006) or cyanobacteria 
(water as electron donor). 
Based on phenotypic characteristics and phylogenetic relationships, anaerobic anoxygenic 
phototrophic bacteria are divided into five major groups of the purple sulfur bacteria (PSB, 
Gammaproteobacteria), purple nonsulfur bacteria (PNSB, Alpha- and Betaproteobacteria), green sulfur 
bacteria (GSB, Chlorobiaceae), green nonsulfur bacteria (GNSB, Chloroflexaceae) and green 
heliobacteria Heliobacteriaceae (Sattley and Madigan, 2014). 
1.4.1 Purple bacteria  
Anoxygenic phototrophic purple bacteria are Proteobacteria and representatives of the 
Gammaproteobacteria (Chromatiaceae and Ectothiorhodospiraceae), Alphaproteobcteria (“Rhodo-
spirillum and relatives”) and Betaproteobacteria (Woese et al., 1984; Woese, 1987). They are 
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pigmented with bacteriochlorophyll a or b, together with various carotenoids, which give them distinct 
colors ranging between purple, red, brown, and orange. 
Anoxygenic phototrophic bacteria are generally found in illuminated anoxygenic parts of fresh and 
seawater habitats and also in marine habitats, sulfur hot springs, soda and salt lake, and intertidal 
microbial mats. They typically develop in all kinds of low or no oxygen tensions aquatic habitats that 
are reached by sunlight. Reduced sulfur compounds (H2S, elemental sulfur, and thiosulfate) are 
important electron donors of the phototrophic sulfur bacteria. The ability to carry out light-dependent 
bacteriochlorophyll mediated energy transfer processes is a common property of phototrophic purple 
bacteria, cyanobacteria, Chlorobiaceae, “Chloroflexaceae”, and heliobacteria. 
Phylogenetically, the purple sulfur bacteria (PSB) are classified into two families within the 
Gammaproteobacteria, Chromatiaceae and Ectothiorhodospiraceae on the basis of fundamental 
phenotypic and phylogenetic differences (Imhoff et al., 1984). The purple sulfur bacteria contain Bchl 
a and b, and all components of the photosynthetic apparatus are located in the intracellular membrane. 
The family Chromatiaceae are Gram-negative, contain internal photosynthetic membranes and 
typically are characterized by accumulation of sulfur globules within the cell (Imhoff et al., 1984). 
With a few exception (e.g. Thiococcus pfennigii), the intracellular membrane system is of the vesicular 
type. During aerobic dark growth, elemental sulfur may support respiration and serve as electron donor 
for chemolithotrophic growth, and under anoxic conditions in the light, all species are capable of 
photolith autotrophic growth with sulfide or S
0
 as electron donor (Imhoff, 2014). In contrast, the 
family of Ectothiorhodospiraceae (Imhoff et al., 1984) form sulfur globules outside the cells and 
contain lamellar intracellular membrane systems. 
Anoxygenic phototrophic purple nonsulfur bacteria（PNSB）represent by far the most diverse group 
of the phototrophic purple bacteria (Imhoff and Trüper, 1989) and preferentially grow under 
photoheterotrophic conditions (Imhoff, 2003). Most of the PNSB are representatives of the 
Alphaproteobacteria (‘‘Rhodospirillum and relatives’’, aerobic bacteriochlorophyll-containing 
bacteria), but a distinct group of species belongs to the Betaproteobacteria. 
1.4.2 Green bacteria  
The green sulfur bacteria (GSB), represented by the family Chlorobiaceae, are obligately anaerobic 
photoautotrophic bacteria. They are non-motile (except Chloroherpeton thalassium which may glide 
(Bryant and Frigaard, 2006) and occur in spheres, rods, and spirals and contain bacteriochlorophyll 
(BChl) a, c, d, or e in light-harvesting complexes. 
GNSB (phylum Chloroflexi) are Gram-negative (Oscillochloris chrysea is an exception because they 
stain Gram-positive). They are aerobic thermophilic phototrophs using oxygen and can grow well in 
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high temperatures (Garrity and Holt, 2001). They can form flexible filaments with gliding motility, 
and also called filamentous anoxygenic phototrophic bacteria (FAP). Most of them do not have gas 
vesicles and include bacteriochlorophylls c, or d, with small amounts of chlorophyll a and carotenoids 
(gamma- and beta-carotene). The most conspicuous representatives are the green- or orange-colored 
thermophilic bacteria which form dense microbial mats in hot springs (Overmann, 2008). The genera 
Chloroflexus, Chloronema, Heliothrix, and Oscillochloris constitute the green nonsulfur bacteria 
group (GNSB) according to Bergey’s Manual of Systematic Bacteriology (Garrity and Holt, 2001), 
and one new genus of Roseiflexus was included (Hanada et al., 2002). 
1.4.3 Heliobacteriaceae 
The cells of family Heliobacteriaceae are rod-shaped to short filaments or spirillum-shaped cells. They 
are anoxygenic phototrophic bacteria, but differ from others by their unique light harvesting and 
reaction center pigment Bchl g and carotenoids (Asao and Madigan, 2009). Bchl g confers to the cells 
a near infrared absorption maximum at 788 nm, which is unique among photosynthetic organisms 
(Gest and Favinger, 1983). The known species of Heliobacteriaceae all grow photoheterotrophically 
and are strict anaerobes. Gas vesicles are not present. 
1.4.4 Aerobic anoxygenic phototrophic bacteria (AAPBs) 
Aerobic anoxygenic phototrophic bacteria (AAPBs) are Alphaproteobacteria and Gamma-
proteobacteria and they comprise a considerable number of species. AAPBs are photoheterotrophic 
bacteria that exist in a variety of aquatic environments. They are obligate aerobes (require oxygen for 
growth) and can capture energy from light by anoxygenic photosynthesis, but are unable to utilize 
carbon dioxide as their primary carbon source. One remarkable aspect of these bacteria unlike other 
similar bacteria is the inability of utilize bacteriochlorophyll (BChl) for anaerobic growth. The only 
bacteriochlorophyll pigment that exists in AAPB is BChl a (Yurkov and Beatty, 1998). However, 
anaerobic phototrophic bacteria, on the contrary, contain a number of different bacteriochlorophylls: a, 
b, c, d, e, and g. 
AAPB are usually pink or orange in color when isolated from water. All species of AAPB produce 
large amounts of carotenoid pigments. The color of each species is due to the presence of carotenoids, 
giving peaks in the blue and green absorption spectra. 
1.5 Aims of this study 
The biomass turnover of marine photosynthetic microorganisms is about 700 times faster than that of 
terrestrial higher plants. Thus, marine photosynthetic organisms contribute significantly to total 
primary productivity (55∙ 109 t dry weight∙year-1, or 44% of the global primary production) (Overmann 
and Garcia-Pichel, 2013). The dominant primary producers are halophilic and halotolerant algae, 
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cyanobacteria, and anoxygenic phototrophic bacteria (Thiel et al., 2010). The role of anoxygenic 
phototrophic bacteria’s contribution to the global primary production is low, for example, phototrophic 
sulfur bacteria altogether contribute only 4% to global primary production (Whittaker and Likens, 
1975). However in certain aquatic environments, APB are important primary producers which can 
contribute up to 83% of the primary production (Van Gemerden and Mas, 1995). As far as we know, 
there is rare research about bioactive compounds of anoxygenic phototrophic bacteria. This work 
studied the bioactive compounds associated with the bacterium Allochromatium vinosum MT86 by 
using cultivation-dependent and molecular-based approaches. 
1) Optimal parameters for cultivation of Allochromatium vinosum strain MT86. 
From Dr. Marcus Tank’s previous work, one anoxygenic phototrophic purple sulfur bacterium with 
antibiotic potential was found. Strain MT86 was isolated from a marine sandy rock pool near 
Trivendrum, southwest coast in the Indian Ocean (sample station CH3) by Dr. Marcus Tank in 2009 
and was identified as Allochromatium species. It was taxonomically characterized and its 16S rRNA 
gene sequence was 97% similar to the type strain of Allochromatium vinosum DSM 180
T
, which is a 
species of the Chromatiaceae. 
The biotechnological potential of anoxygenic phototrophic bacteria was addressed by different 
methods. The cultivation media and conditions have great impact on the searching of the chemicals; 
therefore, much effort (culture-based development, tests of fermentation parameters, salt tolerance and 
so on) were made to screening for bioactive compounds of A. vinosum strain MT86. 
2) Screening and identification of the bioactive compounds from A. vinosum strain MT86. 
Dr. Marcus Tank identified antimicrobial activities in crude extracts of A. vinosum strain MT86, and 
therefore, identification of the antimicrobial activity and structure analysis of bioactive compounds 
produced by A. strain MT86 was one of the main purposes of this study. 
3) Screening for antimicrobial (and other bio-) activity of extracts from other phototrophic 
bacteria. 
Another three selected microorganisms were screened for antimicrobial compounds following the 
same methods as used for A. vinosum strain MT86. 
4) Screening for functional genes of natural product metabolic pathways (pks, nrps, and 
phzE). 
A total of ten selected strains were screened for pks I, pks II, nrps, and phzE genes by PCR 
amplification. Sequences of fragments were submitted to NCBI for BLASTn and functional genes can 
give metabolite information. 
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5) Genome evaluation of phototrophic bacteria by antiSMASH. 
The whole genome sequences of 62 phototrophic bacteria were downloaded from NCBI database and 
analyzed online by antiSMASH for secondary metabolites. In comparison with interesting clusters of 
secondary metabolites and similar compounds, further potential of bioactive compounds of 
phototrophic bacteria was predicted. 
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2 MATERIALS AND METHODS 
2.1 Preparation of the medium 
The Pfennigs medium was prepared by the method of Eichler and Pfennig (1988), a defined medium 
for freshwater and marine Chromatium and Allochromatium species (Pfennig, 1965; Pfennig and 
Trüper, 1981; Pfennig and Trüper, 1992). 
The medium was prepared in a 5-liter Erlenmeyer flask bottle (see Figure 2-1) with four openings at 
the top. Two openings were connected to tubings: 1) a short, gas inlet tube with a sterile cotton filter 
and 2) an outlet tube near the bottom at central part of the vessel for the medium, at the other end, a 
silicon rubber tube with a pinchcock and a bell for aseptic dispensing of the medium into bottles. The 
other two openings had gas-tight screw caps. One of these openings was for the addition of sterile 
solutions and the other served as a gas outlet. The medium was dispensed aseptically into sterile 100 
ml, 500 ml or 1000 ml bottles with metal screw caps containing autoclavable rubber seals. 
The Pfennig’s medium was composed as follow: 
Solution 1 (basic medium in 5 L): 
demin. water 4900 ml 
KH2PO4 1.70 g 
NHCl4 1.70 g 
MgSO4·7H2O 1.25 g 
CaCl2·2H2O 1.25 g 
KCl 1.70 g 
Solution 2:   Vitamin B12 5 ml 
Solution 3:   SL-12 5 ml 
Solution 4:   NaHCO3 7.5 g in 100 ml demin. water. 
Solution 5:   Na2S·9H2O 2.0 g in 20 ml demin. water. 
Solution 2 of vitamin B12 was prepared by 2 mg vitamin B12 in 100 ml demin water, and then filtered 
by a 0.2 μm filter to the sterile tubes and stored at 4°C. 
Solution 3, trace element solution SL-12 (Pfennig and Trüper, 1992) included the following 
ingredients: 3.0 g EDTA-Na2, 1.1 g FeSO4·7H2O, 300 mg H3BO3, 190 mg CoCl2·6H2O, 50 mg 
MnCl2·7H2O, 42 mg ZnCl2, 24 mg NiCl2·6H2O,18 mg Na2MoO4·2H2O, and 2 mg CuCl2·2H2O 
dissolved in 1 L demin. water in order. The pH was adjusted to 2-3 with HCl. SL-12 was stored at 4°C. 
When adding to 5 L basic medium (solution 1) of Pf medium, 5 ml was added sterilized by a 0.2 μm 
filter. 
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Figure 2-1. The apparatus for preparation of Pfenning medium. 
 
 
 
Figure 2-2. The apparatus for preparation of AT medium. 
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Solution 4 was a 7.5% NaHCO3 solution that contained 7.5 g NaHCO3 in 100 ml demin. water. After 
saturated with CO2, the solution was autoclaved under CO2 atmosphere in a tightly closed bottle. 
Solution 5 was a 10% Na2S·9H2O solution (2.0 g Na2S·9H2O in 20 ml demin. water) prepared in a 
screwed-cap bottle. After replacement of the air by N2, the bottle is tightly closed and autoclaved 
under an N2 atmosphere. 
Chemicals of the solution one were dissolved in the order given. Solution one was autoclaved for 45 
min at 121°C in the 5-liter bottle, together with a Teflon-coated magnetic stir bar. After the medium 
had been autoclaved and cooled to room temperature under an atmosphere of N2 with a positive 
pressure of 0.05-0.1 atm, the cold medium was saturated with CO2 by magnetic stirring for 30 min 
under CO2 atmosphere of 0.05-0.1 atm (100 mbar). 
The sterile solutions 2 through 5 were added aseptically through one of the screw-cap openings while 
access of air was prevented by continuous flushing with N2 while the medium was magnetically stirred. 
After combining and carefully mixing solutions 1 through 5, the pH of the medium was adjusted to pH 
7.2 by stirring under an atmosphere of CO2 (0.5 bar pressure) for approximately 40 min (if the pH 
required for 6.8, longer time of stirring under CO2 gas was needed). The medium was then 
immediately dispensed aseptically under pressure of N2 (0.05-0.1 atm) into sterile 100 ml, 500 ml, or 1 
L bottles with metal screw caps containing autoclavable rubber seals. A small, pea-sized air bubble 
was left in each bottle to accommodate possible pressure changes. The tightly sealed screw-cap bottles 
can be stored for several weeks to a month in the dark. During the first 24 hours, some trace metal 
(mainly iron) sulfides of the medium precipitate in the form of fine black particles. No other sediment 
should arise in the otherwise clear medium. 
Additionally, sulfide solution was necessary for purple sulfur bacteria during the growth. It contained 
7 g Na2S·9H2O and 2.65 g Na2CO3 dissolved in 250 ml demin. water. The pH of the sulfide solution 
was adjusted by CO2 gas to 7.2-7.8. 
Salt solution included 58 g NaCl and 8 g MgCl2·6H2O dissolved in 200 ml demin. water in a srewed-
cap bottle. The solution was autoclaved and stored at room temperature. 
Salt solution:   
demin. water 200 ml 
NaCl 58 g 
MgCl2·6H2O 8 g 
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The basic Pf medium was modified for the growth of A. vinosum strain MT86 by replacing  
MgSO4·7H2O by MgCl2·6H2O and by addition of thiosulfate and acetate. 
The salt solution was according to (Imhoff, 2014) was used to adjust the salt concentration of the 
medium to determine the salt optimum of A. vinosum strain MT86 (1% salt = 3 ml salt solution into 
100 ml modified Pf medium). 
 
The AT medium for cultivation of purple nonsulfur bacteria was prepared in a 5 L Erlenmeyer flask. 
The two side openings of flask were closed by two silicon rubber stoppers with an inlet for gas and an 
outlet near the bottom with a screw-cap glass tube (the same one as Pf medium). One of the stoppers 
was closed during the medium preparation and anther one was used for adding other solutions. A 
silicon rubber tube interlinked the outlet to a filter, and another silicon rubber tube from filter outlet 
connected with a pinchcock and a bell for aseptic distribution of the medium into bottles (see Figure 
2-2). The defined basal medium and additional solutions had the following composition: 
Solution 2 of NaHCO3 was saturated with CO2 and autoclaved under a CO2 atmosphere. The yeast 
extract solution was autoclaved too. 
Solution 3 of Na-ascorbate (L (+)-Ascorbic acid sodium salt/C6H7NaO6) was freshly prepared before 
adding to the flask. 2.5 g of Na-ascorbate was dissolved in 50 ml demin. water and added to the basal 
medium by 0.2 µm filter. 
Solution 4, vitamin A (Imhoff, 2006) contained 10 mg biotin, 35 mg niacin amide, 30 mg thiamine 
dichloride, 20 mg p-aminobenzoic acid, 10 mg pyridoxal hydrochloride, 10 mg calcium pantothenate, 
and 5 mg vitamin B12 in 100 ml demin. water. Solution 4 was filtered by a 0.2 μm filter to the sterile 
tubes and stored at 4°C. 
 
 
Solution 1 (basic medium in 5 L): 
demin. water 4900 ml 
KH2PO4 1.70 g 
NHCl4 1.70 g 
MgCl2·6H2O 2.06 g 
CaCl2·2H2O 1.25 g 
KCl 1.70 g 
Thiosulfate 5.00 g 
NH4·Acetate 1.25 g 
Mg·Acetate 1.25 g 
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Solution 1: (basic medium in 5 L): 
demin. water 4700 ml 
KH2PO4 5.0 g 
MgCl2·6H2O 2.5 g 
CaCl2·2H2O 0.5 g 
NHCl4 5.0 g 
Na2SO4 3.5 g 
Na(C2H3O2)  5.0 g 
C3H3NaO3 5.0 g 
NaCl 5.0 g 
Solution 2:     
NaHCO3 15 g in 200 ml demin. water. 
Yeast extract 2.5 g in 50 ml demin. water. 
Solution 3:     
L(+)-Ascorbic acid sodium 
salt/C6H7NaO6 
2.5 g in 50 ml demin. water.  
Solution 4:   Vitamin solution A 5 ml 
Solution 5:   SLA 5 ml 
Solution 5 of sulfate-free trace element solution SLA (Imhoff, 2006) contained 1.8 g FeCl2·4H2O, 250 
mg CoCl2·6H2O, 10 mg NiCl2·6H2O, 10 mg CuCl2·2H2O, 70 mg MnCl2·7H2O, 100 mg ZnCl2, 500 mg 
H3BO3, 30 mg Na2MoO4·2H2O dissolve in 800 ml demin. water in order. The pH of the medium was 
adjusted to 1.0 with 1 M HCl demin. water to 1000 ml. SLA solution was stored at 4°C. When adding 
to 5 L basic medium (solution 1) of AT medium, 5 ml of sterilized solution SLA was added by a 0.2 
μm filter. 
After the medium had been autoclaved and cooled under an atmosphere of N2, the five additional 
components were added in order aseptically while the medium was magnetically stirred and the access 
of air was prevented by continuous flushing with the gas of N2. 
The bottle of the AT medium with additions was tightened to the filter and both of the side openings 
were closed. The N2 was opened firstly and then the clips were opened from gas side to other. The 
medium was then immediately dispensed aseptically under pressure of N2 (0.05-0.1 atm) into sterile 
100 ml, 500 ml, or 1 L bottles with metal screw caps containing autoclavable rubber seals. A small, 
pea-sized air bubble was left in each bottle to accommodate possible pressure changes. 
2.2 Bacterial strains 
All the information (i.e. taxonomic classification, type strains of genus, media for cultivation) of 
strains is given in Table 2-1. 
MATERIALS AND METHODS 
 
 
 
29 
Table 2-1. Strains’ information. 
No. 
strain 
Media Class Group Family (Type) strains of genus 
5212
T
 Pf, 2% S, pH 7.2+Ac Gammaproteobacteria PSB Chromatiaceae 
Marichromatium gracile DSM 203
 T
  
(DSM203
 T
 = =BN5210
 T
) 
5410
T
* Pf, 0% S, pH 7.2+Thio Gammaproteobacteria PSB Chromatiaceae 
Thiocystis violascens DSM 198
 T
  
(DSM198
 T
 =BN 5410
 T
) 
5110
 T
 Pf, 0% S, pH 7.2 Gammaproteobacteria PSB Chromatiaceae 
Allochromatium vinosum DSM 180
 T
  
(DSM 180 
T
 = BN 5110
 T
) 
2310 Pf, 0% S, pH 6.8+Ac Chlorobia GSB Chlorobiaceae Chlorobium limicola  
2410
 
 Pf, 1% S, pH 6.8 Chlorobia GSB Chlorobiaceae Prosthecochloris aestuarii  
2360
 
 Pf, 0% S, pH 6.8 Chlorobia GSB Chlorobiaceae Chlorobium phaeobacteroides  
120/1 AT Alphaproteobacteria PNSB Bradzrhiyobiaceae Rhodopseudomonas palustris 
182 AT Alphaproteobacteria PNSB Rhodobacteraceae Rhodobacter capsulatus 
151 AT Betaproteobacteria PNSB Comamonadaceae Rubrivivax gelatinosus 
MT86 Pf, 0% S, pH 7.2+Ac+Thio Gammaproteobacteria PSB Chromatiaceae Allochromatium vinosum MT86 
PSB: Purple sulfur bacteria; PNSB: Purple nonsulfur bacteria; GSB: Green sulfur bacteria; GNSB: Green nonsulfur bacteria 
Thio: Thiosulfate solution; Ac: Actate solution; S: salt solution; T: Typical strain 
*: Strain 5410 was identified to Thiocystis violascens, later in my study, 16S rRNA BLASTn result showed different.  
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2.3 Cultivation experiments 
An overview of the cultivation experiment of A. vinosum strain MT86 is seen in flowchart of Figure 
2-3. 
 
Figure 2-3. The flowchart of A. vinosum strain MT86. 
 
 
2.3.1 Optimization of the growth condition for the cultivation of A. vinosum MT86 
The A.vinosum strain MT86 was grown in liquid culture (100 ml or 1000 ml screw cap bottles) using 
freshly prepared Pf medium (no salt solution included) or Pf medium with salt solution (0%-3.33%). 
A new fresh 100 ml Pf media was inoculated with a 5 ml of A. vinosum MT86 culture. The inoculated 
bottle was stored in the dark condition for 2 hours, then placed under the light of a tungsten lamp (ca. 
1000 lux), and incubated at 28°C until turbidity was visible. Sulfide solution was added every two 
days until the bacteria grow well via microscopic observation, such as the state of movement, sulfur 
globules within the cells and the size of the cells. Afterwards, a 1 L fresh Pf medium was inoculated 
with the preculture mentioned above, and incubated under the same conditions. Finally, when the color 
of the broth became dark red and the bacteria grew well, new ten 1 L bottles (5% of each bottle) were 
inoculated with the aim to get enough biomass to analyze the produced compounds. Three times 10 L 
cultures of strain MT86 were incubated and grown at 28°C for 14 days before extraction according to 
the paragraph 2.4.1, on page 33. 
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2.3.2 Media for screening of optimal cultivation condition 
A. vinosum strain MT86 was cultivated using several modifications of Pf medium. All changed 
parameters are shown in Table 2-2. Because thiosulfate and acetate were added into the basic medium, 
no more sulfide solution was needed during growth. All bottles of A. vinosum MT86 grew at 28°C and 
1000 lux light intensity. 
Table 2-2. Changed parameters of Pf media. 
 New parameters Old parameters 
Basic medium MgCl2ˑ6H2O MgSO4ˑ7H2O 
Thiosulfate 
Acetate 
/ 
/ 
Sulfide New crystal Old sulfide 
Trace element solution SLA SL-12 
Preparation no N2 gas N2 gas 
Pre-culture liquid N2 vial 4°C stored culture 
Additional sulfide solution / added every 2 days 
                /: not used 
 
Table 2-3. The protocol of incubation of A. vinosum strain MT86 in different Pf media and control media. 
No. of bottles Name of medium Volume 
1 Pf (MgSO4) + Thiosulfate 100 ml 
2 Pf (MgSO4) + Thiosulfate + Acetate 100 ml 
3 Pf (MgCl2) + Thiosulfate 100 ml 
4 Pf (MgCl2) + Thiosulfate + Acetate 100 ml 
5 Pf (MgSO4) 100 ml 
6 Pf (MgCl2) 100 ml 
7 Control of Pf (MgSO4) 100 ml 
8 Control of Pf (MgCl2) 100 ml 
9 Control of Pf (MgCl2) without Sulfide 100 ml 
10 Control of Pf (MgCl2) without Sulfide 1 L 
 
After 10 days of incubation, the cultures and corresponding controls of Pf medium (Table 2-3) media 
were extracted using ethyl acetate and analyzed by HPLC-DAD/MS and used for bioassays.  
2.3.3 Scale up to a 36 L culture volume of A. vinosum strain MT86 
The extracts were analyzed and Pf medium amended with 1% thiosulfate and 1% acetate-solution 
(NH4-acetate/Mg-acetate, 2.5 g each/100 ml) was the best stable incubation condition for A. vinosum 
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strain MT86. Scale up to a 36 L (36 bottles of 1 L Pf medium) approach was preformed using this 
optimal condition. 
36 L Pfennig´s medium with 5% bacteria (50 ml preculture per 1 L Pf medium) was inoculated. All 
the bottles were stored in the dark condition for 2 hours, then placed under the light of a tungsten lamp 
(ca. 1000 lux), and incubated at 28°C for 11 days. 36 L of culture broth was extracted by ethyl acetate. 
The crude supernatant extract for HPLC-DAD/MS was prepared by the method as described in 
paragraph 2.4.1, on page 33. 
2.3.4 Salt tolerance of A. vinosum strain MT86 
According to Bergey’s Manual of Systematic Bacteriology (Imhoff, 2005b), the mesophilic freshwater 
bacterium A. vinosum showed an optimal growth at 25-35°C and pH 7.0-7.3 (range pH 6.5-7.6). There 
were no distinct requirements for salt of the mesophilic bacterium, except for strains that originate 
from the marine and brackish water environment and may tolerate or require low concentrations of 
NaCl. A. vinosum was enriched at high sulfide concentrations (3-4 mM), at high light intensities of 
more than 1000 lux and at incubations temperature of 20-30°C. Some interesting results were shown 
by Dr. Marcus Tank (2010) about the salt concentration for phenotypes related to Allochromatium 
vinosum. They obviously tolerated elevated salt concentrations and can compete even at hypersaline 
conditions, which contrasted to the properties known from the genus Allochromatium. Previous work 
was based on the properties of the genus Allochromatium. Therefore, for experiments on the first 
screening and optimal cultivation conditions, Pf medium without salt solution was used for cultivation. 
If these bacteria can tolerate salt, the addition of salt might stimulate the secondary metabolites of A. 
vinosum strain MT86. 
2.3.4.1 100 ml Pf medium approach 
In order to study the influence of salt concentration to the compounds production, different salt 
concentrations (0%, 0.33%, 0.67%, 1%, 1.67%, 2.33%, 2.5%, 2.67%, and 3.33%) were used (see in 
Table 2-4). 
Table 2-4. Growth parameters for cultivation at different salt concentrations. 
Salt concentration 0%, 0.33%, 0.67%, 1%, 1.67% 2.33%, 2.5%, 2.67%, 3.33% 
Incubation time 7 days 10 days 15 days 20 days* 
Culture volume 100 ml 
Mg
2+
 MgCl2ˑ6H2O 
Thiosulfate & acetate 1% thiosulfate, 1% acetate 
Light intensity 1000 lux 
Temperature 28-30°C 
*: Culture broth at 2.67% salts after 20 days was contaminated.  
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2.3.4.2 Scale up to a 50 L approach using optimized Pf medium 
From the former part of screening, the crude supernatant extract of culture grown at 0.67% salt after 10 
days showed the maximum numbers of peaks from the HPLC-DAD/MS chromatogram and crude 
supernatant extract from culture grown at 2.33% salts after 15 days showed another series of UV 
absorption peaks. Thus, 0.67% and 2.5% salts of Pf media were chosen for scaling up for cultivation 
and extraction. The Pf medium with MgCl2·6H2O, 1% thiosulfate solution, and 1% acetate solution 
were incubated at 1000 lux, 28-30°C. 
Table 2-5. Growth parameters for 50 L cultivation at different salt concentrations. 
Parameters Value of each parameter 
Salt  0.67% 2.5% 
Incubation time 10 days 15 days 
Culture volume 50 L 50 L 
Extraction volume 45 L 50 L 
 
2.4 Chemical screening and structure identification 
The culture broth of A. vinosum strain MT86 was centrifuged to separate the cell biomass and liquid 
supernatant. HPLC-DAD/MS and semi-preparative HPLC were used to set first insights into the 
presence of compounds in the crude extracts. Using the semi-preparative HPLC, most peaks seen from 
the analytical HPLC chromatogram were separated and used for biological activity tests. Selected 
fractions which showed bioactivity were purified and their chemical structure was analysed by 
different methods (MS, NMR). 
2.4.1 Extraction procedures  
The culture broth was centrifuged to separate cell biomass and supernatant. These two parts were 
extracted in different approaches to determine whether the compounds exist in the cells or are secreted 
into the medium. 
2.4.1.1 Separation of cells and supernatant by centrifugation  
Centrifugation steps were done as follows: 
1) The centrifuge tubes were weighted before and after centrifugation. The broth was centrifuged 
in 500 mL centrifuge tubes at 10,000 rpm × 15 min, 4°C. For 100 ml culture broth, 50 ml 
centrifugation tubes were used at 4670 rpm × 20 min, 4°C. 
2) Upper supernatant was collected in new blue-screw glass bottles and the cell pellets were left 
in the bottle with the next centrifugation. 
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3) For the cell part, 250 ml of MeOH was added to each centrifugation tube and homogenized by 
use the Ultraturrax for 1 min. 
4) All extraction tubes were kept in the darkness overnight at 4°C until further treatment. 
2.4.1.2  Extraction of the supernatant/control medium and evaporation 
The supernatant was extracted in a 2 L separation funnel as follow: 
1) 500 ml/100 ml supernatant was transferred into a 2000 ml/500 ml separatory funnel and the 
same volume (1:1) of ethyl acetate (EtOAC) was added. 
2) The separatory funnel was shaken for 1 min and the phases were allowed to separate.  
3) The lower water phase was discarded. 
4) 100 ml demin. water was added to wash the ethyl acetate phase. The funnel was shaken again 
and after phase separation, the lower water phase was discarded. 
5) The upper phase was collected and filtered through a 1PS paper phase separator (GE Health 
Waterman
TM
, 180 mm), a high-grade filter paper impregnated with a stabilized silicone that 
renders it hydrophobic, retaining the aqueous phase and any solid impurities and passing the 
solvent phase through. 
6) EtOAc was evaporated using a rotational evaporator at the 40°C water bath with 200 mbar. 
7) The round-bottom flasks were weighed before and after evaporation to get the dry weight of 
the total supernatant extract. 
8) MeOH was added to the dry crude supernatant extract and the dissolved extract was 
transferred to a brown bottle for storage at 4°C. 
For control experiment, Pf medium was extracted directly by ethyl acetate without centrifugation steps. 
2.4.1.3 Extraction of the cell pellets and evaporation 
After centrifugation of a 500 ml culture, 100 ml MeOH was added to the cell pellets for extraction. 
The solvent suspension is kept in the darkness overnight and further extraction steps were performed 
as following described. 
1) The cell suspension of a 100 ml culture was evaporated to dryness. 
2) A suitable volume of MeOH (1-5 ml) was added to the dried cells and cell extract. 
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3) 500 ml demin. water was added and the sonic bath was used to wash the flask for several times. 
4) 500 ml above dissolved extract was taken to the separator funnel. 
5) 500 ml of EtOAc was added to the cell/methanol suspension, and the mixture was shaken for 
extraction. After phases’ separation, the lower water phase was discarded and the upper 
solvent phase was collected. 
6) 100 mL demin. water was added to wash the ethyl acetate phase. The mixture was shaken and 
after phase separation, the lower water phase was discarded and the upper solvent phase was 
collected. 
7) A 1 PS paper phase separator was used to retain the aqueous phase and any solid impurities. 
8) The round-bottom flasks were weighed before and after evaporation to get the dry weight of 
the crude cell extract. 
9) MeOH was added to the dry crude cell extract and the dissolved extract was transferred to a 
brown bottle for storage at 4°C. 
For cells from 100 ml cultures, the volume of solvents used for extraction was one-fifth of the values 
shown above. 
2.4.2 Analytical HPLC-DAD/MS 
All crude extracts were analyzed by HPLC-DAD/MS. The HPLC samples were prepared as following 
described. 
1) 0.3 ml extracts were taken by a syringe and filtered (0.25µm) into a HPLC weighed vial. 
2) The extracts were evaporated to dryness in a flow of nitrogen gas generator LCMS 30-0 
(Domnick Hunter) until dry. The vials were weighed after evaporation of the solvent. 
3) MeOH was added to adjust the concentration for injection into HPLC to 1.0 mg/ml. 
4) Pf medium extract was chosen as negative control and MeOH was as solvent control. 
The analytical HPLC was performed using a system comprised of a Hitachi Elite LaChrom system; it 
contains the autosampler L2200 injection port (Rheodyne LLC, Rohnert Park, CA, USA), organizer, 
diode array detector L 2450 (DAD), the column oven L 2300, and a L2130 pump (Hitachi Ltd. Tokyo, 
Japan). The crude extracts were subjected to HPLC-DAD/MS using a reversed phase C18 column 
(100 × 3.00 mm, Phenomenex Onyx Monolithic) with solvent A (0.1% formic acid in 100% 
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acetonitrile) and solvent B (0.1% formic acid in 100% miliQ H2O) with the gradients shown in Table 
2-6.  
Table 2-6. The solvent gradients for analytical HPLC using a flow of 2 ml/min. 
Time 
Gradient 
A B 
0 min 95% 5% 
4 min 40% 60% 
6 min 0% 100% 
Solvent A: 0.1% formic acid in 100% acetonitrile;  
Solvent B: 0.1% formic acid in 100% miliQ H2O. 
 
By using of an ESI-ion trap detector (Esquire 400, Bruker Daltonics) along with LaChrom system, the 
samples were measured with positive and/or negative ionization (Esquire 4000, Bruker Daltonics). The 
mass spectra and UV chromatograms of the extracts were analyzed by using of Bruker Daltonics-
Compass Analysis 4.0 and Compass Hystar Post Processing software respectively. Molecular weight, 
UV maxima and biological sources were used for identification of the compounds by using of 
dictionary of natural products DNPs (Chapman, 2012). 
2.4.3 Fractionation of crude supernatant extract by semi-preparative HPLC 
All samples were dissolved in MeOH and filtered through 0.2μm PTFE syringe filters before applying 
to analytical HPLC and semi-preparative HPLC. 
Semi-preparative HPLC was performed using a VWR Hitachi Elite LaChrom HPLC system. This 
system consisted of a C18 column (110A AXIA, 100 × 50.00 mm, Phenomenex Gemini) or polar 
column (4 µl Polar-RP 80A, 250 × 21.20 mm, Phenomenex Synergi), a L-2200 autosampler, a fraction 
collector (Foxy Jr. ISCO), a L-7150 pump, and an L-2450 diode array detector (DAD). Solvents A 
(0.1% formic acid in 100% acetonitrile) and B (0.1% formic acid in 100% miliQ H2O) were used as 
solvents for semi-preparative HPLC. 
Specific gradient (Table 2-7) of solvent A and solvent B were applied to this semi-preparative HPLC 
system for fractionation. Hitachi HPLC system separated the compounds or fractions by monitoring 
UV absorption between at 200 to 550 nm wavelengths. The injection concentration was 100 mg/ml, 
and injection volume was 300-900 μl. Finally, fractions were collected. 
Semi-preparative HPLC programs for 1
st
 (10 L) and 2
nd
 & 3
rd
 (totally 20 L: 10 L + 10 L) extracts were 
identical. However, there were differences in the collection methods (according to time or UV 
absorption). 
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Table 2-7. The gradient used for semi-preparative HPLC  
of the extract from the 36 L culture of A. vinosum strain MT86. 
Time 
Gradient 
Flow/ml 
A B 
0 min 90% 10% 5 
0.5 min 80% 20% 10 
26 min 0% 100% 15 
30 min 0% 100% 15 
Solvent A: 0.1% formic acid in 100% acetonitrile;  
Solvent B: 0.1% formic acid in 100% miliQ H2O. 
 
The injection of 1
st
 extracts of A. vinosum strain MT86 was 900 µl and fractions were collected 
according to time. The whole separation time of the preparation run was 24 minutes and every minute 
a fraction was collected. Because the first two fractions were mixed together, they were combined to 
one fraction. In total, 23 fractions were obtained. 
The combined 2
nd
 & 3
rd
 crude extracts were fractionated according to UV absorption. An injection 
volume of 900 µl was applied for four times. All fractions showing a clear UV signal were manually 
collected. Finally, 10 fractions were obtained, and fraction tube nine (named F9) was mixed from the 
semi-preparative HPLC chromatogram. 
The solvents were removed by rotation in vacuum. Then, fractions were resuspended in methanol, 
which was evaporated by nitrogen flow at 40°C and stored at 4°C. The purification of the fractions 
was checked by analytical HPLC-DAD/MS. 
In comparison of the two different methods of collection, UV signal dependent fractionation was a 
better way to obtain pure fractions. Later all samples (crude supernatant extracts of 36 L, 45 L and 50 
L) were fractionated by UV absorption manually and with a modified gradient program (Table 2-8). 
Table 2-8. Modified gradient used for semi-preparative HPLC  
of the 36 L, 45 L and 50 L A. vinosum strain MT86 supernatant extracts. 
Time 
Gradient 
Flow/ml 
A B 
0 min 80% 20% 5 
0.5 min 80% 20% 10 
26 min 0% 100% 10 
30 min 0% 100% 10 
Solvent A: 0.1% formic acid in 100% acetonitrile;  
Solvent B: 0.1% formic acid in 100% miliQ H2O. 
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2.4.4 Screening of crude cell extract (TLC)  
Crude cell extracts were performed by thin layer chromatography (TLC). The crude cell extracts 
(MeOH as solvent) were filtered (the filtered fraction) and the residue was treated with acetone. The 
acetone-dissolved compounds were separated by filtration (acetone-extract fraction) and the residue 
was extracted with methyl dichloride if the undissolved material was left. The methyl dichloride 
extract was filtered again (methyl dichloride extract fraction) and separated according to Prof. Dr. A. 
Zeeck (personal communication).  
2.4.5 Antimicrobial activities screening 
The crude extracts and fractions were assayed for their antimicrobial activity by cell based assays. The 
test organisms used are listed in Table 2-9. 
Antimicrobial activity tests against Bacillus subtilis, Staphylococcus aureus, Staphylococcus lentus, 
Propionibacterium acnes (representatives of Gram-positive bacteria) and Escherichia coli, 
Pseudomonas syringe, Xanthomonas campestris, Erwinia amylovora, and Ralstonia solanacearum 
(representative of Gram-negative bacteria) were performed as described by Schneemann et al. (2010), 
Silber et al. (2013), Alfano and Collmer (1996), Mitchell and Teh (2005), and Yin et al. (2004). A 
phytopathogenic Septoria tritici, dermatophyte Trichophyton rubrum, Candida albicans, and Candida 
glabrata were employed for antifungal tests according to Jansen et al. (2013). Four enzymes, 
acetylcholinesterase (AchE), glycogen synthase kinase 3β (GSK-3β), phosphodiesterase 4 (PDE-4β2) 
and protein-tyrosine-phosphatase (PTP) were used for enzyme inhibition assays. 
The acetylcholinesterase (AchE) is an enzyme to cleave the neurotransmitter acetylcholine. It is used 
as a target for the treatment of Alzheimer's disease (Bolognesi et al., 2008). Inhibitory activity against 
AchE and the human pathogenic yeast C. albicans were performed according to Ohlendorf et al. 
(2012).  
The enzyme glycogen synthase kinase 3β (GSK-3β) is a key regulator of many signal transduction 
pathways. The therapeutic benefits of glycogen synthase kinase inhibitors was in the treatment of type 
II diabetes, neurological diseases and cancer (Martinez et al., 2002). The assay was performed 
according to Baki et al. (2007). 
Phosphodiesterase 4 (PDE-4β2) forms second messengers such as cyclic andenosin monophosphat 
(cAMP) and cyclic guanosine monophosphate (cGMP), and PDE-4β2 inhibitors were applied for 
treatment of depression and Alzheimer's disease (Houslay and Adams, 2003). The inhibitory activity 
against PDE-4β2 were determined according to Schulz et al. (2011). 
The test for protein tyrosine phosphatase (PTP) was implemented following to Helaly et al. (2009). 
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Table 2-9. Microbial strains and enzymes used for the bioactivity assay. 
 Strains* Abbreviation DSMZ No. 
Gram-positive 
bacteria 
 
Bacillus subtilis Bs DSM 347 
Staphylococcus aureus MRSA DSM 18827 
Staphylococcus lentus Sl DSM20352. 
Propionibacterium acnes Pa DSM 1897 
Gram-negative 
bacteria 
Escherichia coli Ec DSM 498 
Pseudomonas syringae Ps DSM 10604 
Xanthomonas campestris Xc DSM 3586 
Erwinia amylovora Ea DSM 30165 
Ralstonia solanacearum Rs DSM 9544 
Yeast and fungi  Candida albicans Ca DSM 1386 
Septoria tritici Sep / 
Trichophyton rubrum Tru / 
Candida glabrata Cg DSM 6425 
Enzymes Acetylcholinesterase AchE / 
 Glycogen synthase kinase 3β GSK-3β / 
 Phosphodiesterase 4 PDE-4β2 / 
 Protein-tyrosin-phosphatase PTP / 
*All obtained from DSMZ (Braunschweig, Germany); /: no DSMZ number. 
 
The crude extracts and fractions were added to the wells (10 µl) in a 96-well microtiter plate for 
inhibitory bioassay and pure substances were dissolved in dimethyl sulfoxide (DMSO) and added to a 
concentration of 100 µM for antibacterial and antifungal activity, and to 10 µM for enzymatic assays 
for IC50. The pure substances were pipetted in a 96-well microtiter plate and the solvent evaporated in 
vacuum. All media used for bioassay tests are shown in Table 2-10. 
The test samples (crude extracts, fractions, or substances) were pipetted to the wells in a 96-well 
microtiter plate (two wells for every sample), and positive control (chloramphenicol solution), 
negative control (wells without extract or positive control, just bacteria cells), and blank value (just 
medium) were set. The microplate was placed into a centrifugal evaporator to eliminate solvent in 
order to have a dry microplate with the substances. 
The respective indicator organisms were cultured overnight in corresponding medium (TSB medium 
and M186/3 media were used for bacteria and yeast cultivation, respectively), and diluted with 
medium to a final optical density (OD600) of 0.01 for B. subtilis and S. lentus, and 0.02 for X. 
campestris.  
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Table 2-10. Media and solutions used for bioactivity tests. 
Medium name Composition 
TSB medium 1.2% tryptic soy broth 
0.5% NaCl 
M186/3 medium 0.1% yeast extract 
0.1% malt extract 
0.17% peptone from soybeans 
0.33% glucose 
Resazurin solution 0.2 mg ml
-1
 phosphate-buffered saline 
Positive control 10 μM chloramphenicol for bacteria 
10 μM nystatin for the yeast 
Negative control blank/no compound 
 
To the dry microplate, 200 µl of the diluted test organism was added into each well and incubated for 5 
h, 37°C, 200 rpm (B. subtilis and S. lentus), or for 6 h, 28°C, 200 rpm (X. campestris). 10 µl resazurin 
solution was added to each well, and the microplate was incubated for 5-60 min (37°C, 120 rpm) until 
color changed. To evaluate cell viability, the reduction of resazurin to resorufin was assessed by 
measuring the absorbance at 600 nm (600 nm was a modified wavelength; the reference absorbance 
was 690 nm). The resulting values were compared with a positive and a negative control (100% 
growth = 0% inhibition) on the same plate. The calculation of the inhibition of the extracts (in %) was 
carried out over the rule of proportion. If the accurate mass of substance was known, the IC50 value can 
be calculated. 
2.4.6 NMR analysis 
Fractions which showed high purity (a single UV signal or > 90%) were analyzed by different NMR 
methods, such as 
1
H NMR, and 
13
C NMR. 
1
H and 
13
C NMR spectra were recorded on a Bruker DRX 500 (600 and 150 MHz) with 
tetramethylsilane (TMS) as the internal standard. Methanol-d4 (MeOD) (residual peaks are δH 3.31 
ppm, and δC 49.0 ppm) was used as the solvent in 
1
H NMR and 
13
C NMR. Coupling constants (J) were 
given in Hz. NMR measurements were performed at the Otto-Diels-Institute of Organic Chemistry 
(Christian-Albrechts University of Kiel, Prof. Dr. Frank Sönnichsen). MestReNova was used for 
spectra analysis (Version 9.0.1, 2014, Mestrelab Research S. L., Santiago de Compostela, Spain). 
2.4.7 TOF-MS 
Measurements of high-resolution mass spectra were performed on a benchtop time-of flight 
spectrometer (TOF-MS, Agilent 6210 TOF LC/MS Spectrometer) with positive and negative ESI by 
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Dr. Bin Wu at Zhejiang University (Hangzhou, China) and Prof. Dr. Axel Zeeck at BioViotica 
Naturstoffe GmbH (Göttingen, Germany). 
2.5 Other strains of phototrophic bacteria 
From the established global sampling collection of anaerobic photosynthetic bacteria, three potential 
antimicrobial purple nonsulfur bacteria (Rhodopseudomonas palustris strain 120/1, Rhodobacter 
capsulatus strain 182, Rubrivivax gelatinosus strain 151) were chosen for products research and 
analysis.  
2.5.1 First screening of selected strains 
Firstly, 500 ml of each strain was incubated and the supernatants were extracted as the same method as 
strain MT86. The incubation parameters are given in Table 2-11. All strains were grown in 500 ml AT 
medium with 1% inoculation preculture. The bacteria were grown at 1000 lux, 28°C for 7 days and 
then extracted with ethyl acetate. Crude extracts were used for bioassays. 
Moreover, for optimal growth determination, these three strains were incubated under the same 
parameters as above for 7 d and 10 d in 100 ml bottle with AT medium. Extraction, HPLC analysis, 
and bioassay tests were performed by the same methods as previous described (paragraph 2.4, on page 
33). 
Table 2-11. Growth conditions of strains 120/1, 151, and 182. 
Parameters Values 
Incubation time 7 d 
Basic medium AT 
Volum of medium 500 ml 
Inoculation percentage 1% 
Light intensity 1000 lux 
Temperature 28°C 
 
2.5.2 Scale up of cultivation of Rubrivivax gelatinosus strain 151 and fractionation the 
crude extract by semi-preparative HPLC 
Rubrivivax gelatinosus 151 was chosen for 20 L scale up approach because the HPLC results showed 
that there were interesting compounds at Rt 5.0 to Rt 6.5 min. Extraction, HPLC analysis, and semi-
preparative HPLC were performed by the same methods as previous used for A. vinosum strain MT86 
(paragraph 2.4, on page 33). 
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2.6 Molecular screening 
Molecular screening contains the DNA extraction, PCR amplification, sequencing and BLASTn 
analysis of selected phototrophic bacteria. For whole genome sequences analysis, antiSMASH was 
used for secondary metabolites screening. 
2.6.1 DNA extraction 
The DNA extraction of strains was performed by two different kits, Biofilm
®
 DNA Isolation Kit was 
used for fresh culture samples and DNeasy
®
 Blood & Tissue Kit was used for both fresh culture 
samples and frozen samples (stored at -20°C) as recommended by the manufacture. 
2.6.2 PCR and sequencing 
PCR amplification of the 16S rRNA, pks I, pks II, nrps and phzE genes were performed using 
modified primer sets based on primers previously published. The primer sequences are seen in Table 
2-12. 
16S rRNA gene sequences were amplified using the primers 27F and 1492R PCR and amplificates 
were sequenced with the primers 342f, 790f and 543r. The 16S rRNA gene sequence was submitted to 
the GenBank database for BLASTn similarity analysis. Sequencing of the pks I, pks II, nrps, and phzE 
gene fragments were assembled by using their pairs of PCR primers, respectively. Amplification of 
pks I, pks II, nrps, and phzE were used to screen the potential of secondary metabolite biosynthesis on 
the molecular level. The PCR systems and programs are shown in Table 2-13, Table 2-14, Table 2-15, 
Table 2-16, and Table 2-17.  
 
MATERIALS AND METHODS 
 
 
 
43 
Table 2-12. Primers used in this study. 
Primers Sequence 
Expected fragment 
length 
References 
16S rRNA 27F 5’- AGAGTTTGATCMTGGCTCAG-3’ 1500 nt Brosius et al. (1978) 
1492R 5’- TACGGYTACCTTGTTACGACTT-3’ Suzuki and Giovannoni (1996) 
342f 5’-TACGGGAGGCAGCAG-3’ Stackebrandt and Goodfellow (1991)  
790 f 5’-GATACCCTGGTAGTCC-3’ Muyzer et al. (1993) 
543 r 5’-ATTACCGCGGCTGCTGG-3’ Muyzer et al. (1993) 
pks I K1F 5´TSAAGTCSAACATCGGBCA3´ 
1200-1400 nt Ayuso-Sacido and Genilloud (2005) 
M6R 5´CGCAGGTTSCSGTACCAGTA3´ 
pks II 945f 5´TSG CST GCT TCG AYG SA TC3´ 
600-613 nt Metsä-Ketelä et al. (1999) 
945r 5´TGG AAN CCG CCG AAB CCG CT3´ 
nrps A2f 5´AAG GCN GGC GSB GCS TAY STG CC 3´ 
300 nt Doekel and Marahiel (2001) 
A3r 5´TTG GGB IKB CCG GTS GIN CCS GAG GTG 3´ 
phzE phzEf 5´-GAAGGCGCCAACTTCGTYATCAA-3´ 
450 nt Schneemann et al. (2011) 
phzEr 5´-GCCYTCGATGAAGTACTCGGTGTG-3´ 
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Table 2-13. PCR system of 16S rRNA and program. 
PCR system (25 µl) PCR Program 
ddH2O 3.0 µl 95°C 5 min 
27F (10 pmol/µl) 1.0 µl 95°C 30 sec 
1492R (10 pmol/µl) 1.0 µl 55°C 2 min 
2 × DreamTaq Green Mastermix 12.5 µl 72°C 4 min         to 2) 35× 
DMSO 2.5 µl 72°C 10 min 
Template 5.0 µl 10°C ∞ 
Negative control was 5.0 µl ddH2O as template. 
 
Table 2-14. PCR system of pks I and program. 
PCR system (25 µl) PCR Program 
ddH2O 3.0 µl 95°C 5 min 
K1F (10 pmol/µl) 1.0 µl 95°C 30 sec 
M6R (10 pmol/µl) 1.0 µl 55°C 2 min 
2 × DreamTaq Green Mastermix 12.5 µl 72°C 4 min         to 2) 35× 
DMSO 2.5 µl 72°C 10 min 
Template 5.0 µl 10°C ∞ 
Positive control for pks I was 1.5 µl Streptomyces clavuligerus DSM 738 and 3.5 µl ddH2O, and negative 
control was 5.0 µl ddH2O as template. 
 
Table 2-15. PCR system of pks II and program. 
PCR system (25 µl) PCR Program 
ddH2O 3.0 µl 95°C 5 min 
945f (50 pmol/µl) 1.0 µl 95°C 30 sec 
945r (50 pmol/µl) 1.0 µl 55°C 2 min 
2 × DreamTaq Green Mastermix 12.5 µl 72°C 4 min        to 2) 35× 
DMSO 2.5 µl 72°C 10 min 
Template 5.0 µl 10°C ∞ 
Positive control for pks II was 5 µl Streptomyces achromogenes DSM 40789, and negative control was 5.0 µl 
ddH2O as template. 
 
Table 2-16. PCR system of nrps and program. 
PCR system (25 µl) PCR Program 
ddH2O 5.5 µl 95°C 2 min 
A2f (10 pmol/µl) 1.0 µl 95°C 1 min 
A3r (10 pmol/µl) 1.0 µl 68°C 1 min 
2 × DreamTaq Green Mastermix 12.5 µl 72°C 2 min         to 2) 39× 
Template 5.0 µl 72°C 7 min 
  10°C ∞ 
Positive control for nrps was 1.5 µl Pseudomonas sp. DSM 50117 and 3.5 µl ddH2O, and negative control was 
5.0 µl ddH2O as template. 
 
Table 2-17. PCR system of phzE and program. 
PCR system (25 µl) PCR Program 
ddH2O 5.5 µl 95°C 2 min 
phzE f (10 pmol/µl) 1.0 µl 95°C 1 min 
phzE r (10 pmol/µl) 1.0 µl 68°C 1 min 
2 × DreamTaq Green Mastermix 12.5 µl 72°C 2 min         to 2) 39× 
Template 5.0 µl 72°C 7 min 
  10°C ∞ 
Positive control for phzE was 1.5 µl Pseudomonas sp. DSM 50117 and 3.5 µl ddH2O, and negative control was 
5.0 µl ddH2O as template. 
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2.6.3 Gel electrophoresis 
1.0% 1×TBE agarose gel (1.0 g agarose dissolved in 100 ml TBE solution with SYBR
®
 safe staining 
for pks I, pks II, and phzE, GelGreen
TM
 staining for nrps) was prepared and the gel electrophoresis was 
performed at 130 V for 30 min for detection or 80 min for gel purification. The ingredients of 1 × TBE 
solution (pH 8.0) were 121.14 g Tris, 51.32 g boric acid, and 3.72 g EDTA. 
The marker for pks I, and pks II was 8 µl Marker X and for nrps was 3 µl GeneRuler
TM
 100 bp DNA 
Ladder Plus. Both markers were used for phzE. 
2.6.4 Purification 
The DNA bands of the PCR amplification were cut from the TBE agarose gel and purified using 
UltraClean
®
 15 DNA Purification Kit (extracting DNA from a TBE agarose gel) according to the 
manufacture. 
2.6.5 BLASTn analyses 
Sequencing was performed at the Institut für Klinische Molekularbiologie (Christian-Albrechts 
University of Kiel) using the BigDye Terminator v1.1 Sequencing Kit (Applied Biosystems, USA) in a 
3730-DNA-Analyzer (Applied Biosystems, USA) as specified by the manufacturer. Sequences were 
edited by ChromasPro (ChromasPro version 1.7.6, 2012, Technelysium Pty Ltd, South Brisbane, 
Queensland, Australia), and deposited in the NCBI database for BLASTn research 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC
=blasthome).  
Isolates were identified using 16S rRNA gene sequencing combined with BLASTn analysis. The 
established pks I, pks II, nrps, and phzE sequences were deposited in NCBI databases and used for 
BLASTn analyses with available genome information on secondary metabolite biosynthesis genes. 
2.7 Genome evaluation of phototrophic bacteria from databases 
As far as known, phototrophic bacteria were not paid much attention in secondary metabolites research. 
Except the traditional natural compounds screening and isolation, the completely genome-based 
molecular screening was a useful way to predetermine the potential of bioactive compounds of these 
bacteria. Completed sequences or accession numbers were obtained from GenBank databases (ftp site 
or Genome searching). Automated gene prediction and functional annotation was performed by 
antiSMASH for detecting biosynthetic clusters of secondary metabolites in the genomes of 
phototrophic bacteria. 
A complete overview of all available genome sequence from the phototrophic bacteria can be seen in 
Table 2-18. 
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Table 2-18. Overview of 62 genera belonging to anerobic  
anoxygenic phototrophic bacteria, genome sequences are available of taxa in bold. 
Class Order Family Abb. Genus * 
Gamma-
proteobacteria 
(phototrophic 
purple sulfur 
bacteria, PSB) 
Chromatiales Chromatiaceae 
 
Chr Chromatium  
Alc Allochromatium 1 
Hch Halochromatium  
Isc Isochromatium  
Lpb Lamprobacter  
Lpc Lamprocystis (previous 
name Pfennigia) 
 
Mch Marichromatium 1 
Rbc Rhabdochromatium***  
Tch Thermochromatium  
Tac Thioalkalicoccus  
Tca Thiocapsa  
Tco Thiococcus  
Tcs Thiocystis 1 
Tdc Thiodictyon  
Tfc Thioflavicoccus 1 
Thc Thiohalocapsa  
Tlp Thiolamprovum  
Tpd Thiopedia  
Trc Thiorhodococcus  
Trv Thiorhodovibrio  
Tsp Thiospirillum  
Tba Thiobaca***  
Tpc Thiophaeococcus***  
Ectothiorhodospiraceae 
 
Ect Ectothiorhodospira  
Hlr Halorhodospira 1 
Trs Thiorhodospira  
Alpha-
proteobacteria 
 
(purple 
nonsulfur 
bacteria, PNSB) 
I. Rhodospirillales I. Rhodospirillaceae Rsp I. Rhodospirillum 4 
Phs V. Phaeospirillum  
Rcs VI. Rhodocista  
Rsa VII. Rhodospira  
Rhv VIII. Rhodovibrio  
Ros IX. Roseospira  
Rss X. Roseospirillum  
II. Acetobacteraceae Rpi XI. Rhodopila  
III. 
Rhodobacterales 
I. Rhodobacteraceae Rba I. Rhodobacter 5 
Rbc XIII. Rhodobaca  
Rvu XIV. Rhodovulum  
Rts XXVI. Rhodothalassium  
VI. Rhizobiales X. Rhodobiaceae Rbi I. Rhodobium  
VIII. 
Hyphomicrobiaceae 
Blc VII. Blastochloris  
Rmi XVI. Rhodomicrobium 1 
Rpl XVII. Rhodoplanes  
VII. Bradyrhizobiaceae Rbl VIII. Rhodoblastus  
Rps IX. 
Rhodopseudomonas 
7 
Beta- I. Burkholderiales IV. Comamonadaceae Rfx IX. Rhodoferax  
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proteobacteria 
(purple 
nonsulfur 
bacteria, PNSB) 
Rvi XV. Rubrivivax 1 
VI. Rhodocyclales I. Rhodocyclaceae Rcy I. Rhodocyclus 
 
Green sulfur 
bacteria (GSB) 
Phylum: Chlorobi 
Class I: Chlorobia 
Subclass I: 
Order I: Chlorobiales 
Family I: Chlorobiaceae 
Green Sulfur Bacteria 
Chl I. Chlorobium 7 
Anc II. Ancalochloris  
Chp III. Chloroherpeton 1 
Pld IV. Pelodictyon**    1 
Ptc V. Prosthecochloris 1 
Cba Chlorobaculum***  1 
Green nonsulfur 
bacteria (GNSB) 
(Filamentous 
anoxygenic 
phototrophic 
bacteria) 
Phylum: Chloroflexi 
Class I: Chloroflexi 
Order I: Chloroflexales 
Family I: Chloroflexaceae 
 
Cfl Chloroflexus 3 
Cln Chloronema   
Htr Heliothrix  
Osc Oscillochloris  
Rof Roseiflexus  2 
Heliobacteria 
 
Phylum: Firmicutes 
Class I: Clostridia 
Order I: Clostridiales 
Family VI: Heliobacteriaceae 
Hbt Heliobacterium 1 
Hba Heliobacillus  
Hph Heliophilum   
Hrs Heliorestis  
Sum    62/18 32 
*: Number of strains which genome sequence available; 
**: There are two species of Pelodictyon, and one of them has changed the name to Chlorobium luteolum 
DSM 273; 
***: The strains are new ones after Bergey’s Manual of Systematic Bacteriology (2nd Edition). 
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Total 62 genera were known belonging to anaerobic anoxygenic phototrophic bacteria (Table 2-18), 
including purple sulfur bacteria (PSB), purple nonsulfur bacteria (PNSB), green sulfur bacteria (GSB), 
green nonsulfur bacteria (GNSB), and heliobacteria. Number of species for a genus ranged from one to 
eight. Among them, there are 32 genome sequences available for 18 genera. 
18 specific species for which a genome sequence was available were summarized in Table 2-19. Those 
whole genome sequences or NCBI reference accession numbers were uploaded to online antiSMASH 
for secondary metabolites prediction screening. The results were collected and analyzed compare with 
the PCR amplification of ten strains’ pks I, pks II, nrps, and phzE results. 
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Table 2-19. Summarized overview of the strains which genome sequences were available. 
Class Order Family Genera Species Submitter BioProject 
Length 
(Mb) 
Acc.-No. 
Gamma-
proteobacteria 
(phototrophic 
purple sulfur 
bacteria, PSB) 
  
  
  
  
  
Chromatiales Chromatiaceae Allochromatium A.vinosum DSM 180
T
 JGI PRJNA46083 3.53 NC_013851.1 
Marichromatium M. purpuratum 984 JGI PRJNA72575 
PRJNA224116 
PRJNA62513 
3.78 
NZ_CP00703
1.1 
Thiocystis T. biolascens  
DSM 198 
JGI PRJNA74025 
PRJNA60641 
5.02 NC_018012.1 
Thioflavicoccus T. mobilis 8321 JGI PRJNA184343 
PRJNA60883 
4.05 NC_019940.1 
Ectothiorhodo-
spiracea 
Halorhodospira H. halophile SL1 JGI PRJNA58473, 
PRJNA15767 
2.68 NC_008789.1 
Alphaproteobaceria 
(purple nonsulfur 
bacteria, PNSB) 
Rhodospirillales Rhodospirill-
aceae 
Rhodospirillum R. centenum SW TGen PRJNA58805 
PRJNA18307 
4.36 NC_011420.2 
R. rubrum ATCC11170 JGI PRJNA57655 
PRJNA58 
4.35 NC_007643.1 
R. photometricum 
DSM122 
CNRS PRJEA81611, 
159003 
3.88 NC_017059.1 
R. rubrum F11 Gonzaga 
University  
PRJNA162149 
PRJNA67413 
4.35 NC_017584.1 
Rhodobacterales Rhodobacter-
aceae 
Rhodobacter R. capsulatus SB1003 University 
Chicago 
PRJNA47509, 
PRJNA55 
3.74 NC_014034.1 
R. sphaeroides 2.4.1 JGI PRJNA57653, 
PRJNA56 
3.19 NC_007493.2 
R. sphaeroides ATCC 
17025 
JGI PRJNA58451, 
PRJNA15755 
3.22 NC_009428.1 
R. sphaeroides ATCC 
17029 
JGI PRJNA58449, 
PRJNA15754 
3.15 NC_009049.1 
R. sphaeroides KD131 GenoTech 
corp. 
PRJNA59277, 
PRJNA31111 
 NC_011960.1 
Rhizobiales Hyphomicrobi
-aceae 
Rhodomicrobium R. vannielii ATCC 
17100 
JGI PRJNA38253, 
43247 
4.01 NC_014664.1 
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Bradyrhizobi-
aceae 
Rhodopseudo-
monas 
R. palustris CGA009 JGI PRJNA62901 
PRJNA57 
5.46 NC_005296.1 
R. palustris DX-1 JGI PRJNA43327, 
PRJNA38503 
5.4 NC_014834.1 
R. palustris HaA2 JGI PRJNA58439, 
PRJNA15747 
5.33 NC_007778.1 
R. palustris BisB5 JGI PRJNA58441, 
PRJNA15749 
4.89 NC_007958.1 
R. palustris BisB18 JGI PRJNA58443, 
PRJNA15750 
5.51 NC_007925.1 
R. palustris BisA53 JGI.  PRJNA58445, 
PRJNA15751 
5.51 NC_008435.1 
R. palustris TIE-1 JGI  PRJNA58995, 
PRJNA20167 
5.74 NC_011004.1 
Betaproteobacteria 
(purple nonsulfur 
bacteria, PNSB) 
Burkholderiales Comamonad-
aceae 
Rubrivivax R. gelatinosus IL144 NITE  
PRJNA158163, 
PRJNA62703 
5.04 NC_017075.1 
Green sulfur 
bacteria (GSB) 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Chlorobiales  Chlorobiaceae Chlorobium C. phaeovibrioides  
DSM 265 
JGI PRJNA12607 
PRJNA58129 
1.97 NC_009337.1 
C. phaeobacteroides 
DSM 266 
JGI PRJNA58133, 
PRJNA12609 
3.13 NC_008639.1 
C. limicola DSM 245 JGI PRJNA12606, 
58127 
2.76 NC_010803.1 
C. tepidum TLS TIGR PRJNA57897, 
PRJNA302 
2.15 NC_002932.3 
C. chlorochromatii 
CaD3 
JGI PRJNA13921, 
58375 
2.57 NC_007514.1 
C. luteolum DSM 273 JGI PRJNA13012, 
58175 
2.36 NC_007512.1 
C. phaeobacteroides 
BS1 
JGI PRJNA58131, 
PRJNA12608 
2.74 NC_010831.1 
Pelodictyon   P. phaeoclathratiforme 
BU-1 
JGI PRJNA13011, 
58173 
3.02 NC_011060.1 
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  Prosthecochloris P. aestuarii DSM 271 JGI PRJNA12749, 
58151 
2.51 NC_011059.1 
Chloroherpeton C. thalassium 
ATCC35110 
JGI PRJNA29215, 
59187 
3.29 NC_011026.1 
Chlorobaculum C. parvum NCIB 8327 JGI  PRJNA29213, 
59185 
2.29 NC_011027.1 
Chloroflexus C.aggregans DSM 9485 JGI PRJNA16708, 
58621 
4.68 NC_011831.1 
Chloroflexus. sp.  
Y-400-fl 
JGI PRJNA59085, 
PRJNA21119 
5.27 NC_012032.1 
C. aurantiacus J-10-f1 JGI PRJNA57657 
PRJNA59 
5.26 NC_010175.1 
Green nonsulfur 
bacteria (GNSB) 
Chloroflexales  
 
Chloroflex-
aceae 
Roseiflexus  R. castenholzii  
DSM 13941  
JGI  PRJNA13462, 
58287 
5.72 NC_009767.1 
Roseiflexus RS-1  JGI PRJNA58523, 
PRJNA16190 
5.8 NC_009523.1 
heliobacteria Clostridiales 
 
Heliobacteri-
aceae 
Heliobacterium H. modesticaldum Ice1 Arizona 
State 
University 
PRJNA13427, 
58279 
3.08 NC_010337.2 
NITE: National Institute of Technology and Evaluation; JGI: DOE Joint Genome Institute 
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3 RESULTS 
3.1 First screening of A. vinosum strain MT86 
According to the previous experiments from Dr. Marcus Tank, Pf medium without salt solution was 
used for cultivation of A. vinosum MT86 at 1000 lux and 28°C for 10-17 days. A total of 30 L of 
cultures were grown in 1 L bottles (three times of 10 L). The cultures were extracted (10 L each in 1
st
, 
2
nd
 and 3
rd
 extraction) for screening of secondary metabolites from A. vinosum MT86 and the 
combined 2
nd
 & 3
rd
 extracts were analyzed (see paragraph 2.4, on page 33). 
Single cells of A. vinosum strain MT86 were colorless, but the color of growing culture was firstly 
pink to dark red (Figure 3-1). The microscopic observation showed that cells were rod shaped, 2 × 2.5-
6 µm and occasionally longer. Globules of S
0
 were evenly distributed within some of the cells, and 
some cells were motile and dividing. 
 
Figure 3-1. Cultures and microscopic observation of A. vinosum strain MT86. 
 
3.1.1 Metabolite profiles of A. vinosum MT86  
The ethyl acetate extracted supernatant extract and methanol extracted cell extract were used for 
analytical HPLC analysis. 
The amount of all extracts was shown in Table 3-1 and their color was shown in Figure 3-3. The 
results of HPLC analyses were shown in Figure 3-2. The extraction results of the second 10 L culture 
showed the lowest amount of wet cells but highest amount of dried supernatant (64 mg). All three 
extraction of the culture supernatant yielded a total of 110 mg dried extract, which were used for 
fractionation of the components. The 1
st
 supernatant extract was further fractionated by the semi-
preparative HPLC by per minute and the combined 2
nd
 and 3
rd
 supernatant extracts were fractionated 
manually by semi-preparative HPLC by using the UV absorption to separately fractionate peaks. The 
HPLC-DAD/MS chromatograms and colors of supernatant extract and cell extract are shown in Table 
3-1 and Figure 3-2.  
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Table 3-1. The amounts of extracts of A. vinosum MT86. 
 1
st
 (10 L) 2
nd
 (10 L) 3
rd
 (10 L) 
Incubation time 14 d 16 d 17 d 
Wet cells 28.218 g 23.296 g 25.919 g 
Dried supernatant extract 27 mg 64 mg 18.7 mg 
Dried cell extract 4.973 g 6.402 g 7.8313 g 
 
 
 
 
 
Figure 3-2. HPLC chromatograms of three extractions of A. vinosum MT86. 
 
In extracts from the culture supernatants, 8 to 11 UV absorption peaks can be seen, and the UV 
absorptions between Rt 2-3 min looked identical. The methanolic cell extracts showed dark green 
color due to the presence of large amounts of pigments and this also can be seen in the HPLC-
DAD/MS chromatograms (after Rt 4 min). The chromatograms showed several pigments of UV 
absorption at 300-500 nm wavelength after Rt 5.5 min which correspond to the UVmax absorption 
wavelength of bacteriochlorophyll a (375, 590, 805, and 830-911 nm in the whole cells, and 358, 578, 
and 771 nm in acetone extracts) and carotenoids. Because large amount of pigments in the cell extracts, 
no matter which solvents were used for extraction, only analytical HPLC-DAD/MS chromatograms 
were obtained. For the same reason, HPLC separation was made only with extracts of the culture 
supernatants in the following. 
 
Figure 3-3. The color of extracts from culture supernatant and cell extracts of A. vinosum MT86. 
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3.1.2 Fractionation of supernatant extracts by semi-preparative HPLC 
The 1
st
 10 L extract was fractionated by per minute. The whole duration of the preparation was 24 
minutes and 24 fractions were achieved technically. For the operation reason, the first two fractions 
were combined automatically, thus, 23 fractions were obtained for further analysis. There was no or 
very weak UV absorption of the 23 fractions according to the analytical HPLC chromatograms (data 
are not shown). 
The extract of 20 L supernatant culture (2
nd
 & 3
rd
 extract) was fractionated by per UV absorption and 
10 fractions were obtained, named P1 to P10 (0.3 mg of P1, 0.7 mg of P2, 0.2 mg of P3, 0.6 mg of P4, 
1.0 mg of P5, 0.6 mg of P6, 0.5 mg of P7, 0.2 mg of P8, and 0.2 mg of P10). Semi-preparative HPLC 
chromatogram of crude supernatant extract is shown in Figure 3-4. Analytical HPLC-DAD/MS 
chromatograms of each fraction (data are not shown) showed that fraction P9 was not pure. There were 
at least three UV peaks which were not easily separated and the amount was not enough for a second 
fractionation. Except fractions P9 (not pure) and P5 (one main absorption and another weak one), there 
was only one main UV absorption of other eight fractions. 
 
Figure 3-4. The semi-preparative HPLC chromatogram of  
crude supernatant extract of 2
nd
 & 3
rd
 combined 20 L culture. 
 
3.1.3 NMR analysis of the fractions from the 20 L supernatant extract 
Although fractions P1, P3, P8 and P10 were pure according to analytical HPLC-DAD/MS 
chromatograms and were used for 
1
H NMR analysis, not sufficient material was available for further 
studies (
13
C NMR etc.). Information of these four fractions is shown in Table 3-2. P10 was the most 
interesting fraction after comparison with databases and used for further NMR experiments such as 
13
C 
NMR, 
1
H-
1
H COSY and HSQC (NMR chromatograms are identical to those of F13 and are not 
shown). Due to the limited amount of the purified substance, more supernatant extract was necessary 
for metabolites analysis. 
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Table 3-2. NMR experiments of four fractions isolated from 20 L supernatant extract of A. vinosum MT86. 
Peak No. Amount m/z Dissolve solvent 
1
H-NMR 
1
H-COSY 
13
C-HSQC 
P1 0.3 mg 243, 279 MeOD × / / 
P3 0.2 mg 152 MeOD × / / 
P8 0.2 mg 182 MeOD × / / 
P10 0.2 mg nd MeOD × × × 
nd: not determined; ×: analysis was performed; /: the amount was not enough and not interesting for further analysis. 
 
3.1.4 Bioactivity of crude supernatant and cell extracts from the 20 L culture  
The results of bioassay tests of controls, supernatant and cell extracts are shown in Table 3-3. The 
different extractions revealed some differences in inhibition of the test strains. In addition to X. 
campestris, the supernatant and cell extracts showed good to moderate activity against B. subtilis, S. 
lentus, and C. albicans, which indicated that bioactive substances exist in the crude extracts. 
For the tests against X. campestris, nearly all the samples showed inhibition, but also Pf medium 
showed 98% inhibition. The basis of inhibition by the medium extract is not known and this extract 
may not represent a good reference point because the inhibitory activity may be consumed by the cells 
during growth and not be present in the culture extract. 
Most of the tests did not show bioactivity, probably because the concentration of substances was too 
low to affect the microorganisms. Production of more biomass was necessary for further tests of 
bioactivity. 
The 23 fractions from the 1
st
 10 L culture supernatant extract were used for bioactivity tests with four 
microorganisms of B. subtilis, S. lentus, X. campestris and C. albicans. All concentrations of the 
assays were too low to be calculated and the fractions showed low or no activities.  
Table 3-3. The results of bioassay tests of controls, supernatant and cell extracts
*
.  
Extracts 
Inhibition (%) 
Bacillus 
subtilis 
Staphylococcus 
lentus 
Xanthomonas 
campestris 
Candida 
albicans 
1
st
_Supernatant 23 37 90 45 
1
st
_Cell 84 51 95 92 
2
nd
_Supernatant 99 84 83 - 
2
nd
_Cell - - 25 - 
3
rd
_Supernatant - 25 48 - 
3
rd
_Cell 98 - 86 - 
Pf media 67 23 98 - 
*: The bioassay concentration of all extracts was 476 µg/ml. 
Note: The results of the bioassays are defined as follows: ≥ 80% inhibition: very good activity; < 80% and ≥ 60% 
inhibition: moderate activity; < 60% and > 30% inhibition: low activity; ≤ 30% inhibition & -: no activity. 
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Table 3-4. The bioactivity tests of 10 fractions from the 2
nd
 and 3
rd
 supernatant extracts. 
Extract/ 
Fractions 
Concentration
*
 
(µg/ml) 
Inhibition (%) 
Bs Sl Ec MRSA Xc Pa Ca Sep Tru 
20 L-Sup / - - - - - - - - 20 
P1 / - - - - - - - - - 
P2 476 - - - - - - - - - 
P3 762 - - - - - - - - - 
P4 38 - - - - - - - - - 
P5 / - - - - - - - - - 
P6 / 95 82 - 85 93 - 85 92 100 
P7 / - - - - - - - - - 
P8 / - - - - - - - - - 
P9 19.05 - - - - - - - - - 
P10 57.14 89 80 - 80 65 62 - - 31 
1.Bs: Bacillus subtilis, Sl: Staphylococcus lentus, Ec: Escherichia coli, MRSA: methicillin-resistant Staphylococcus 
aureus, Xc: Xanthomonas campestris, Pa: Propionibacterium acnes, Ca: Candida albicans, Sep: Septoria tritici, Tru: 
Trichophyton rubrum; Sup: supernatant; 
2. Note: The results of the bioassays are defined as follows: ≥ 80% inhibition: very good activity; < 80% and ≥ 60% 
inhibition: moderate activity; < 60% and > 30% inhibition: low activity; ≤ 30% inhibition & -: no activity. *: assay 
concentration. 
 
The 10 fractions obtained from the 2
nd
 & 3
rd
 20 L supernatant extracts were used for bioassays with 
nine microorganisms. As shown in Table 3-4, only P6 and P10 indicated bioactivities. In comparison 
with analytical HPLC data and DNP database, P10 appeared of interest because no hits were found in 
databases and the bioactivities showed good results. Only fractions P6 and P10 showed good 
inhibition of several test strains. According to analysis of analytical HPLC chromatograms and NMR 
chromatograms, fraction P10 was almost pure and identified to be a bioactive compound produced by 
A. vinosum strain MT86. 
3.2 Optimization of the growth conditions and culture of 36 L of A. vinosum 
strain MT86.  
During the first screening of A. vinosum strain MT86, methods for preparation and cultivation 
conditions were used according to the Bergey’s Manual of Systematic Bacteriology (Imhoff, 2005a). 
As mentioned above, the optimization of the growth conditions of A. vinosum MT86 for production of 
secondary metabolites was necessary. The components of the medium and incubation parameters were 
modified and the biomass production was analyzed in 100 ml culture bottles. In addition, a scale up to 
36 L cultures in modified Pf medium was performed to obtain more supernatant extract for the 
analysis of bioactive compounds. 
3.2.1 Media for screening of optimal cultivation conditions 
A. vinosum MT86 was grown in six different media (paragraph 2.3.2, on page 31) in order to achieve 
the best conditions for the production of metabolites. 
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The amounts of extracts of six different media and four controls of Pf media are shown in Table 3-5. 
Accordingly, the highest amounts of wet cells (437.2 mg and 406.8 mg) were obtained from Pf 
medium No. 2 and 4 (Pf medium with thiosulfate and acetate), compared to less than 300 mg with 
other media. The amounts of dried supernatants were within a range from 2 to 7 mg in different media. 
Pf media with thiosulfate and/or acetate were extracted much more than Pf medium without 
supplements. 
The photos (Figure 3-5) of the cultures and extracts of A. vinosum MT86 indicate that the best growth 
and the most intensively colored extracts were obtained in Pf medium with thiosulfate and acetate. The 
color of the cultures (and thereby the pigments content) can be used as an indicator for growth of A. 
vinosum MT86. The lack of obvious difference in the content of dried extracts could be due to the 
small volume (100 ml) used.  
The HPLC-DAD/MS chromatograms of the extracts are shown in Figure 3-6 and Figure 3-7. The 
extract of the culture supernatant using Pf medium with MgCl2 showed the highest number of peaks 
according to UV absorption. This indicated that production of secondary metabolites in Pf medium 
with MgCl2 is better than with MgSO4. Considering that cultures with Pf media containing thiosulfate 
and acetate are easier to handle, because feeding with sulfide solution is not necessary. Thus, Pf 
medium with MgCl2, thiosulfate and acetate was considered as the best condition for cultivation of A. 
vinosum MT86. 
 
Figure 3-5. Photos of cultures and extracts of A. vinosum MT86 in different media. 
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Table 3-5. Extraction of A. vinosum MT86 in 6 different modifications and 4 controls of Pf media. 
 1 2 3 4 5 6 CK CK CK CK 
Medium Pf (MgSO4) 
Thiosulfate 
Pf (MgSO4) 
Thiosulfate 
Acetate 
Pf (MgCl2) 
Thiosulfate 
Pf (MgCl2) 
Thiosulfate 
Acetate 
Pf 
(MgSO4)* 
Pf 
(MgCl2)* 
Pf 
(MgSO4) 
Pf 
(MgCl2) 
Pf(MgCl2) 
no Sulfide 
Pf(MgCl2) 
no Sulfide 
Volume 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 1 L 
Incubation time 10 days 10 days 10 days 10 days *10 days *10 days / / / / 
Wet Cell 258.2 mg 437.2 mg 271.5 mg 406.8 mg 289 mg 243 mg / / / / 
Dried Cell 7 mg 6 mg 7 mg 5 mg 5 mg 6 mg / / / / 
Dried supernatant 7 mg 7 mg 5 mg 4 mg 2 mg 2 mg - - - - 
Volume of MeOH 2 ml 2 ml 2 ml 2 ml 2 ml 2 ml 2 ml 2 ml 2 ml 2 ml 
*Addition of 1 % sulfide solution every 2 days.  
All cultures grown at 28°C, 500 lux in Pf medium 
/ : no results 
-: amount is too low to calculate 
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Figure 3-6. HPLC chromatograms of six different supernatant extracts. 
 
 
 
Figure 3-7. HPLC chromatograms of six different cell extracts. 
 
 
MT86_Cell_SO4
MT86_Cell_ST
MT86_Cell_STA
MT86_Cell_Cl
MT86_Cell_ClT
MT86_Cell_ClTA
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Table 3-6. Bioassay tests with extracts of A. vinosum MT86 grown in 100 ml flasks in 6 different media. 
Crude extracts 
Concentration
*
 
(µg/ml) 
Inhibition (%) 
Bs Sl Ec MRSA Xc Pa Ca Sep Tru 
MT86-Sup-MgSO4 476 35 - - 63 - - - - - 
MT86-Sup-ST    455 - - - 69 - - - - 23 
MT86-Sup-STA    476 - - - - - - - - - 
MT86-Sup-MgCl2 476 - - - - - - - - - 
MT86-Sup-ClT 455 22 - - - - - - - - 
MT86-Sup-ClTA 452 - - - - - - - - - 
MT86-Cell-MgSO4     476 - - - - - - - - 29 
MT86-Cell-ST     476 74 - - - - - - 22 89 
MT86-Cell-STA    476 68 - - - - - - - 97 
MT86-Cell-MgCl2  476 74 - - - - - - 32 96 
MT86-Cell-ClT 476 68 - - - - - - - 100 
MT86-Cell-ClTA 476 66 - - - - - 21 - 99 
Pf-100ml-MgSO4  433 33 - - - 49 - - 96 90 
Pf-100ml-MgCl2 476 40 - - 25 45 - - 100 100 
Pf-1L-no sulfide 476 31 - - 31 74 - - - 79 
1. Bs: Bacillus subtilis, Sl: Staphylococcus lentus, Ec: Escherichia coli, MRSA: methicillin-resistant Staphylococcus aureus, 
Xc: Xanthomonas campestris, Pa:Propionibacterium acnes, Ca: Candida albicans, Sep: Septoria tritici, Tru: Trichophyton 
rubrum; 
2. -Sup: Crude medium extract from A. vinosum MT86 culture which was incubated with Pf medium (MgSO4); -Cell: Crude 
cell extract from MT86 which was incubated with Pf medium (MgSO4); -MgSO4: Pf (MgSO4); -ST: Pf (MgSO4) + 
Thiosulfide; -STA: Pf (MgSO4) + Thiosulfide + Acetate; -MgCl2: Pf (MgCl2); -ClT: Pf (MgCl2) + Thiosulfide; -ClTA: Pf 
(MgCl2) + Thiosulfide+Acetate; 
3. Note: The results of the bioassays are defined as follows: ≥ 80% inhibition: very good activity; < 80% and ≥ 60% 
inhibition: moderate activity; < 60% and > 30% inhibition: low activity; ≤ 30% inhibition &-: no activity. *: assay 
concentration. 
 
All supernatant and cell extracts were tested for bioactivity with nine test microorganisms. Some of the 
test strains, for example Bacillus, Trichophyton and Xanthomonas, are more sensitive to compounds 
than others are. The results are seen in Table 3-6. Bioactive tests with extracts of uninoculated Pf 
media with MgSO4, MgCl2 and without sulfide to X. campestris showed low and moderate activity 
(49%, 45%, and 74%), and high inhibition to S. tritici (96%, 100% in the presence of sulfide) and T. 
rubrum (90%, 100%, and 79%), respectively. There is no explanation for this inhibition and the 
sensitivity of these strains to extracts of the Pf medium itself. 
It was interesting that five cell extracts showed moderate activity (< 80% and ≥ 60% inhibition), but 
all six supernatant extracts showed no inhibition to T. rubrum, whereas the uninoculated medium 
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extracts did. A reason for this effect could be that the strain used the inhibitory components of the Pf 
medium, but the cells apparently did not secrete bioactive metabolites. 
In the bioassay tests to B. subtilis, five cell extracts showed moderate activity (< 80% and ≥ 60% 
inhibition) while supernatant extracts of all cultures showed no inhibition of B. subtilis. Apparently, no 
or only low amount of secondary metabolites are produced under the tested conditions/media. 
From this comparison of six different Pf media, the modification shown in Table 3-7 was chosen for 
the following studies on metabolite production by A. vinosum MT86.  
Table 3-7. Basic Pf medium for A. vinosum strain MT86. 
Ingredients 5 L 
H2O 4900 ml 
KH2PO4 1.70 g 
NHCl4 1.70 g 
MgCl2ˑ6H2O 2.05 g 
CaCl2ˑ2H2O 1.25 g 
KCl 1.70 g 
Thiosulfate 5.0 g 
NH4ˑAcetate 6.25 g 
MgˑAcetate 6.25 g 
Additional solutions for 5 L Pf medium: 
B12: 5 ml, SLA: 5 ml, NaHCO3: 7.5 g /100 ml, Na2S: 2.0 g/20 ml 
 
3.2.2 Scale up to a 36 L volume culture of A. vinosum MT86 
In order to obtain sufficient supernatant extract for tests and structure elucidation of bioactive 
compounds from A. vinosum strain MT86, a total of 36 L culture was grown in this modification of Pf 
medium (Table 3-7). 
3.2.2.1 Cultivation, Extraction and HPLC-DAD/MS analysis 
After 11 days of incubation, the 36 L culture broth was extracted. The amount of extracts is shown in 
Table 3-8. The HPLC-DAD/MS chromatogram showed at least 11 UV absorption peaks (data are not 
shown). 
Table 3-8. The amount of extract from a 36 L culture of A. vinosum strain MT86. 
 4
th
 (36L) 
Incubation time 11 d 
Wet Cell deposit 124.0549 g 
Dried supernatant extract 283 mg 
The amount of the dried cell extract could not be determined, because it could not be completely dried. 
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3.2.2.2 Fractionation by semi-preparative HPLC of the 36 L crude supernatant extract 
After the supernatant extract was concentrated to 100 mg/ml, semi-preparative HPLC was used for 
fractionation following the UV absorption. Finally, 17 fractions (named F1-F17, Figure 3-8) were 
obtained. 
 
Figure 3-8. Semi-preparative HPLC chromatogram of  
supernatant extract of 36 L culture broth of A. vinosum strain MT86. 
 
These fractions were evaporated to dry and dissolved in MeOH to a concentration of 1 mg/ml. 
Analytical HPLC-DAD/MS was performed to check the purity and determine m/z of each fraction 
(data are not shown). 
3.2.2.3 NMR analysis and TOF-MS analysis 
From the analytical HPLC-DAD/MS analysis (data are not shown), three (F4, F13, and F15) of 
seventeen fractions were considered as pure compounds and 
1
H NMR analysis was performed with 
these fractions (Table 3-9). With fraction F4, only 
1
H NMR analysis could be made because the 
amount was insufficient for further analysis. Fraction F15 was a pigment and was not of interest for 
bioactive screening. 
Only fraction F13 was pure and available in sufficient amount (1.1 mg) to perform more detailed 
NMR analysis. The HPLC-DAD/MS chromatogram of F13 is seen in Figure 3-9, and 
1
H-NMR, 
1
H-
1
H 
COSY, 
1
H-
13
C HMBC, and 
1
H-
13
C HSQC were identical to those shown in Figure 3-26, Figure 3-28, 
Figure 3-29 and Figure 3-30. 
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Table 3-9. NMR analysis of compounds from 36 L supernatant extract. 
No. Amount 
Dissolve 
solvent 
1
H-NMR 
1
H-
1
H COSY 
1
H-
13
C 
HSQC 
1
H-
13
C 
HMBC 
F4 0.4 mg MeOD ×    
F13 1.1 mg MeOD × × × × 
F15 2.8 mg MeOD ×    
×: analysis was performed; /: the amount was not enough and not interesting for further analysis. 
 
 
Figure 3-9. HPLC-DAD/MS chromatogram of fraction F13 isolated from A. vinosum MT86. 
 
 
Table 3-10. The cultivation parameters for extraction of compound P10/F13. 
               Parameters 20 L 36 L 
Medium 
(Pf) 
Salt concentration 0% 0% 
Thiosulfate  0% 1% 
Acetate 0% 1% 
Mg
2+
 MgSO4·7H2O MgCl2·6H2O 
Trace Element solution SL-12 SLA 
Adding sulfide solution 1%, every 2 days / 
Inoculation time in twice (16 d+17 d) in once (11 d) 
Inoculation present (%) 5% 5% 
Light intensity (lux) 1000 1000 
Temperature (°C) 28-30 28-30 
Dried weight of supernatant crude extract 
64 mg+18.7 mg = 
82.7 mg 
283 mg (oil-gel 
like) 
/: not used 
 
From the NMR data together with the analytical HPLC-DAD/MS analysis, compound F13 was the 
same as the previous fraction P10 isolated from 20 L supernatant extract. It was interesting that F13 
and P10 were isolated from different Pf media and incubated under different cultivation conditions 
(Table 3-10). It is concluded that F13 was produced as a secondary metabolite of A. vinosum strain 
Fraction F13_36L Supernatant extract
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MT86 under different conditions and F13 was identical to the P10 from a previous preparation. Later 
in the following, the compound name F13 is used (F13 = P10).  
3.3 Salt tolerance of A. vinosum MT86 
Some strains of Allochromatium originate from marine and brackish water habitats and may tolerate or 
require low concentrations of salt. Therefore, the response of A. vinosum strain MT86 to low salt 
concentrations was tested. As shown in Figure 3-10, strain MT86 in Pf media with different salt 
concentrations grew in different speed as indicated by the color development in the cultures. After 5 
days of cultivation, A. vinosum strain MT86 grew faster in the medium (0%-1.67% salts) than those at 
higher salt concentrations (2.33%-3.33%). Best growth was obtained at up to 1.67% salts. 
 
Figure 3-10. Cultivation of MT86 in of different salt concentrations after 5 days. 
 
The cultures grown at salt concentrations of 0%, 0.33%, 0.67%, 1%, and 1.67% were extracted after 7 
and 10 days. Cultures grown at higher salt concentrations of 2.33%, 2.5%, 2.67%, and 3.33% were 
extracted after 15 and 20 days. 
3.3.1 Comparison of culture broths with 0%, 0.33%, 0.67%, 1%, and 1.67% salts 
The cultures of A. vinosum strain MT86 grown in salt concentrations from 0% to 1.67% salts were 
compared after cultivation times of 7 and 10 days. 
3.3.1.1 Comparison of 7 d’s and 10 d’s crude extracts (0%, 0.33%, 0.67%, 1%, and 1.67% 
salts) 
The HPLC chromatograms of extracts obtained after 7 and 10 days’ incubation are shown in Figure 
3-11 and Figure 3-12. 22 distinct UV absorption peaks were visible and assigned to peak numbers 1 to 
22. Detailed information of UV absorption and m/z or mass analysis is shown in Table 3-11.  
From these HPLC chromatograms, there were all numbers of UV absorption peaks (peak 1 to peak 22) 
in the extract of culture broth grown at 1% salts for 7 days. 
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Figure 3-11. Comparison of chromatograms of extracts from  
A. vinosum strain MT86 grown at salt concentrations from 0-1.67% salts for 7 days. 
 
 
 
Figure 3-12. Comparison of chromatograms of extracts from  
A. vinosum strain MT86 grown at salt concentrations from 0-1.67% salts for 10 days. 
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Table 3-11. UV and m/z information of each peak of extracts from cultures grown for 7 and 10 days. 
Peak 
No. 
Rt/min UV/nm m/z 
7 d 10 d 
0% 1% 2% 3% 5% 0% 1% 2% 3% 5% 
1 1.83 228 183    +   + +   
2 1.99 218 , sh238, 274 196 +  + + + + + + + + 
3 2.40 222, 275 
mass 213 (+Na, +K), 
m/z 402 
   +  +  + + + 
4 2.60 226 /    +   + **   
5 3.39 226 293 + +  +   + + + + 
6 3.49 226 / + + + +   + + + + 
7 3.65 227, 280 297    +   +  + + 
8 3.75 226 /    +   + + + + 
9 3.82 224, 275 /  +  +   + + + + 
10 3.92 229 279  +  +   + + + + 
11 4.05 227 279    +   + + + + 
12 4.15 220, sh228, sh255, 296 279    +  +  + + + 
13 4.30 227 295 + + + + + + + + + + 
14 4.39 227 295 + + + + + + + + + + 
15 4.48 227 / + + + + + + + + + + 
16 4.66 227, 275, 277 279 + + + + + + +    
17 4.85 220, 267, 276 253 + + + + + + + + + + 
18 5.14 227 267   + +    + +  
19 5.53 227 281* + + + + + + + + + + 
20 5.95 227, sh264 
mass: 749/705/ 661/ 617/ 
573/529 
+ + + + +  + + + + 
21 6.27 228 /    + +    +  
22 6.52 228 / +   +       
+: peak presents in this position; Blank: no peak presents /: from the mass chromatography, the intensity is too low to consider and/or there is no accurate m/z 
information; mass: there is no distinct evidence to make sure the m/z, so the mass number is the number which shows directly from mass chromatogram.*: m/z=281, this 
compound always present and is not in consider**: additional peak is in Rt 3.15 min of 10 days, 2% salt concentration, which m/z is 224. 
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3.3.1.2 Comparison of extracts after growth at 1% salts for 7 and 10 days. 
The extract of cultures grown at 1% salts for 7 days showed 22 UV absorption peaks and was used as a 
reference for comparison with the other growth conditions. 
Comparison of the chromatograms showed that peaks 1, 4, 16 and 22 were present after 7 days, but 
disappeared after 10 days of cultivation (Figure 3-13). However, the main peaks (peak 2, 5-21) were 
present under both conditions. In addition, the intensity of peak 2 (Rt 1.99 min, UV 218, sh238, and 
274 nm, m/z 196) was higher in the extract after 10 days. In contrast, the intensity of peak 20 (Rt 5.95 
min, UV 227, sh264 nm, mass 749, 705, 661, 617, 573, and 529) decreased from 7 to 10 days of 
incubation. The extract after 10 days was more interesting in regard to UV absorbing peaks. 
 
Figure 3-13. Comparison of extracts from A. vinosum MT86 grown at 1% salts for 7 and 10 days. 
 
3.3.1.3 Comparison of extracts of cultures grown at 0.67% and 1% salts for 10 days 
Peaks 2, 3, 5-6, and 8-10 were present in extracts of cultures grown at 0.67% and 1% salts (Figure 
3-14). Peak 1 was found in the extract from the culture grown at 0.67% salts only. While peaks 7 and 
21 were found in cultures grown at 1% salts only, an additional peak (peak *, Rt 3.15 min, UV 226 nm, 
m/z 224) was found in the culture grown at 0.67% salts. 
Because m/z 281 (peak 19) was present in all chromatograms, it is considered as a contamination and 
can be ignored. From HPLC chromatograms of extracts from cultures grown for 10 days, peak 20 
showed lower intensity than others did. An additional peak at Rt 3.15 min of extract from culture at 
0.67% salts after 10 days was the only peak presented obviously.  
Incubation of A. vinosum strain MT86 at 0.67% salts concentration after 10 days is the preferred 
cultivation condition if compared with salt concentration up to 1.67% (≤ 1.67%).  
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Figure 3-14. Comparison of extracts from cultures of A. vinosum MT86 grown at 0.67% and 1% salts. 
 
3.3.2 Comparison of culture broths with 2.33%, 2.5%, 2.67%, and 3.33 % salts 
Because the metabolite profiles of cultures grown at salt concentrations of 2.33% and higher were 
clearly different from those grown up to 1.67% salts, different numbers were used for a first 
identification of the peaks. The peaks in these chromatograms were assigned peak numbers 1’ to 18’. 
3.3.2.1 Comparison of crude extracts after 15 and 20 days (with 2.33%, 2.5%, 2.67%, 
and 3.33 % salts) 
The HPLC chromatograms of extracts in total 18 peaks can be pointed out (Figure 3-15, and Figure 3-
16). 
A total of 18 peaks were present in extracts from cultures grown at 2.5% salts for 15 days’ incubation. 
Under these conditions, the intensity of peaks 1’ and 2’ were lower than those in extracts from cultures 
grown at 2.33% salts for 15 days and at 2.67% salts for 15 days. Peaks 6’, 7’ (Rt 4.41 min, UV 227 nm, 
mass 296; same as peak 14), 14’, and 18’ (Rt 5.95min, UV 228 nm, sh262 nm, mass 749/705/ 661/ 
617/ 573/529; same as peak 20) showed highest intensity in the extract from the culture grown at 2.5% 
salts for 15 days. Furthermore, peak 9’ only existed in the extract from the culture at 2.5% salts for 15 
days. 
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Figure 3-15. Comparison of extracts from cultures of A. vinosum MT86  
grown at salt concentrations of 2.33%, 2.5%, 2.67%, and 3.33 % for 15 days. 
 
 
 
 
Figure 3-16. Comparison of extracts from cultures of A. vinosum MT86  
grown at salt concentrations of 2.33%, 2.5%, 2.67%, and 3.33 % for 20 days. 
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Table 3-12. UVmax and m/z information of peaks of extracts from cultures of A. vinosum MT86 grown for 15 and 20 days. 
Peak 
No. 
Rt/min UV/nm m/z 
15 d 20 d 
7% 7.5% 8% 10% 7% 7.5% 10% 
1’ 1.98 220, 261, 348 170 + + + + + + + 
2’ 3.4 225 293 + + + + + + + 
3’ 3.5 227 728  +      
4’ 3.84 227 291  +   +   
5’ 3.94 228 451  +   +   
6’ 4.32 227 mass 296 + + + + + + + 
7’ 4.41 227 mass 296 + + + + + + + 
8’ 4.50 228 610 + + + + + + + 
9’ 4.58 
227, 346, 350, sh410, 
513 
mass 280 + +      
10’ 4.67 227 / + + + + +   
11’ 4.86 221 253 + + + + + +  
12’ 4.93 228 610 + + + + + + + 
13’ 5.01 418 610 + +  + + + + 
14’ 5.06 230 279 + + + + + + + 
15’ 5.23 228, 356, sh388, 526 255 + + + + + + + 
16’ 5.54 227 281 + + + + + + + 
17’ 5.69 413 880 + + + + + +  
18’ 5.95 228, sh262 
mass: 749/705/ 661/ 617/ 
573/529 
+ +  + + +  
+: peak presents in this position; Blank: no peak presents; /: from the mass chromatography, the intensity is too low to consider and/or there is no accurate m/z information; mass: 
there is no distinct evidence to make sure the m/z, so the mass number is the number which shows directly from mass chromatogram. 
 
RESULTS 
 
 
 
71 
3.3.2.2 Comparison of extracts of cultures grown at 2.5% salts for 15 and 20 days. 
Because the extract from the culture grown at 2.5% salts for 15 days showed all 18 UV absorption 
peaks, it was used as a reference HPLC chromatogram for comparison with the other HPLC 
chromatograms of other extracts. The comparison of different time of cultivation was included. 
The comparison of the HPLC chromatograms of extracts is shown in Figure 3-17. Peaks 3’ 4’, 5’, 9’, 
and 10’ disappeared in the extract from the culture grown at 2.5% salts for 20 days if compared with 
the extract for 15 days. Other peaks in the extract from cultures grown at 2.5% salts showed lower 
intensity for 20 days than for 15 days. 
 
Figure 3-17. Comparison of extracts from cultures of  
A. vinosum MT86 grown at 2.5% salts for 15 and 20 days. 
 
During the growth experiments with different salt concentrations, it was shown that A. vinosum strain 
MT86 tolerated higher salt concentrations up to 3.33%, but did grow slowly. Some interesting peaks 
were seen in the chromatograms. According to UV-absorption, cells grown at 2.5 % salts for 15 days 
produced several interesting peaks. Peaks 6’, 7’, 8’ were identical to peaks 13, 14, and 15 of cultures 
grown at 0.67% (10 days). Peaks 9’, 14’, 15’, and 17’ maybe pigments according to the absorption 
wavelength. Peak 18’ had the same Rt as peak 20, but had a different m/z (mass 573 or m/z: 528). 
Extract from culture of strain MT86 grown at 2.5% salts for 15 days were the most interesting. 
 
RESULTS 
 
 
 
72 
3.3.3 Bioactivity tests of crude extracts from controls Pf media and from cultures grown 
at different salt concentrations. 
Bioassays were performed with four test microorganisms and the results are shown in Table 3-13. As a 
control, Pf media with different salt concentrations were extracted with the same method as culture 
broth. Some of the medium extracts showed inhibition of B. subtilis. Culture extracts after 7 days 
grown at 0.33%, 0.67%, and 1% salts showed moderate to high inhibition of B. subtilis. 
Table 3-13. Inhibition of test strains by different extracts of A. vinosum strain MT86. 
Samples 
Concentration* 
(µg/ml) 
Bs MRSA Xc Tru 
Control 
Pf_0% 476  - - - 69 
Pf_0.33% 429 - - - 93 
Pf_0.67% 47.62 85 - - 60 
Pf_1% 476 52 - - 83 
Pf_1.67% 95.24 - - - 78 
Pf_2.33% 429 - - - 74 
Pf_2.5% 476 82 - - 66 
Pf_2.67% 429 - - - 69 
Pf_3.33% 333 23 - - 72 
7 d 
MT86_0% 476 - - - 99 
MT86_0.33% 476 77 - 26 100 
MT86_0.67% 476 96 - 32 100 
MT86_1%  476 100 - 43 100 
MT86_1.67%  476 - - - 100 
10 d 
MT86_0% 476 - - - 69 
MT86_0.33% 476 - - - 100 
MT86_0.67%  476 - - - 91 
MT86_1% 476 - - - 81 
MT86_1.67%  476 - - - 92 
15 d 
MT86_2.33%  476 - 24 - 100 
MT86_2.5%  476 - - - 100 
MT86_2.67%  476 - 33 - 41 
MT86_3.33%  476 - - - 100 
20 d 
MT86_2.33%  476 - - - 100 
MT86_2.5% 476 - - - 100 
MT86_3.33% 476 42 - - 100 
1. Bs: Bacillus subtilis, MRSA: methicillin-resistant Staphylococcus aureus, Xc: Xanthomonas campestris, Tru: 
Trichophyton rubrum; 
2. Note: The results of the bioassays are defined as follows: ≥ 80% inhibition: very good activity; < 80% and ≥ 60% 
inhibition: moderate activity; < 60% and > 30% inhibition: low activity; ≤ 30% inhibition &-: no activity. *: assay 
concentration. 
 
RESULTS 
 
 
 
73 
All extracts including the control Pf medium extracts did not inhibit MRSA but showed moderate to 
high inhibition of the fungus T. rubrum. Extracts from cultures grown at 0.33%, 0.67% and 1% salts 
(for 7 days) showed no or very low inhibition of X. campestris, but moderate (77%) to high (96%, and 
100%) inhibition of B. subtilis. 
3.3.4 Scale up of cultures to a 50 L volume at two salt concentrations 
Pfennig media with 0.67% and 2.5% salts were identified as the best conditions for secondary 
metabolite production of A. vinosum MT86. Therefore, 50 L cultures were grown both at 0.67% salts 
(10 days) and at 2.5% salts (15 days), respectively. The supernatant of both cultures were extracted 
with ethyl acetate (EtOAc) and cell deposits were extracted by MeOH, acetone, and dichloromethane 
for TLC analysis. The incubation parameters of A. vinosum MT86 are shown in Table 3-14. 
Table 3-14. Incubation parameters for scale up experiments. 
Salts 0.67% 2.5% 
Incubation time 10 days 15 days 
Culture volume 50 L 50 L 
Extract volume 45 L 50 L 
Mg
2+
 MgCl2·6H2O 
Thiosulfate & acetate 1% thiosulfate, 1% acetate 
Light intensity 1000 lux 
Temperature 28-30°C 
 
3.3.4.1 Cultures grown at 0.67% salts 
After 10 days’ incubation, 45 L of the cultures (five bottles of media were broken) were extracted. 318 
mg dried supernatant extract was obtained and then dissolved in MeOH. The HPLC chromatogram is 
shown in Figure 3-18. Fractionation was performed by semi-preparative HPLC, and 18 fractions were 
obtained (see in Figure-19). Detailed information on the peaks is contained in Table 3-15. 
 
 
Figure 3-18. HPLC chromatogram of supernatant extract from 
45 L culture of A. vinosum MT86 grown at 0.67% salts for 10 days. 
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Figure 3-19. Semi-preparative HPLC chromatogram of supernatant extract 
from 45 L culture of A. vinosum strain MT86 grown at 0.67% salts. 
 
From the chromatogram of analytical HPLC-DAD/MS and in comparison with the Dictionary of 
Natural Products, seven fractions F3, F4, F5, F6, F11, F13, and F17 were selected for NMR analyses. 
With the exception of F3 (only 
1
H NMR), these fractions were analyzed by 
1
H NMR, 
13
C NMR, 
HMBC, HSQC, DEPT, and NOESY. Fraction F13 was identical to the same compound F13/P10 from 
previous analyses (paragraph 3.1.3 on page 54, and paragraph 3.2.2.3 on page 62) by comparison of 
the UVmax, mass, and NMR data. The analytical HPLC chromatogram of F13 is shown in Figure 3-20. 
. 
 
 
Figure 3-20. HPLC chromatogram of  
compound F13 isolated from 45 L culture grown at 0.67% salts. 
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Table 3-15. Detailed information on fractions of extract from 45 L culture broths of A. vinosum MT86 grown at 0.67% salts. 
Com. 
Weight 
(mg) 
Rt of UVmax 
(min) 
Mass information (Rt/min) 
MW DNP 
HRESIMS 
& Formula 
NMR 
Pos. Neg. 1 H
 
1
3
C
 
H
M
B
C
 
H
S
Q
C
 
D
E
P
T
 
N
O
E
S
Y
 
F1 2.0 / / / / - - - - - - - - 
F2 0.6 / / / / - - - - - - - - 
F3 0.2 Rt 2.40 Rt2.3, m/z 266 Rt 2.3, m/z 264 265 36 hits - + - - - - - 
F4 0.5 Rt 2.24 Rt 2.2, m/z 243 Rt 2.2, m/z 240 241/242 37 hits - + + + + + + 
F5 1.7 Rt 2.07 / / / / - + + + + + + 
F6 1.4 
Rt2.26 
Rt 2.31 
Rt2.2, 
m/z 197.9, m/z 151.9 
Rt 2.2, 
m/z 149.7 
/ / - + + + + + + 
F7 0.4 Rt 2.08 / / / / - - - - - - - 
F8 - not pure / / / / - - - - - - - 
F9 - not pure / / / / - - - - - - - 
F10 - not pure / / / / - - - - - - - 
F11 0.4 Rt 4.43 Rt 2.2, m/z 243 Rt 2.2, m/z 241 242 519 hits - + + + + + + 
F12 0 / / / / - - - - - - - - 
F13 5.2 
Rt 4.61 
Rt 4.89 
Rt 5.1, m/z 623 
(m/z 173, m/z 301) 
Rt 5.1, m/z 621 622? 93 hits - + + + + + + 
F14 3.5 not pure / / / - - - - - - - - 
F15 1.2 not pure / / / - - - - - - - - 
F16 1.5 not pure / / / - - - - - - - - 
F17 1.4 Rt 3.59 Rt 5.1, m/z 627 Rt 5.1, m/z 625 626 70 hits - + + + + + + 
F18 3.3 Rt 3.63 not pure / / - / - - - - - - - 
/: not sure; -: no experiments; +: experiments done. 
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The accurate mass of compound F13 was obtained by the high-resolution mass detection (TOF and 
micrOTOF). The accurate mass of F13 can be seen in Figure 3-21. The positive method showed the 
m/z [M+H]
+
 was 301.1 and the negative method showed the m/z [M-H]
- 
was 299.2. Thus, the accurate 
mass of F13 is MW 300. 
 
(a) 
 
(b) 
Figure 3-21. Mass spectrum of compound F13 isolated from culture extract  
grown at 0.67% salts with (a) positive method and (b) negative method. 
 
3.3.4.2 Cultures grown at 2.5% salts 
After 15 days’ incubation, 50 L culture broths were extracted. 570 mg dried supernatant extract was 
obtained and then dissolved in MeOH. The HPLC chromatogram is shown in Figure 3-22. The semi-
preparative HPLC chromatograms with two different columns are shown in Figure 3-23 and Figure 3-
24. The 18 fractions of a reverse-phase C18 column (2/3 crude supernatant extract) are named C1 to 
C18 and those from a polar column (1/3 crude supernatant extract) are named P1 to P18.  
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Figure 3-22. HPLC chromatogram of extracts from 50 L supernatant 
culture broth of A. vinosum strain MT86 grown at 2.5% salts for 15 days. 
 
 
Figure 3-23. Semi-preparative HPLC (C18 column) chromatogram of 
supernatant extract from 50 L culture of A. vinosum MT86 at 2.5% salts for 15 days. 
 
 
 
 
Figure 3-24. Semi-preparative HPLC (polar column) chromatogram of 
supernatant extract from 50 L culture of A. vinosum MT86 at 2.5 salts for 15 days. 
 
The comparison of semi-preparative HPLC chromatograms showed the most significant differences 
after Rt 28 min, with the intensity of P17 being higher than C17, and no corresponding compound to 
P19 was detected. P13 and C13 showed almost the same Rt and shape. These indicated that the polar 
column was a better method for fractionation than C18 column. 
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The comparison of semi-preparative HPLC chromatograms of extracts from culture of A. vinosum 
MT86 grown at 0.67% salts for 10 days and at 2.5% salts for 15 days, which were separated on the 
same polar column, showed one additional UV absorption peak around Rt 32 min (P19) in the later 
chromatogram (culture at 2.5% salts). In addition, peaks P6 and P7 (ca. 100 mAU) were separated 
better without overlapping and P17 (180 mAU) showed much higher intensity in extract from the 
culture grown at 2.5% salts than F17 (20 mAU) in that from cultures grown at 0.67% salts.The most 
important feature of these three semi-preparative chromatograms (Figure 3-19, Figure 3-23 and Figure 
3-14) was that the obvious UV absorption peaks, namely F13, C13 and P13, existed with highest 
intensity than all other peaks. Their identity was approved by NMR spectra. The intensity of F13 was 
400 mAU which was higher than the intensity of C13 (160 mAU) and P13 (220 mAU). This indicated 
that F13 was the compound that can be reproduced under different cultivation conditions and columns 
used for fractionation. However, according to the comparison of cultivation time and fractionation 
methods, incubation at 0.67% salts concentration after 10 days was the best conditions for isolation of 
compound F13. 
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Table 3-16. Comparison of fractions from different cultures of A. vinosum strain MT86. 
 
0.67% Salts 
(Polar) 
amount real 
mass 
2.5% Salts 
(C18) 
amount real mass 2.5% Salts 
(Polar) 
amount real mass Note 
F1 2.0 mg not pure C1 - no UV P1 0.6 mg not pure   
F2 0.6 mg not pure C2 3.8 mg not pure P2 - no   
F3 0.2 mg 265 C3 - UV pure, 397 not pure enough P3 - 643? 671?   
F4 0.5 mg 241? 
242? 
C4 1.3 mg not pure (one strong, one weak) 
pos m/z 243, 266 
neg m/z 240.9, 263 
P4 - 265 probably 
they are the 
same 
F5 1.7 mg not pure C5 0.3 mg not pure P5 - not pure   
F6 1.4 mg not pure C6 - not pure P6 - no   
F7 0.4 mg not pure C7 - no UV P7 - no   
F8 - not pure C8 - too weak UV P8 - no   
F9 - not pure C9 - UV pure, m/z not pure P9 - no   
F10 - not pure C10 0.7 mg UV pure,  
neg pure m/z277 
pos m/z>3 peaks  
P10 - no   
F11 0.4 mg 142 C11 - not pure P11 0.4 mg UV pure, m/z 
no 
  
F12 0 mg not pure C12 0.9 mg UV pure, m/z not pure P12 - not pure   
F13 5.2 mg 622 
oil-like 
C13 0.6 mg >2 UV 
neg m/z 621 
pos m/z 173 
P13 0.7 mg 622 F13 = C13 = 
P13  
(= P10 from 
20 L) 
F14 3.5 mg not pure C14 - not pure P14 0.5 mg no UV   
F15 1.2 mg not pure C15 - not pure P15 0.2 not pure   
F16 1.5 mg not pure C16 - not pure P16 - UV pure, m/z 
no 
  
F17 1.4 mg 626 C17 - not pure P17 0.8 mg UV pure, m/z 
no 
  
F18 3.3 mg not pure C18 - not pure P18 0 not pure   
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3.3.5 NMR analysis of compound F13 from 0.67% salts concentration 
NMR chromatograms of 
1
H NMR (Figure 3-26), 
13
C NMR and DEPT (Figure 3-27), 
1
H-
1
H COSY 
(Figure 3-28), 
1
H-
13
C HMBC (Figure 3-29), 
1
H-
13
C HSQC (Figure 3-30) and NOESY (Figure 3-31) of 
compound F13 were obtained with the substance purified from the crude supernatant extract of a 45 L 
A. vinosum MT86 cultures grown at 0.67% salts for 10 day. The NMR spectroscopic data information 
is shown in Table 3-17 and Table 3-18. The ESI mass spectra (positive and negative ions) provided 
that the molecular weight was 300 and molecular formula was C20H28O2. The predicted formula and 
the mass from the HPLC were corresponding well. The formula indicated the presence of seven 
degrees of unsaturation.  
The 
1
H NMR spectra gave the H atom information. J values of δ7.14, δ6.95, and δ6.84 indicated that 
there were three aromatic-H, which were corresponding to a trisubstituted phenyl ring. J values of 
δ2.85 and δ2.78 indicated the presence of three aliphatic-H. 
The 
13
C-NMR in connection with the DEPT and HSQC measurement gave 20 C atoms information. 
The C atom of δ183.45 was an acid carboxyl C, δ150-125 signals showed six aromatic-C (according to 
a phenyl group), and δ46.67-17.24 signals indicated 12 aliphatic-C, among them were 4 CH3, 5 CH2, 2 
CH and a quaternary C.  
According to the NMR analyses, structure information was obtained. There were three ring units in 
compound F13. The 
13
C NMR and DEPT spectrum showed that this compound had 20 carbons (Table 
3-18). The 
1
H spectrum showed there were 28 H protons which corresponding to the results of HSQC 
and DEPT. The structure of F13 was obtained as shown in Figure 3-25. 
 
Figure 3-25. Structure of compound F13 repurified from combined fractions of F13, P13 and C13. 
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Table 3-17. 
1
H NMR (600 MHz, MeOD), 
1
H-
1
H COSY and 
1
H-
13
C HMBC correlation for compound F13. 
No. 
δH 
/ppm 
δH type, J/Hz 
No. of H 
proton 
1
H-
1
H COSY 
(δH/ppm) 
HSQC δC, type HMBC 
1 7.14 d, 8.2 1 6.95 125.20 CH C-4 
2 6.95 dd, 8.2, 1.9 1  124.83 CH C-3 
3 6.84 d, 1.9 1  127.75 CH C-1 
5 2.85 ddd, 54.02, 8.2, 3.5 2 1.84, 1.53 31.23 CH2 C-10 
6 2.78 hept, 7.0 1  34.86 CH C-11 
7 2.33 dt, 13.3, 3.2 2 1.43, 39.51 CH2 C-5 
8 2.17 m 1  46.67 CH C-8a 
9 1.83 m 2 1.65 38.15 CH2 C-7 
10 1.64 m 2 1.83 19.77 CH2 C-6 
11 1.52 ddt, 13.0, 5.7, 2.3 2 1.83 22.90 CH2 C-9 
12 1.43 td, 12.7, 4.3 1     
13 1.26 d, 20.6 3  17.24 CH3 C-17 
14 1.20 m 9    C-14, 
C-12,  
C-15 
Sum of H proton 28     
d = doublet, dd = doublet of doublets, ddt = doublet of doublet of triplets, ddd = doublet of doublet of doublets, 
dt = doublet of triplets, m = multiplet, td = triplet of doublets, hept = heptet. 
 
Table 3-18. 
13
C NMR (150 MHz, MeOD) spectroscopic data for F13. 
No. of C δC/ppm C-Atom H-Atom δH/ppm Position 
1 183.45 COOH 1 1.25 C16 
2 148.34 C - - C-4a 
3 146.83 C - - C-2 
4 135.78 C - - C-10a 
5 127.75 CH 1 6.84 C-1 
6 125.20 CH 1 7.14 C-4 
7 124.83 CH 1 6.95 C-3 
8 48.41 C - - C-8 
9 46.67 CH 1 2.18 C-8a 
10 39.51 CH2 2 2.33/1.43 C-5 
11 38.15 CH2 2 1.83/1.65 C-7 
12 38.07 C - - C-5a 
13 34.86 CH 1 2.78 C-11 
14 31.23 CH2 2 2.85 C-10 
15 25.55 CH3 3 1.20 C-14 
16 24.49 CH3 3 1.20 C-12 
17 24.49 CH3 3 1.20 C-13 
18 22.90 CH2 2 1.83/1.52 C-9 
19 19.77 CH2 2 1.83/1.70 C-6 
20 17.24 CH3 3 1.25 C-15 
Total  20 C 28 H   
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Figure 3-26. 
1
H NMR chromatogram of compound F13. 
 
 
Figure 3-27. 
13
C NMR and DEPT chromatogram of compound F13. 
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Figure 3-28. 
1
H-
1
H COSY chromatograms of compound F13.  
 
 
Figure 3-29. 
1
H-
13
C HMBC chromatogram of compound F13. 
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Figure 3-30. 
1
H-
13
C HSQC chromatogram of compound F13. 
 
 
Figure 3-31. NOESY chromatogram of compound F13. 
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3.3.6 Bioactivity tests of fractions from cultures grown at 0.67% salts 
Seven fractions (F3, F4, F11, and F17, including the impure F5, F6 and F18) and pure compound F13 
were selected for antibacterial, antifungal, and enzyme activities. Seven antibacterial tests, one 
antifungal test, and four enzymes inhibition tests were performed. 
The IC50 values for compound F13 in tests with B. subtilis, S. lentus, and AchE were 70.5 µM (± 2.9), 
57.0 µM (± 3.3), and >10 µM, respectively. The seven fractions showed no antibacterial and 
antifungal inhibition. However, it was very interesting that the fraction F5 and F18 showed inhibition 
of AchE with IC50 of 3.95 µM (± 1.9) and IC50 of 8.91 µM (± 3.28), respectively. Other fractions and 
compound F13 showed low inhibition of AchE (IC50 valuce of > 10µM). There were no bioactivities 
against the other three enzymes. 
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Table 3-19. Bioactivities of fractions from A. vinosum strain MT86. 
 Antibacterial Antifungal Enzyme 
Fractions/ 
compounds 
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M
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%
) C. glabrata                             
100 µM 
(%) 
AchE                 
10 µM 
(%) 
AchE                              
IC50 
GSK 
10 µM 
(%) 
PDE-4β2 
10 µM 
(%) 
PTP                              
10 µM 
(%) 
MT86_F3 - - - - - - - - - - 49 > 10 µM - - - 
MT86_F4 - - - - - - - - - - 46 > 10 µM - - - 
MT86_F5* - - - - - - - - - - 86 3.95 µM (± 1.9) - - - 
MT86_F6* - - - - - - - - - - - > 10 µM - - - 
MT86_F11 - - - - - - 24 - - - - > 10 µM - - - 
MT86_F13 100 
70.5 µM 
(± 2.9) 
100 
57.0 µM 
(± 3.3) 
27 - - - - - - > 10 µM - - - 
MT86_F17 - - - - - - - - - - 33 > 10 µM - - - 
MT86_F18* - - - - - - - - - - 83 8.91 µM (±3.28) - - - 
1. B. subtilis: Bacillus subtilis, S. lentus: methicillin-resistant Staphylococcus lentus, E. coli: Escherichia coli, MRSA: Staphylococcus aureus, X campestris: Xanthomonas campestris, P. 
syringae:  Pseudomonas syringae; R. solanacearum: Ralstonia solanacearum; C. glabrata: Candida glabrata; AchE: acetylcholinesterase, GSK: glycogen synthase kinase, PDE-4β2: 
phosphodiesterase 4, PTP: protein-tyrosine-phosphatase. 
2. Note: The results of the bioassays are defined as follows: ≥ 80% inhibition: very good activity; < 80% and ≥ 60% inhibition: moderate activity; < 60% and > 30% inhibition: low activity; ≤ 
30% inhibition &-: no activity. 3. *: fraction was not pure 
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3.3.7 Screening of crude cell extract for compound F13 by TLC 
TLC was carried out on precoated silica gel 60 F254 plates (0.25 mm, Merck); spots were visualized by 
spraying with anisaldehyde in 10% H2SO4 solution followed by heating.  
 
A: TLC chromatogram before staining;  
B: TLC chromatogram of extracts after spraying with 10% H2SO4 solution followed by heating.  
1: MeOH-extract; F13: compound F13; 2: Acetone-extract; 3: dichloromethane-extract 
Figure 3-32. The TLC chromatograms of compound F13 and cell extracts. 
 
The TLC chromatogram (Figure 3-32) shows that the spot of compound F13 was not present in any of 
the cell extracts, no matter what kind of solvent was used for extraction.  
3.4 Properties of compound F13 from A. vinosum. MT86 
Compounds F13 isolated from supernatant extract of a 45 L culture grown at 0.67% salts for 10 days, 
P13, and C13 isolated from supernatant extract of a 50 L culture grown at 2.33% salts for 15 days 
(fractionated by polar and C18 reverse columns) were collected for purification to obtain substance of 
sufficient purity for structure elucidation (purification and elucidation of IR, CD and polarimetry are 
not shown, personal communication to Prof. Dr. A. Zeeck) . 
There were 12 apparent absorption peaks from IR spectrum of F13 (Figure 3-33 and Table 3-20). 
Absorption at 1698 cm
-1
 was significant which indicates the presence of a carboxyl group (CO-
stretching vibration).  
The CD spectrum (Figure 3-34) showed a signal at 220 nm wavelength. The CD effects were not 
significant. 
1      F13      2       3 1      F13      2       3
A B
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Figure 3-33. IR spectrum of compound F13 from A. vinosum MT86. 
 
 
Table 3-20. The results of peak picking from the IR spectrum of compound F13. 
No.  Position/cm
-1
 Intensity Identification of absorption peaks 
1 3412.42 97.2348  
2 29.55.38 87.0512  
3 2926.45 84.0294  
4 2865.7 91.3928  
5 1698.02 91.549 Carboxyl group (CO-stretching vibration) 
6 1546.63 93.9369  
7 1456.96 93.316  
8 1382.71 92.8089  
9 1265.07 91.9499  
10 1187.94 94.7089  
11 1129.12 95.1132  
12 820.563 94.9275  
 
 
 
 
Figure 3-34. The CD spectrum of compound F13. 
 
F13 was isolated as a yellowish oil-like compound that gave a pseudomolecular ion [M+H]
+
 at m/z 301, 
[M+Na]
+
 at m/z 323, [M-H]
-
 at m/z 299 in the HRESIMS, indicating the molecular formula C20H27O2 
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(299.2017) (calcd. for C20H28NaO2, 323.1982) (7° of unsaturation). The IR spectrum of F13 showed IR 
(neat) Vmax 3412.42 cm
-
1 a broadband at 1698.02 cm
-1
, consistent with the presence of carboxyl group 
(CO-stretching vibration). The optical rotation [α]D
25  of compound F13 was + 42 (MeOH), and no effect 
from CD spectrum showed that CD effects were not significant. 
Compound F13 (Table 3-21) is the first antibiotic substance (an aromatic tricyclic diterpenoid) isolated 
from anoxygenic phototrophic bacteria, although the measured activities were moderate. IC50 values 
for F13 against Bacillus subtilis, and Staphylococcus lentus were 70.5 µM (± 2.9) and 57.0 µM (± 3.3), 
respectively.  
 
Table 3-21. Summary of  structural features of F13. 
Compound name F13 
Isolated from Allochromatium vinosum strain. MT86, supernatant extract 
MW 300 
Formula C20H28O2 
UV maxima (nm) 225, 268, sh271, 275/276 
[α]
D
25 + 42° 
 
3.5 Metabolite profiles of other phototrophic bacteria 
Purple nonsufur bacteria (PNSB) Rhodopseudomonas palustris strain 120/1, Rhodobacter capsulatus 
strain 182, and Rubrivivax gelatinosus strain 151 were selected for secondary metabolites screening. 
The first screening of these three strains was performed in 500 ml AT medium and antibiotic activities 
were tested against nine microorganisms. The second screening of them was performed in 100 ml AT 
medium to compare the UV absorption peaks. 
3.5.1 First screening of strains 120/1, 182, and 151  
From the HPLC chromatograms (Figure 3-35), there are some UV absorption peaks (200 to 540 nm) 
from Rt 4.8 min to Rt 6.2 min in the crude extracts of all three strains. These peaks are correlated to 
pigments from these bacteria. The results of bioassay tests to nine organisms are seen in Table 3-22. 
There is no inhibition of extracts from these three strains of E. coli, X. campestris, P. acnes, and C. 
albicans. The extract of strain 120/1 showed no activity against T. rubrum, low activities to B. subtilis 
(50%), MRSA (39%) and S.tritici (35%) but moderate activity against S. lentus (72%). The extract of 
strain 182 showed no activities against B. subtilis (23%), S. tritici (21%), low activity against MRSA 
(38%), moderate activity against T. rubrum (67%) and good activity against S. lentus (81%). The 
extract of strain 151 showed low activities against B. subtilis (34%), MRSA (42%), and T. rubrum 
(53%) but very good activities against S. lentus (82%) and S. tritici (80%), the later organism was only 
inhibited very well by the extract of strain 151. 
RESULTS 
 
 
 
90 
The HPLC chromatograms (Figure 3-35) showed that strain 151 has the highest number of UV peaks 
and the crude culture extract of strain 151 showed moderate to very good inhibitions of several test 
microorganisms (Table 3-22). 
 
 
(a) 
 
(b) 
 
(c) 
Figure 3-35. HPLC-DAD/MS results of strains 120/1, 182 and 151. 
 
 
Table 3-22. Bioassay results of extracts from Rhodopseudomonas  
palustris 120/1, Rhodobacter capsulatus 182, and Rubrivivax gelatinosus 151. 
Crude extracts 
Inhibitions 
Bs Sl Ec MRSA Xc Pa Ca Sep Tru 
120/1-500ml 50 72 - 39 - - - 35 - 
182-500ml 23 81 - 38 - - - 21 67 
151-500ml 34 82 - 42 - - - 80 53 
1. Bs: Bacillus subtilis, Sl: Staphylococcus lentus, Ec: Escherichia coli, MRSA: 
Staphylococcus aureus, Xc: Xanthomonas campestris, Pa:Propionibacterium acnes, Ca: 
Candida albicans, Sep: Septoria tritici, Tru: Trichophyton rubrum. *: assay concentration 
was 476 µg/ml; 
2. Note: The results of the bioassays are defined as follows: ≥ 80% inhibition: very good 
activity; < 80% and ≥ 60% inhibition: moderate activity; < 60% and > 30% inhibition: low 
activity; ≤ 30% inhibition & -: no activity. 
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3.5.2 Screening of culture broth in a 100 ml volume  
Rhodopseudomonas palustris strain 120/1, Rhodobacter capsulatus strain 182, and Rubrivivax 
gelatinosus strain 151 were inoculated in 100 ml AT medium for comparison of metabolite profiles 
according to UV absorption and mass. 
The HPLC-DAD/MS chromatograms of extracts obtained after 7 and 10 days’ incubation showed 24 
distinct peaks of strain 120/1 (Figure 3-36), 25 peaks of strain 182 (Figure 3-37), and 20 peaks of 
strain 151 (Figure 3-38).  
3.5.2.1 Screening of crude extract of Rhodopseudomonas palustris strain 120/1 grown 
for 7 and 10 days 
The HPLC chromatograms are shown in Figure 3-36. 24 UV absorption peaks (p1-p24) are present 
(UVmax and mass information is in Table 3-23). 
Peak p22 (UV maximum at 228 nm and m/z 821, belonging to an arithmetic progression from m/z 865 
to m/z 425, common difference is 44) found in the HPLC chromatogram of extract from culture grown 
for 10 days was absent in the extract from culture grown for 7 days.  
There was not much difference between the extracts from cultures grown for different incubation time 
(7 and 10 days). Peaks p1, p2, p3, p21 and p24 in extracts of cultures grown for 7 and 10 days showed 
small difference in UV absorption (some shoulder UV absorption), but had the same MW (or obvious 
m/z, arithmetic progression) in mass spectra. Peak p6 showed the same UV absorption but different 
MW in extracts from cultures after 7 and 10 days. Peak p5 had m/z 294 in extract obtained after 7 days, 
but m/z 295 (MW 294) in extract obtained after 10 days. In consideration of the intensity of UV 
absorption, peaks p11-p19 of extract from culture grown for 10 days showed higher intensity than for 
7 days. Comparison of p22, p23 and p24 revealed that these peaks belonged to a serial arithmetic 
progression from m/z 865 to 425, with the common difference (d value) of 44. 10 days of cultivation 
of Rhodopseudomonas palustris strain120/1 was better than 7 days. 
 
Figure 3-36. HPLC chromatograms of extracts from 100 ml supernatant culture broth of 
Rhodopseudomonas palustris strain 120/1 grwon for 7 and 10 days. 
  
120/1_7 d
120/1_10 d
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Table 3-23. Comparison of extracts from cultures of strain 120/1 grown for 7 and 10 days. 
120/1 7 d 10 d 
Peak Rt/min UVmax /nm MW or m/z Rt/min UVmax /nm MW or m/z 
p1 2.01 
220 nm, 460 mAU 
263 nm, 257 mAU 
sh282nm, 150 mAU 
170 2.05 
220 nm, 461 mAU 
sh 240 nm, 304 mAU 
262 nm, 373 mAU 
sh 271 nm, 200 mAU 
356 nm, 85 mAU 
170 
p2 2.07 
214 nm, 411 mAU 
220 nm, 340 mAU 
282 nm. 57 mAU 
170 2.11 
214 nm, 514 mAU 
220 nm, 431 mAU 
sh 247 nm, 142 mAU 
287 nm, 59 mAU 
170 
p3 2.42 
220 nm, 249 mAU 
sh 237 nm, 178 mAU 
277 nm, 139 mAU 
/ 2.44 
222 nm, 120 mAU 
275 nm, 49 mAU 
/ 
p4 3.2 226 nm, 133 mAU 224 3.2 226 nm, 121 mAU 224 
p5 3.47 222 nm, 171 mAU m/z 294 3.45 220 nm, 166 mAU 294 
p6 3.56 226 nm, 167 mAU 293 3.55 226 nm, 167 mAU m/z 551 
p7 3.76 226 nm, 153 mAU 297 3.74 226 nm, 154 mAU 297 
p8 3.83 226 nm, 150 mAU / 3.80 226 nm, 155 mAU / 
p9 3.91 227 nm, 167 mAU m/z 310 3.88 227 nm, 172 mAU m/z 310 
p10 4.01 227 nm, 186 mAU 279 4.01 227 nm, 161 mAU 279 
p11 4.38 227 nm, 332 mAU 295 4.39 227 nm, 364 mAU 295 
p12 4.45 227 nm, 312 mAU 295 4.41 227 nm, 432 mAU 295 
p13 4.47 227 nm, 364 mAU 295 4.49 227 nm, 283 mAU 295 
p14 4.56 226 nm, 250 mAU 295 4.52 226 nm, 252 mAU 295 
p15 sh 4.59 226 nm, 187 mAU 297 4.62 227 nm, 215 mAU 297 
p16 4.69 227 nm, 205 mAU m/z 280 4.65 227 nm, 213 mAU m/z 280 
p17 4.73 227 nm, 234 mAU 362 4.70 227 nm, 196 mAU 362 
p18 4.80 227 nm, 267 mAU 227 4.72 227 nm, 192 mAU 227 
p19 4.92 221 nm, 336 mAU 253 4.84 221 nm, 306 mAU 253 
p20 5.21 228 nm, 164 mAU 267 5.21 228 nm, 204 mAU 267 
p21 5.61 227 nm, 202 mAU 281 5.60 
sh 219 nm, 102 mAU 
227 nm, 200 mAU 
281 
p22 - - - 6.22 228 nm, 228 mAU 
865- 425, 
d=44 
p23 6.35 227 nm, 243 mAU 865-425, 
d=44 
6.26 228 nm, 241 mAU 
865- 425, 
d=44 
p24 6.39 227 nm, 236 mAU 865-425, 
d=44 
6.30 
sh 219 nm, 106 mAU 
228 nm, 235 mAU 
865- 425, 
d=44 
-: not existed; /: not sure 
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3.5.2.2 Screening of crude extract of Rhodobacter capsulatus strain 182 grown for 7 and 
10 days 
The HPLC chromatograms of extracts from cultures of strain 182 after 7 and 10 days are shown in 
Figure 3-37, in which 25 distinct peaks (named c1 to c25) are present (UVmax and mass information in 
Table 3-24). 
Eight peaks (c5-c11, c17) were absent in extract from culture grown for 7 days compared to extract for 
10 days. However, two other peaks (c15’, MW 796 and c16’, MW 521) appeared next to their 
neighbors c15 (MW 796) and c16 (MW 521) only in extract from culture grown for 7 days. 
Peak c23 belonged to an arithmetic progression, which began from m/z 837 to m/z 441, and the 
common difference (d) was 44. Peaks of c24 and c25 (same UVmax absorption and m/z) belonged to 
another arithmetic progression (m/z 865 to m/z 425, d = 44) which was the same arithmetic 
progression as p22, p23 and p24 in the extracts from cultures of strain 120/1. 
From the previous analyses, cultivation for 10 days of Rhodobacter capsulatus strain 182 was better 
than that for 7 days. 
 
Figure 3-37. HPLC chromatogram of extracts from 100 ml supernatant  
culture broth of Rhodobacter capsulatus strain 182 grown for 7 and 10 days. 
 
 
182_7 d
182_10 d
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Table 3-24. Comparison of extracts from cultures of strain 182 grown for 7 and 10 days. 
Peak 
7 d 10 d 
Rt/min UVmax /nm MW or m/z Rt/min UVmax /nm MW or m/z 
c1 1.93   
217 nm, 496 mAU 
240 nm, 250 mAU 
265 nm, 235 mAU 
170 2.02   
220 nm, 473 mAU 
241 nm, 287 mAU 
262 nm, 332 mAU 
170 
c2 1.99   214 nm,  404 mAU 170 2.08   
213 nm, 300 mAU 
286 nm, 30 mAU 
170 
c3 2.32   
222 nm, 124 mAU 
236 nm, 91 mAU 
276 nm, 60 mAU 
/ 2.42   
222 nm, 85 mAU 
276 nm, 24 mAU 
/ 
c4 2.54   226 nm, 108 mAU 280 2.64   225 nm, 113 mAU 280 
c5 - - - 3.17   226 nm, 99 mAU / 
c6 - - - 3.43   222 nm, 146 mAU 452 
c7 - - - 3.53   226 nm, 155 mAU 477 
c8 - - - 3.73   226 nm,142 mAU 553 
c9 - - - 3.82   226 nm, 145 mAU 553 
c10 - - - 3.88   228 nm,162 mAU 538 
c11 - - - 3.98   228 nm, 192 mAU m/z 292  
c12 4.24 227 nm, 212 mAU 710 4.36   227 nm, 425 mAU 710 
c13 4.31   227 nm, 206 mAU 295 4.43   227 nm, 391 mAU 295 
c14 4.33   227 nm, 232 mAU 295 4.45   227 nm, 480 mAU 295 
c15 4.43   227 nm, 194 mAU 796 4.54   227 nm, 294 mAU 796 
c15’ 4.46   227 nm, 215 mAU 796 - - - 
c16 4.56   227 nm, 237 mAU 521 4.70   225 nm, 215 mAU 521 
c16’ 4.59   227 nm, 256 mAU 521 - - - 
c17 - - - 4.76   228 nm, 888 mAU m/z 279  
c18 4.78   221 nm, 313 mAU 227 4.90   221 nm, 333 mAU 227 
c19 5.08   228 nm, 161 mAU 279 5.20   228 nm, 170 mAU 279 
c20 5.43   228 nm, 194 mAU 255 5.53   228 nm, 200 mAU 255 
c21 5.48    228 nm, 197 mAU 281 5.59   228 nm, 213 mAU 281 
c22 5.55   228 nm, 205 mAU 281 5.67   228 nm, 200 mAU 281 
c23 5.87   228 nm, 202 mAU 
837-441, 
d=44 
5.98   228 nm, 214 mAU 837-441, d=44 
c24 6.23   228 nm, 222 mAU 
865-425, 
d=44 
6.33   228 nm, 235 mAU 865-425, d=44 
c25 6.27   228 nm, 217 mAU 
865-425, 
d=44 
6.37   228 nm, 230 mAU 865-425, d=44 
-: not existed; /: not sure 
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3.5.2.3 Screening of crude extract of Rubrivivax gelatinosus strain 151 grown for 7 and 
10 days 
HPLC chromatograms of extracts from cultures of strain 151 after 7 and 10 days are shown in Figure 
3-38, and 23 distinct UV absorption peaks (g1 to g20, and gA, gB, gC) were identified. 
Peaks g3, g5 and g15 were absent in extract from the culture grown for 10 days compared to that for 7 
days, however, extra peaks of gA, gB and gC appeared in the extract from the culture grown for 10 
days. 
According to Table 3-25, peaks g1, g2 and g4 showed different intensity of UV absorption and MW 
(or m/z). Peak g12 showed different intensity of UV absorption but same m/z value. Peaks g13 and 
g14 in 7 d gave same UVmax (228 nm) and m/z 883, however, g13 and g14 in extract from culture 
grown for 10 days showed UVmax of 227 nm and m/z 298. 
The extra UV absorption peaks gB and gC belonged to an arithmetic progression (start from m/z 837 
to m/z 441, d = 44). In addition, this arithmetic progression was the same one as c23’s arithmetic 
progression in Rhodobacter capsulatus strain 182. In Rhodopseudomonas palustris strain 120/1, there 
was not such a progression. 
Peak g20 belonged to one arithmetic progression (m/z 864 to m/z 425, d = 44) which was same as c24 
and c25 in Rhodobacter capsulatus strain 182, and p22, p23 and p24 in Rhodopseudomonas palustris 
strain 120/1. 
Because interesting extra UV absorption peaks (gA, gB, and gC) were present in extracts from cultures 
of Rubrivivax gelatinosus strain 151 grown for 10 days, this was the better conditions for cultivation of 
the strain. 
 
Figure 3-38. HPLC chromatogram of extracts from supernatant  
cultures of Rubrivivax gelatinosus strain 151 grown for 7 and 10 days. 
 
 
151_7 d
151_10 d
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Table 3-25. Comparison of extracts from cultures of strain 151 grown for 7 and 10 days. 
Peak 
7 d 10 d 
Rt/min UVmax /nm MW or m/z Rt/min UVmax /nm 
MW or 
m/z 
g1 2.00 
220 nm, 983 mAU 
sh240 nm, 536 mAU 
266 nm, 468 mAU 
sh280 nm, 449 mAU 
170 2.03 
223 nm, 1541 mAU 
241-262 nm, 2000 mAU 
345 nm, 868 mAU 
sh 389 nm, 678 mAU 
m/z 243 
(+Na) 
g2 2.05 
217 nm, 946 mAU 
220 nm, 898 mAU 
246 nm, 322 mAU 
280 nm, 146 mAU 
287 nm, 143 mAU 
170 sh2.1 214 nm, 503 mAU 
m/z 243 
(+Na) 
g3 2.38 
223 nm, 130 mAU 
sh 234 nm, 100 mAU 
275 nm, 60 mAU 
/ - - - 
g4 2.50 
215 nm, 133 mAU 
220 nm, 127 mAU 
257 nm, 131 mAU 
668 2.57 227 nm, 184 mAU / 
g5 3.13 226 nm, 132 mAU 224 - - - 
g6 3.34 227 nm, 247 mAU / 3.45 222 nm, 205 mAU / 
g7 3.49 227 nm, 199 mAU / 3.54 226 nm, 191 mAU / 
g8 3.95 225 nm, 150 mAU 538 3.99 227 nm, 187 mAU 538 
gA - - - 4.24 227 nm, 289 mAU m/z 280 
g9 4.29 228 nm, 185 mAU m/z 296 4.37 227 nm, 342 mAU m/z 296 
g10 sh 4.36 228 nm, 196 mAU m/z 296 4.43 227 nm, 327mAU m/z296 
g11 4.38 228 nm, 220 mAU m/z 296 4.46 227 nm, 388 mAU m/z296 
g12 4.50 
226 nm, 227 mAU 
280 nm, 33 mAU 
421 nm, 26 mAU 
m/z 296 4.55 228 nm, 263 mAU m/z 296 
g13 4.61 228 nm, 208 mAU m/z 883 4.68 227 nm, 193 mAU m/z 298 
g14 4.64 228 nm, 200 mAU m/z 883 4.71 227 nm, 211 mAU m/z 298 
g15 4.83 
222 nm, 974 mAU 
269 nm, 120 mAU 
276 nm, 117 mAU 
227 - - - 
g16 5.12 228 nm, 164 mAU 279 5.20 227 nm, 175 mAU 279 
g17 5.47 228 nm, 185 mAU m/z 256 5.56 228 nm, 201 mAU m/z 256 
g18 5.51 228 nm, 196 mAU 281 5.60 227 nm, 221 mAU 281 
g19 5.58 228 nm, 192 mAU 281 5.67 228 nm, 202 mAU 281 
gB - - - 6.01 227 nm, 266 mAU 
837-441, 
d=44 
gC - - - 6.15 227 nm, 244 mAU 
837-441, 
d=44 
g20 6.25 228 nm,230 mAU 
865-425, 
d=44 
6.34 228 nm, 263 mAU 
865-425, 
d=44 
-: not existed; /: not sure  
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3.5.3 Scale up of cultures of Rubrivivax gelatinosus strain 151 to a 20 L volume  
Comparison of the HPLC chromatograms and bioassays, extract from the culture broth of Rubrivivax 
gelatinosus strain 151 was more interesting than compared to extracts from Rhodopseudomonas 
palustris strain 120/1 and Rhodobacter capsulatus strain 182. An additional aspect is the analysis of 
the whole genome of Rubrivivax gelatinosus IL144 from antiSMASH screening. The potential 
bioactive synthesis gene cluster of terpenes and T1pks-other cluster (very poor similarity to a 
zainomycin biosynthetic cluster) can be found. 
Therefore, 20 L cultures were grown at 1000 lux light and 28°C anaerobically. After 10 days’ 
incubation, the pale peach/ dirty yellowish brown cultures appeared. Only the supernatant part of 
culture was extracted by ethyl acetate by the method described in paragraphs 2.4 on page 33. The 
HPLC chromatogram of extract from culture broth of 20 L supernatant is seen in Figure 3-39. 
 
Figure 3-39. HPLC chromatogram of the 20 L supernatant  
extract of Rubrivivax gelatinosus strain 151 grown for 10 days. 
 
A large number of UV absorption peaks were visible in the HPLC chromatogram (Figure 3-39) 
compared to extracts from 100 ml cultures (Figure 3-38). Especially between Rt 4.8-6.2 min, at least 
nine UV absorption peaks existed in the wavelength range of 200-550 nm which were indicated as 
pigments (Bchl c and/or carotenoids) (Pierson and Castenholz, 1974). 300 mg dried supernatant 
extract was obtained and then dissolved in MeOH and adjusted to 100 mg/ml. Fractionation was 
performed by semi-preparative HPLC, and 21 fractions were obtained (see in Figure 3-40).  
All 21 fractions were collected and further analyzed by analytical HPLC-DAD/MS (Figure 3-41). As 
the weight of each fraction was too low (0.1-0.5 mg) to perform further NMR or bioassay tests, the 
bioactivities were not tested. A large volume of culture is required to obtain sufficient extract.  
According to the results, it was concluded that Rubrivivax gelatinosus strain 151 may have the 
potential to produce bioactive secondary metabolites in AT medium, but the proof for this needs 
further studies. 
151 Supernatant extract _20L
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Figure 3-40. Semi-preparative HPLC chromatogram of extract of supernatant (20 L) of strain 151. 
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Figure 3-41. HPLC-DAD/MS chromatograms of 21 fractions from strain 151. 
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3.6 Genetic screening of selected anoxygenic phototrophic bacteria 
Genetic screening includes the DNA extraction, PCR amplification, sequencing and BLASTn analysis 
of selected anoxygenic phototrophic bacteria, and the antiSMASH analysis of whole genome 
sequences of phototrophic bacteria available in database (NCBI). 
3.6.1 DNA extraction of these bacteria 
DNA was extracted from representative strains of green sulfur bacteria (Chlorobium phaeobacteroides 
strain 2360
T
, Chlorobium limicola strain 2310
T
, and Prosthecochloris aestuarii strain 2410
T
), purple 
sulfur bacteria (Marichromatium gracile strain 5212
T
, Allochromatium vinosum strain 5110
T
, 
Thiocystis violascens strain 5410, and Allchromatium vinosum strain MT86) and purple nonsulfur 
bacteria (Rhodopseudomonas palustris strain 120/1, Rhodobacter capsulatus strain 182, and 
Rubrivivax gelatinosus stain 151). DNA could be successfully extracted from all strains as is shown by 
gel electrophoresis by the method described in paragraph 2.6.3 (on page 45 ) (Figure 3-42). The bands 
of each lane were clear and the concentrations of all DNA extracts were sufficient for further PCR 
amplification. 
 
M: Marker X 
Figure 3-42. DNA extraction of ten representative strains. 
 
3.6.2 PCR amplifications and sequences analyses 
PCR amplifications and sequences analyses of pks I, pks II, nrps, phzE fragments of selected 
phototrophic bacteria were done according to the paragraph 2.6.2, on page 42. 
3.6.2.1 Classification of strains by 16S rRNA analysis 
The fragments of 16S rRNA genes are approximately 1500 nt, and these are shown in the results of the 
gel electrophoresis (Figure 3-43) performed as described in paragraph 2.6.3 (on page 45). With the 
exception of Rhodopseudomonas palustris strain 120/1, all strains were pure isolates as demonstrated 
by the BLASTn results (Table 3-26) and the microscopic observation. For strain 120/1, only 679 nt of 
the sequence were assembled and 45% of query cover with partial sequence of Rhodopseudomonas 
palustris, but 91% similarity. Strain MT86 was identified as A. vinosum strain MT86, because the 
sequence of the 16S rRNA gene showed 99.73% similarity with A. vinosum DSM180
T
 (GenBank 
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accession number NR_074584.1), and 99.72% sequence similarity with A. vinosum strain 5110 
(GenBank accession number NR_044605.1).  
Query cover (query coverage) indicates the percent of the query length that is included in the aligned 
segments how long piece of the sequences is covered by the amplified fragments 
(http://www.ncbi.nlm.nih.gov/Web/Newsltr/V15N2/BLView.html). By aligning query sequence 
against all sequences in a database, alignment can be used to search database for similar sequences.  
 
M: marker X; -: negative control (ddH2O as PCR template) 
Figure 3-43. 16S rRNA of ten strains. 
 
From the microscopic, growth observations and 16S rRNA band in Figure 3-43, strain 5410 showed to 
be pure. However, the BLASTn result of 16S rRNA was 93% similar to an uncultured bacterium clone 
EMIRGE OUT s7t4e93, which was not the same species as the classification species as original 
collection and definition. 
The remaining seven strains were identified according to origin and previous classification (Table 2-1). 
 
Table 3-26. 16S rRNA analysis of selected anoxygenic phototrophic bacteria. 
Sample Length  Next related strains Accession No. Ident 
5212 1492 nt Marichromatium gracile strain DSM 203
T 
 NR_116468.1 99% 
5410 1485 nt Uncultured bacterium clone EMIRGE OUT s7t4e 93  JX224500.1 93% 
5110 1434 nt Allochromatium vinosum strain DSM 180
 T
 NR_074584.1 99% 
2310 1466 nt Chlorobium limicola strain DSM 245 
T
 NR_074355.1 99% 
2410 1423 nt Prosthecochloris aestuarii strain DSM 271
 T 
  NR_074364.1 99% 
2360 1462 nt Chlorobium phaeobacteroides strain Glu AM050128.1 99% 
120/1 697 nt Rhodopseudomonas palustris CGMCC:9632  KM875706.1 91% 
182 1430 nt Rhodobacter capsulatus SB 1003  NR_102927.1 99% 
151 1495 nt Rubrivivax gelatinosus IL144  NR_074794.1 99% 
MT86 1495 nt Allochromatium vinosum strain DSM 180
 T
  NR_074584.1 99.73% 
Allochromatium vinosum strain 5110
 T 
  NR_044605.1 99.72% 
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3.6.2.2 PCR amplification of pks I fragments 
The fragments of pks I were amplified from the genomic DNA of all the ten strains with the primers 
K1F and M6R as outlined in the methods (paragraph 2.6.2, on page 42). The lengths of the 
amplificates were controlled by gel electrophoresis as shown in Figure 3-44 and Figure 3-45.  
The positive control showed one weak but clear band with about 1700 nt and one main band with 1500 
nt. There was no PCR band of pks I from the DNA of strain MT86, and a very weak band of strain 
5110. The other eight strains showed one clear band around 600 nt. Strain 120/1 and 151 showed an 
additional band around 1000 nt, and strain 2410 showed a clear band at 1700 nt which was the only 
band corresponding in length to the positive control.  
 
M: marker X; +: the extracted DNA of Streptomyces clavuligerus  
DSM 738 as the positive control; -: ddH2O as the negative control 
Figure 3-44. Gel electrophoresis of pks I amplified fragments. 
 
PCR amplifications of pks I were re|peated from all other strains (except A. vinosum strain MT86). 25 
µl of PCR (instead of 5 µl, Figure 3-44) of each amplificate was taken to the gel electrophoresis. The 
results of the gel separation are shown in Figure 3-45. Major bands were excised from the gel and 
purified by the method according to paragraph 2.6.4 (on page 45). The results of the sequence 
comparison and the detailed information for each band of PCR amplification is shown in Table 3-27, 
including the sequencing and BLASTn results. 
 
M: marker X; +: the extracted DNA of Streptomyces clavuligerus 
DSM 738 as the positive control; -: ddH2O as the negative control 
Figure 3-45. Gel electrophoresis of pks I amplified from nine strains and identification of purified bands. 
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Table 3-27. PCR amplification, sequencing results, and BLASTn results of pks I. 
Stains 
Expected 
length (nt) 
Length  
(nt) 
Next related sequences 
Max 
score 
Query 
cover 
Ident Accession Features 
Streptomyces 
clavuligerus 
DSM 738 
(Positive 
Control) 
  
  
  
  
  
  
①1636 ND -  -  -  -  -  - 
②1200 
-1400 
  
  
  
  
  
  
1302  
  
  
  
  
  
  
Streptomyces neyagawaensis concanamycin A 
biosynthetic gene cluster 
220 41% 74% DQ149987.1  NF 
Streptomyces sp. WAC5292 putative PKS gene, 
partial cds; and putative PKS gene, complete cds 
167 26% 76% JQ768039.1  NF 
Streptomyces amakusaensis gene for polyketide 
synthase, partial cds, strain: NBRC 12835, clone: 
amak12835m-N4 
134 21% 76% AB431358.1  NF 
Streptomyces cyaneogriseus subsp. 
noncyanogenus strain NMWT 1, complete 
genome 
152 22% 77% CP010849.1 
3598 bp at 5' side: short-chain 
dehydrogenase; 4109 bp at 3' 
side: methyltransferase 
Streptomyces violaceusniger Tu 4113, complete 
genome 
190 16% 75% CP002994.1 
①Acyl transferase 
②Beta-ketoacyl synthase 
Streptomyces leeuwenhoekii genome assembly 
sleC34, chromosome : chromosome 
80.5 14% 74% LN831790.1 
Polyketide synthase, type I, 
modules: 4, 5 and 6 
Streptomyces albulus strain NK660, complete 
genome 
69.4 5% 85% CP007574.1 
25238 bp at 5' side: GDP-
mannose 4,6-dehydratase 
3396 bp at 3' side: type I 
modular polyketide synthase 
5212 
  
  
①1600 ND -  -  -  -  -  - 
②1020 ND -  -  -  -  -  - 
③600 520  Marichromatium purpuratum 984 344 98% 79% CP007031.1 diguanylate cyclase 
5110 
  
  
  
  
  
①2036 ND -  -  -  -  -  - 
②1600 ND -  -  -  -  -  - 
③1020 ND -  -  -  -  -  - 
④900 ND -  -  -  -  -  - 
⑤800 ND  -  -  -  -  -  - 
⑥400 ND  -  -  -  -  -  - 
5410 
  
①2036 ND  -  -  -  -  -  - 
②1300 ND  -  -  -  -  -  - 
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③1200 ND  -  -  -  -  -  - 
④1000 ND  -  -  -  -  -  - 
⑤800 760  Thiocystis violascens DSM 198 1382 99% 99% CP003154.1 
signal transduction histidine 
kinase 
2410 ①700 616  Prosthecochloris aestuarii DSM 271 1074 100% 98% CP001108.1 NF 
2310 
  
  
  
①700-800 
  
  
  
647  
  
  
  
Rhodopseudomonas palustris CGA009 complete  
genome; segment 12/16 
1066 96% 96% BX572604.1 NF 
R. palustris TIE-1 647 96% 95% CP001096.1 NF 
R. palustris DX-1 431 84% 87% CP002418.1 NF 
2360 
  
  
  
①1636 ND  -  -  -  -  -  - 
②1020 ND  -  -  -  -  -  - 
③1000 ND  -  -  -  -  -  - 
④700 ND  -  -  -  -  -  - 
120/1 
  
  
  
①700-800 
  
  
  
674  
  
  
  
R. palustris CGA009 996 92% 95% BX572604.1 NF 
R. palustris TIE-1 601 92% 92% CP001096.1 NF 
R. palustris DX-1 412 81% 86% CP002418.1 NF 
R. palustris BisB5 327 75% 84% CP000283.1 NF 
182 
  
  
  
  
  
  
  
①1600 ND  -  -  -  -  -  - 
②1300 ND  -  -  -  -  -  - 
③700 
  
703  
  
Rhodobacter capsulatus SB 1003 431 51% 95% CP001312.1 conserved hypothetical protein 
R. capsulatus strain SB1003 431 51% 95% AF010496.1 transposase, IS3/IS911 family 
④650 ND  -  -  -  -  -  - 
⑤500 ND  -  -  -  -  -  - 
⑥400 ND  -  -  -  -  -  - 
⑦350 300  R. capsulatus SB 1003 327 84% 90% CP001312.1 peptidase, M10 family 
151 
  
  
  
  
①1000 ND  -  -  -  -  -  - 
②900 ND  -  -  -  -  -  - 
③700-800 
  
  
772  
  
  
R. palustris CGA009  1347 97% 99% BX572604.1 NF 
R. palustris TIE-1 811 97% 98% CP001096.1  NF 
R. palustris DX-1 573 87% 91% CP002418.1  NF 
④360 ND  -  -  -  -  -  - 
MT86 × × × × ×   × × × 
ND: not detected; NF: no feature; NB: no BLASTn results; -: not available; ×: no results.  
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3.6.2.3 PCR amplification of pks II fragments 
The fragments of pks II were amplified from the genomic DNA of all ten strains using primers 945f 
and 945r (refers to paragraph 2.6.2, and Table 2-12). The separation of the PCR products using gel 
electrophoresis (paragraph 2.6.3, on page 45) is shown in Figure 3-46. 
The positive control (Streptomyces achromogehes DSM40789) showed three main bands; the upper 
two bands (ca. 1200 nt, and 900-1000 nt) were weaker than the brightest band with around 600 nt. The 
pks II amplification result of strain 5212 did not show any band. The other strains showed at least four 
bands in each lane, and the bands that were easier to cut off for purification were given numbers as 
seen in Figure 3-46. The sequencing results and BLASTn results are shown in Table 3-28. 
 
 
      (c) 
M: marker X; +: extracted DNA of Streptomyces achromogehes DSM 40789  
as the positive control;-: ddH2O as negative control. 
 
Figure 3-46. Gel electrophoresis of PCR products amplified with primers  
945f and 945r supposed to amplify pks II from nine strains and numbers of purified bands. 
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Table 3-28. PCR amplification, sequencing results, and BLASTn results of pks II. 
Strains 
Expected 
length (nt) 
Length 
(nt) 
Next related sequences 
Max 
scor
e 
Query 
cover 
Ident Accession   
Streptomyces 
achromogehes 
(Positive 
Control)  
  
  
  
  
①1200 ND  -  -  -  -  -  - 
②900-
1000 
ND  -  -  -  -  -  - 
③600 
  
  
  
614 
  
  
  
Streptomyces sp. PBH53 genome 893 99% 92% CP011799.1 beta-ACP synthase  
Streptomyces hygroscopicus subsp. 
jinggangensis TL01 
881 99% 92% NC_020895.1 beta-ACP synthase  
Streptomyces hygroscopicus subsp. 
jinggangensis 5008 
881 99% 92% NC_017765.1 beta-ACP synthase  
Streptomyces lividans TK24 547 99% 82% 
NZ_CP00912
4.1 
beta-ACP synthase  
5212 × ×  ×  × × ×  ×  × 
5110 
  
  
  
  
  
  
  
  
  
  
  
  
  
①2036 ND  -  -  -  -  -  - 
②1300 ND  -  -  -  -  -  - 
③800 ND  -  -  -  -  -  - 
④700 ND  -  -  -  -  -  - 
⑤650 ND  -  -  -  -  -  - 
⑥350 
  
  
  
  
  
  
  
  
351 
  
  
  
  
  
  
  
  
Allochromatium vinosum DSM 180 518 92% 96% CP001896.1 acriflavin resistance protein 
Rubrivivax gelatinosus IL144 DNA 244 79% 83% AP012320.1 acriflavin resistance protein 
Variovorax paradoxus B4 chromosome 1 222 78% 81% CP003911.1 
putative multidrug efflux 
transporter, AcrB/AcrD/AcrF 
family 
Variovorax paradoxus EPS 222 78% 81% CP002417.1 acriflavin resistance protein 
Leptothrix cholodnii SP-6 217 85% 80% CP001013.1 acriflavin resistance protein 
Acidovorax citrulli AAC00-1 176 78% 78% CP000512.1 acriflavin resistance protein 
Pseudoxanthomonas suwonensis 11-1 172 79% 78% CP002446.1 acriflavin resistance protein 
Acidovorax avenae subsp. avenae ATCC 
19860 
171 78% 78% CP002521.1 acriflavin resistance protein 
Stenotrophomonas rhizophila strain 
DSM14405  
161 70% 79% CP007597.1 
ACR/RND family 
transmembrane transporter 
5410 ①1100 ND  -  -  -  -  -  - 
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②700 ND  -  -  -  -  -  - 
③550 ND  -  -  -  -  -  - 
④400 ND  -  -  -  -  -  - 
2410 
  
  
  
①> 2360 ND  -  -  -  -  -  - 
②1200 518 NB  /  /  /  /  / 
③1000 ND  -  -  -  -  -  - 
④650 ND  -  -  -  -  -  - 
2310 
  
  
  
  
  
  
  
  
  
  
  
  
①1350 ND  -  -  -  -  -  - 
 
②750 
437 
  
  
  
  
  
  
  
  
  
R palustris CGA009; segment 12/16 800 100% 99% BX572604.1  NF 
R. palustris TIE-1, complete genome 767 99% 98% CP001096.1 
urea ABC transporter, permease 
protein UrtC 
R. palustris DX-1, complete genome 540 92% 91% CP002418.1 
urea ABC transporter, permease 
protein UrtC 
R. palustris HaA2, complete genome 494 88% 90% CP000250.1 inner-membrane translocator 
R. palustris BisB5, complete genome 431 88% 87% CP000283.1 inner-membrane translocator 
Agromonas oligotrophica S58 DNA, 
complete genome 
407 88% 86% AP012603.1 
putative branched-chain amino 
acid ABC transporter, permease 
protein 
Bradyrhizobium sp. ORS278,complete 
sequence 
396 88% 85% CU234118.1 
Putative Branched-chain amino 
acid ABC transporter 
(permease protein) 
Bradyrhizobium sp. BTAi1, complete 
genome 
385 88% 85% CP000494.1 
amino acid/amide ABC 
transporter membrane protein 2, 
HAAT family 
Bradyrhizobium japonicum USDA 6 DNA, 
complete genome 
383 88% 85% AP012206.1 
ABC transporter permease 
protein 
R. palustris BisB18, complete genome 381 91% 84% CP000301.1 inner-membrane translocator 
③650 156 NB  /  / /  / / 
④500 ND  -  -  -  -  -  - 
⑤450 ND  -  -  -  -  -  - 
2360 
  
①1200 ND  -  -  -  -  -  - 
②650 ND  -  -  -  -  -  - 
120/1 ①> 3054 ND  -  -  -  -  -  - 
RESULTS 
 
 
 
108 
  
  
  
  
  
  
  
  
  
②1800 ND  -  -  -  -  -  - 
③800 ND  -  -  -  -  -  - 
④750 575 
R. palustris CGA009 complete genome; 
segment 10/16 
1031 100% 99% BX572602.1  NF 
R. palustris TIE-1, complete genome 970 100% 97% CP001096.1 
diguanylate 
cyclase/phosphodiesterase 
⑤600 496 
R. palustris CGA009; segment 13/16 891 100% 99% BX572605.1  NF 
R. palustris TIE-1, complete genome 857 100% 98% CP001096.1 
conserved hypothetical protein 
flagellar motor switch protein 
FliM 
R. palustris DX-1, complete genome 736 100% 93% CP002418.1 
flagellar motor switch protein 
FliM hypothetical protein 
R. palustris BisB5, complete genome 580 96% 89% CP00283.1 NF 
⑥170 ND  -  -  -  -  -  - 
⑦170 169 
R  palustris TIE-1, complete genome 217 91% 92% CP001096.1 
ABC transporter substrate-
binding protein 
R  palustris CGA009; segment 1/16 217 91% 92% BX572593.1  NF 
R  palustris DX-1, complete genome 198 86% 91% CP002418.1 
ABC transporter substrate-
binding protein 
182 
  
  
  
  
  
  
  
  
  
  
  
  
①>3054 ND  -  -  -  -  -  - 
②3054 ND  -  -  -  -  -  - 
③1000 
  
  
  
  
  
974 
  
  
  
  
  
Paracoccus bengalensis strain DSM 17099 
insertion sequence ISPbe1 transposase genes, 
complete cds 
220 16% 92% GQ871936.1  NF 
Rhodobacter sphaeroides ATCC 17025 
plasmid pRSPA01, complete sequence 
174 12% 93% CP000662.1  NF 
Rhodobacter sphaeroides ATCC 17025 174 24% 93% CP000661.1 hypothetical protein  
Rhodobacter sphaeroides KD131 
chromosome 1, complete sequence 
167 12% 92% CP001150.1 
①D12 class N6 adenine-
specific DNA methyltransferase 
②4 bp at 5' side: Hypothetical 
Protein 
516 bp at 3' side: Hypothetical 
Protein 
R. sphaeroides ATCC 17029 chromosome 2 165 11% 93% CP000578.1  NF 
Octadecabacter arcticus 238, complete 
genome 
84.2 8% 85% CP003742.1 putative transposase  
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④750 ND  -  -  -  -  -  - 
⑤600 436 NB  /  /  /  / / 
⑥500 514 Rhodobacter capsulatus SB 1003 623 95% 90% CP001312.1 
NAD(+) kinase transcriptional 
regulatory protein ZraR 
⑦450 436 R. capsulatus SB 1003, complete genome 324 92% 81% CP001312.1 
methionine synthase, A 
subunit-2 
⑧300 307  NB  / /   /  / / 
151 
  
  
  
  
  
  
  
  
  
  
①>3054 ND  -  -  -  -  -  - 
②1000 ND  -  -  -  -  -  - 
③750 ND  -  -  -  -  -  - 
④580 
  
  
  
  
572 
  
  
  
  
Ralstonia solanacearum CFBP2957  
plasmid RCFBPv3 mp 
100 25% 80% FP885907.1  NF 
R. solanacearum strain IPO1609 Genome 
Draft 
100 25% 79% CU914166.1  NF 
R. solanacearum Po82 megaplasmid 95.3 25% 79% CP002820.1  NF 
R. solanacearum PSI07 megaplasmid 
mpPSI07 
84.2 25% 78% FP885891.2  NF 
Chromobacterium violaceum ATCC 12472 73.1 11% 86% AE016825.1 nitrate reductase 
⑤170 
  
  
169 
  
  
R  palustris TIE-1, complete genome 217 91% 92% CP001096.1 
ABC transporter substrate-
binding protein 
R. palustris CGA009 complete genome; 
segment 1/16 
217 91% 92% BX572593.1  NF 
R. palustris DX-1, complete genome 198 86% 91% CP002418.1 
ABC transporter substrate-
binding protein 
MT86 ①1200 ND  -  -  -  -  -  - 
 ②1000 ND  -  -  -  -  -  - 
 ③900 ND  -  -  -  -  -  - 
 ④650 366 Allochromatium vinosum DSM 180 351 97% 85% CP001896.1 
Glucose-1-phosphate adenylyl 
transferase 
 ⑤450 ND  -  -  -  -  -  - 
 ⑥400 ND  -  -  -  -  -  - 
 ⑦280 255 Allochromatium vinosum DSM 180 388 98% 94% CP001896.1 
multi-sensor signal transduction 
histidine kinase 
ND: not detected; NF: no feature; NB: no BLASTn results; -: not available; /: no results, ×: no PCR results. 
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3.6.2.4 PCR amplification of nrps fragments 
The fragments of nrps were amplified from the genomic DNA of all ten strains using the primers A2f 
and A3r. The gel electrophoresis of the PCR products is shown in Figure 3-47.  
The positive control (Pseudomonas sp. DSM50117) showed only one band in the position of 250 nt. 
The nrps amplification results of all ten strains showed one or more (2-7) bands, and those bands that 
were cut off for purification and sequencing were given numbers as seen in Figure 3-47. The 
sequencing results and BLASTn results are shown in Table 3-29. 
 
M: marker 100 bp ladder; +: extracted DNA of Pseudomonas sp. DSM 50117 as positive control; -: ddH2O as negative 
control. 
Figure 3-47. Gel electrophoresis of PCR products from amplification with  
primers designed for nrps gene fragments and identification by numbers of the bands purified. 
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Table 3-29. PCR amplification, sequencing results, and BLASTn results of nrps. 
Strains 
Expected 
length of 
band (nt) 
Sequence 
length (nt) 
Next related sequences 
Max 
score 
Query 
cover 
Ident Accession Features 
Pseudomonas 
sp. 
DSM50117 
(Positive 
control) 
  
  
  
①250 218  
Streptomyces sp. HB157 amino acid adenylation domain-
containing protein-like gene, partial sequence 
279 90% 92% GQ863956.1 NF 
Streptomyces sp. HB102 putative amino acid adenylation domain-
containing protein gene, partial cds 
278 100% 90% GQ863949.1 NF 
Streptomyces sp. HB272 amino acid adenylation domain-
containing protein-like gene, partial sequence 
265 90% 91% GQ863961.1 NF 
Streptomyces sp. HB142 putative amino acid adenylation domain-
containing protein gene, partial cds 
265 90% 91% GQ863953.1 NF 
Streptomyces sp. HB149 amino acid adenylation domain-containing 
protein-like gene, partial sequence 
254 90% 90% GQ863954.1 NF 
5212 
  
  
  
①700 328   NB / / / / / 
②400 ND  -  -  -  -  -  - 
③280 155  NB 
    
 
④200 ND  -  -  -  -  -  - 
⑤150 ND  -  -  -  -  -  - 
5110 
  
  
  
  
  
①800 ND  -  -  -  -  -  - 
②500 241   Allochromatium vinosum DSM 180, complete genome 355 99% 93% CP001896.1 
1289 bp at 5' side: 
hypothetical protein 
560 bp at 3' side: glutamate-1-
semialdehyde-2,1-
aminomutase 
③350 ND  -  -  -  -  -  - 
④300 244   A. vinosum DSM 180, complete genome 252 99% 87% CP001896.1  
acyl-CoA ligase (AMP-
forming), exosortase system 
type 1 associated 
⑤290 135   A. vinosum DSM 180, complete genome 174 85% 93% CP001896.1  
Di-heme cytochrome c 
peroxidase 
⑥280 ND  -  -  -  -  -  - 
⑦200 ND  -  -  -  -  -  - 
5410 
  
①1000 ND  -  -  -  -  -  - 
②600 ND  -  -  -  -  -  - 
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③550 ND  -  -  -  -  -  - 
④450 ND  -  -  -  -  -  - 
⑤300 261   NB / / / / / 
⑥290 157   NB / / / / / 
⑦280 ND  -  -  -  -  -  - 
2410 
①1000 ND  -  -  -  -  -  - 
②150 ND  -  -  -  -  -  - 
2310 
  
①300 190   
R palustris TIE-1, complete genome 270 97% 93% CP001096.1  
AMP-dependent synthetase 
and ligase 
R. palustris CGA009 complete genome; segment 1/16 237 91% 91% BX572593.1 NF 
②200 140   
R. palustris TIE-1, complete genome 132 97% 84% CP001096.1  
urea ABC transporter, 
permease protein UrtC 
R. palustris CGA009 complete genome; segment 12/16 132 87% 86% BX572604.1 NF 
R. palustris DX-1, complete genome 115 89% 83% 
CP002418.1 
 
urea ABC transporter, 
permease protein UrtC 
Bradyrhizobium japonicum USDA 110 DNA, complete genome 111 79% 85% 
BA000040.2 
 
ABC transporter permease 
protein 
Burkholderia thailandensis MSMB121 chromosome 1, complete 
sequence 
110 82% 84% 
CP004095.1 
 
urea ABC transporter, 
permease protein UrtC 
Bradyrhizobium sp. S23321 DNA, complete genome 106 81% 84% 
AP012279.1 
 
ABC transporter permease 
protein 
2360 ①800 559   Chlorobium phaeobacteroides DSM 266, complete genome 905 97% 97% 
CP000492.1 
 
①conserved hypothetical 
protein, protein of unknown 
function DUF1568 
②199 bp at 5' side: conserved 
hypothetical protein 
80 bp at 3' side: protein of 
unknown function DUF1568 
③246 bp at 5' side: conserved 
hypothetical protein 
33 bp at 3' side: protein of 
unknown function DUF1568 
120/1 
  
  
  
①800 ND  -  -  -  -  -  - 
②500 ND  -  -  -  -  -  - 
③300 290   R. palustris TIE-1, complete genome 481 99% 97% CP001096.1  AMP-dependent synthetase 
RESULTS 
 
 
 
113 
  
  
and ligase 
R. palustris CGA009 complete genome; segment 1/16 394 99% 91% BX572593.1 NF 
R. palustris DX-1, complete genome 372 99% 90% CP002418.1  
AMP-dependent synthetase 
and ligase 
R. palustris BisB5, complete genome 259 97% 83% CP000283.1 
AMP-dependent synthetase 
and ligase 
R. palustris BisA53, complete genome 211 99% 80% CP000463.1  
AMP-dependent synthetase 
and ligase 
④200 132   
R. palustris CGA009 complete genome; segment 12/16 156 86% 91% BX572604.1  
urea ABC transporter, 
permease protein UrtC 
R. palustris TIE-1, complete genome 145 97% 87% CP001096.1 NF 
R. palustris DX-1, complete genome 124 89% 86% CP002418.1  
urea ABC transporter, 
permease protein UrtC 
Agromonas oligotrophica S58 DNA, complete genome 122 72% 90% AP012603.1  
putative branched-chain amino 
acid ABC transporter 
permease protein 
Bradyrhizobium japonicum USDA 110 DNA, complete genome 122 86% 86% BA000040.2 
ABC transporter permease 
protein 
Bradyrhizobium sp. S23321 DNA, complete genome 117 88% 85% AP012279.1  
ABC transporter permease 
protein 
Burkholderia thailandensis MSMB121 chromosome 1, complete 
sequence 
106 88% 83% CP004095.1  
urea ABC transporter, 
permease protein UrtC 
182 
  
  
①700 ND  -  -  -  -  -  - 
②400 ND  -  -  -  -  -  - 
③250 266   R. palustris CGA009 complete genome; segment 2/16 261 83% 88% BX572594.1  NF 
④150 ND  -  -  -  -  -  - 
151 
  
  
①800 ND  -  -  -  -  -  - 
②500 245   
R. palustris TIE-1, complete genome 
361 93% 94% 
CP001096.1 
 
AMP-dependent synthetase 
and ligase 
R. palustris CGA009 complete genome; segment 1/16 283 91% 88% BX572593.1 NF 
R. palustris BisB5, complete genome 
195 75% 85% 
CP000283.1 
 
AMP-dependent synthetase 
and ligase 
③300 138   
R. palustris TIE-1, complete genome 150 95% 87% CP001096.1  
urea ABC transporter, 
permease protein UrtC 
R. palustris CGA009 complete genome; segment 12/16 145 84% 89% BX572604.1 NF 
RESULTS 
 
 
 
114 
R. palustris DX-1, complete genome 124 87% 85% CP002418.1  
urea ABC transporter, 
permease protein UrtC 
Bradyrhizobium japonicum USDA 110 DNA, complete genome 121 84% 86% BA000040.2  
ABC transporter permease 
protein 
Bradyrhizobium sp. S23321 DNA, complete genome 115 86% 84% AP012279.1  
ABC transporter permease 
protein 
④200 173  NB / / / / / 
MT86 
  
  
  
  
  
  
  
①500 281   
A. vinosum DSM 180, complete genome 318 85% 90% 
CP001896.1 
 
1466 bp at 5' side: 
hypothetical protein 
378 bp at 3' side: glutamate-1-
semialdehyde-2,1-
aminomutase 
Thioalkalivibrio sulfidophilus HL-EbGr7, complete genome 122 51% 82% CP001339.1  propionate--CoA ligase 
Leisingera methylohalidivorans DSM 14336 strain MB2, DSM 
14336, complete genome 
106 57% 79% CP006773.1  acyl-CoA synthetase 
Azotobacter vinelandii CA6, complete genome 104 54% 79% CP005095.1  acetyl-CoA synthetase 
②300 ND  -  -  -  -  -  - 
③250 191   A. vinosum DSM 180, complete genome 291 96% 95% CP001896.1  acetate/CoA ligase 
④200 149  NB / / / / / 
ND: not detected; NF: no feature; NB: no BLASTn results; -: not available; /: no results. 
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3.6.2.5 PCR amplification of phzE fragments 
The fragments of phzE were amplified from the genomic DNA of all ten strains by using the primers 
phzEf and phzEr. Separation of the PCR products by gel electrophoresis (paragraph 2.6.3, on page 45) 
is shown in Figure 3-48.  
The positive control (Pseudomonas sp. DSM50117) showed one band in the position of 400-450 nt. 
The phzE amplification results of all strains showed one clear band (ca. 420 nt) at the position of the 
positive control (no band was seen in strain 2360). The bands were cut off and purified for sequencing. 
The sequencing results and BLASTn results are shown in Table 3-30. 
 
(a) 
 
(b) 
M: marker X (a) and marker 100 bp ladder (b);  
+: extracted DNA of Pseudomonas sp. DSM50117 as positive control; -: ddH2O as negative control. 
 
Figure 3-48. Gel electrophoresis of PCR products from amplification with primers  
designed for phzE gene fragments and identification by numbers of the bands purified. 
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Table 3-30. PCR amplification, sequencing results, and BLASTn results of phzE. 
Strains 
Expected 
length (nt) 
Length 
(nt) 
Next related sequences 
Max 
score 
Query 
cover 
Ident Accession Features 
Pseudomonas sp. 
DSM50117 
(Positive control) 
  
  
  
  
 
①400-450 425 
Pseudomonas chlororaphis subsp. aurantiaca strain JD37 682 99% 96% CP009290.1  anthranilate*  
P. chlororaphis subsp. aurantiaca DNA, phz gene cluster, 
complete cds, strain: StFRB508 
682 99% 96% AB794886.1 NF 
P. chlororaphis strain GP72 phenazine biosynthesis gene 
cluster 
676 99% 95% HM594285.1 NF 
P. chlororaphis strain PA23 671 99% 95% CP008696.1  anthranilate* 
P. chlororaphis partial phzE gene for Phenazine E, isolate 
Toza7 
634 88% 97% HG800017.1 NF 
Pseudomonas fluorescens strain LBUM223 538 99% 89% CP011117.1  PhzE* 
5212 
  
  
  
  
  
  
  
  
①420 
  
418 
P. chlororaphis subsp. aurantiaca strain JD37 715 99% 98% CP009290.1  anthranilate* 
P. chlororaphis subsp. aurantiaca DNA, phz gene cluster, 
complete cds, strain: StFRB508 
715 99% 98% AB794886.1 NF 
P. chlororaphis strain GP72 phenazine biosynthesis gene 
cluster,  
710 99% 97% HM594285.1 NF 
P. chlororaphis strain PA23 704 99% 97% CP008696.1  anthranilate* 
P. chlororaphis partial phzE gene for Phenazine E, isolate 
Toza7 
645 89% 98% HG800017.1 NF 
P. fluorescens strain LBUM223 571 99% 91% CP011117.1  PhzE* 
5110 
  
  
  
  
  
  
  
  
  
①420 418 
P. chlororaphis subsp. aurantiaca strain JD37  715 99% 98% CP009290.1  anthranilate* 
P. chlororaphis subsp. aurantiaca DNA, phz gene cluster, 
complete cds, strain: StFRB508 
715 99% 98% AB794886.1 NF 
P. chlororaphis strain GP72 phenazine biosynthesis gene 
cluster 
710 99% 97% HM594285.1 NF 
P. chlororaphis strain PA23  704 99% 97% CP008696.1  anthranilate* 
P. chlororaphis partial phzE gene for Phenazine E, isolate 
Toza7 
645 89% 98% HG800017.1 NF 
P. fluorescens strain LBUM223 571 99% 91% CP011117.1  PhzE* 
P. fluorescens strain S2P5 phenazine biosynthetic gene locus,  544 99% 90% AY960782.1 NF 
5410 
  
  
①420 425  
P. chlororaphis subsp. aurantiaca strain JD37 723 99% 97% CP009290.1  anthranilate* 
P. chlororaphis subsp. aurantiaca DNA, phz gene cluster, 
complete cds, strain: StFRB508 
723 99% 97% AB794886.1 NF 
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P. chlororaphis strain GP72 phenazine biosynthesis gene 
cluster 
717 99% 97% HM594285.1 NF 
P. chlororaphis strain PA23 712 99% 97% CP008696.1  anthranilate* 
P. chlororaphis partial phzE gene for Phenazine E, isolate 
Toza7 
645 88% 98% HG800017.1 NF 
P. fluorescens strain LBUM223 579 99% 91% CP011117.1  PhzE* 
2410 
  
  
  
  
  
  
  
  
  
  
①420 421  
P. chlororaphis subsp. aurantiaca strain JD37 723 99% 97% CP009290.1  anthranilate* 
P. chlororaphis subsp. aurantiaca DNA, phz gene cluster, 
complete cds, strain: StFRB508 
723 99% 97% AB794886.1 NF 
P. chlororaphis strain GP72 phenazine biosynthesis gene 
cluster 
717 99% 97% HM594285.1 NF 
P. chlororaphis strain PA23 712 99% 97% CP008696.1  anthranilate* 
P. chlororaphis partial phzE gene for Phenazine E, isolate 
Toza7 
645 88% 98% HG800017.1 NF 
P. fluorescens strain LBUM223 579 99% 91% CP011117.1  PhzE* 
Pseudomonas fluorescens strain S2P5 phenazine biosynthetic 
gene locus, complete sequence 
551 99% 90% AY960782.1 NF 
P. fluorescens autoinducer synthase (phzI) gene, positive 
regulator protein (phzR), phzABCDEFG genes, complete cds 
551 99% 90% L48616.1 NF 
2310 
  
  
  
  
  
  
  
  
  
  
①420 414  
P. chlororaphis subsp. aurantiaca strain JD37 710 100% 98% CP009290.1  anthranilate* 
P. chlororaphis subsp. aurantiaca DNA, phz gene cluster, 
complete cds, strain: StFRB508 
710 100% 98% AB794886.1 NF 
P. chlororaphis strain GP72 phenazine biosynthesis gene 
cluster 
704 100% 97% HM594285.1 NF 
P. chlororaphis strain PA23 699 100% 97% CP008696.1  anthranilate* 
P. chlororaphis partial phzE gene for Phenazine E, isolate 
Toza7 
645 90% 98% HG800017.1 NF 
P. fluorescens strain LBUM223, 566 100% 91% CP011117.1  PhzE* 
P. fluorescens strain S2P5 phenazine biosynthetic gene locus 538 100% 90% AY960782.1 NF 
P. fluorescens autoinducer synthase (phzI) gene, positive 
regulator protein (phzR), phzABCDEFG genes, complete cds 
538 100% 90% L48616.1 NF 
2360 / / / / / / / / 
120/1 ①420 425 
P. chlororaphis subsp. aurantiaca strain JD37 728 99% 98% CP009290.1 anthranilate* 
P. chlororaphis subsp. aurantiaca DNA, phz gene cluster, 
complete cds, strain: StFRB508 
728 99% 98% AB794886.1 NF 
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P. chlororaphis strain GP72 phenazine biosynthesis gene 
cluster 
723 99% 97% HM594285.1 NF 
P. chlororaphis strain PA23  717 99% 97% CP008696.1 anthranilate* 
P. chlororaphis subsp. aurantiaca strain Pcho10 phenazine-1-
carboxamide product biosynthetic and regulatory gene 
cluster, partial sequence 
712 99% 97% KJ457347.1 NF 
P. fluorescens strain LBUM223 584 99% 92% CP011117.1 PhzE* 
182 
  
  
  
  
  
  
  
  
①420 429 
P. chlororaphis subsp. aurantiaca strain JD37 623 98% 93% CP009290.1  anthranilate* 
P. chlororaphis subsp. aurantiaca DNA, phz gene cluster, 
complete cds, strain: StFRB508 
623 98% 93% AB794886.1 NF 
P. chlororaphis strain GP72 phenazine biosynthesis gene 
cluster 
623 98% 93% HM594285.1 NF 
P. chlororaphis strain PA23 617 98% 92% CP008696.1  anthranilate* 
P. chlororaphis subsp. aurantiaca strain Pcho10 phenazine-1-
carboxamide product biosynthetic and regulatory gene 
cluster, partial sequence 
606 98% 92% KJ457347.1 NF 
P. chlororaphis partial phzE gene for Phenazine E, isolate 
Toza7 
580 87% 94% HG800017.1 NF 
P. fluorescens strain LBUM223 488 98% 87% CP011117.1  PhzE* 
151 ①420 215 NB / / / / / 
MT86 
  
  
  
  
  
  
  
  
  
①420 424  
P. chlororaphis subsp. aurantiaca strain JD37 721 99% 97% CP009290.1  anthranilate* 
P. chlororaphis subsp. aurantiaca DNA, phz gene cluster, 
complete cds, strain: StFRB508 
721 99% 97% AB794886.1 NF 
P. chlororaphis strain GP72 phenazine biosynthesis gene 
cluster 
715 99% 97% HM594285.1 NF 
P. chlororaphis strain PA23 710 99% 97% CP008696.1  anthranilate* 
P. chlororaphis subsp. aurantiaca strain Pcho10 phenazine-1-
carboxamide product biosynthetic and regulatory gene 
cluster, partial sequence 
704 99% 97% KJ457347.1 NF 
P. chlororaphis partial phzE gene for Phenazine E, isolate 
Toza7 
645 88% 98% HG800017.1 NF 
P. fluorescens strain LBUM223 577 99% 91% CP011117.1  PhzE 
P. fluorescens strain S2P5 phenazine biosynthetic gene locus 549 99% 90% AY960782.1 NF 
ND: not detected; NF: no feature; NB: no BLASTn results; -: not available; ×: no results. PhzE*: Phenazine biosynthesis protein/PhzE 2-Amino-2-deoxy-isochorismate synthase; 
anthranilate*: anthranilate synthase  
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3.6.2.6 Sequences analysis 
From the Table 3-27, Table 3-28, Table 3-29, and Table 3-30, a summary can be obtained and is 
shown in Table 3-31. 
BLASTn results of pks I sequences (column 1 of Table 3-31) demonstrated the following: 
1) The pks I fragment of Streptomyces clavuligetus DSM 738 (the positive control) had a 1302 nt 
sequence and showed 74% similarity to a concanamycin A biosynthetic gene cluster (41% 
query cover) of Streptomyces neyagawaensis, 76% similarity to a putative PKS gene cluster 
(26% query cover) of Streptomyces sp. WAC5292 and other PKSs related features of other 
Streptomyces species. This indicates that the primers, PCR system and program for pks I were 
well functioning. 
2) The BLASTn results of the sequences from pks I fragment of all ten strains revealed similar 
features to deposited sequences of the databases. However, relatedness was obtained to several 
other functional genes, but not to the polyketide synthase systems. There is no proof for a type 
I pks gene in the tested phototrophic bacteria by the methods used in the present study. 
3) Although the 16S rRNA result showed the next related strain to Thiocystis violascens 5410 
was an uncultured bacterium (clone EMIRGE OUT s7t4e93), the pks I result of strain 5410 
showed that the 760 nt fragment was 99% similar to a signal transduction histidine kinase 
gene cluster of Thiocystis violascens DSM 198 (which should be the same strain as 5410). The 
discrepancies between the type strains of Thiocystis violascens from different sources, 
respectively of the sequences assigned to this strain, cannot be explained.  
The BLASTn results of fragments of pks II demonstrated that the desired genes of the positive control 
Streptomyces arehromogenes DSM 40789 were amplified with a fragment size of 614 nt. This 
fragment sequence was 92% similar (99% query cover) to the corresponding sequence of the genomes 
of Streptomyces sp. PBH53, Streptomyces hygroscopicus subsp. jinggangensis TL01, and 
Streptomyces hygroscopicus subsp. jinggangensis 5008. All the features can be found as β-ACP 
synthase (EC 2.3.1.41, an enzyme involved in PKS system and results in the formation of acetoacetyl 
ACP). The positive control demonstrated the functionality of the primers and PCR system, but there 
was no indication of a type II pks gene in any of the bacteria analyzed in the present study. 
From the nrps amplification and BLASTn results, some interesting features were found. As the 
positive control Pseudomonas sp. DSM 50117 was used, a 218 nt fragment was 90% similar (100% 
query cover) to the gene of a putative amino acid adenylation domain-containing protein of 
Streptomyces sp. HB102. The amplified nrps fragment from strain 5110 was 244 nt and 87% similar, 
with 99% query cover, to an exosortase system type 2 associated AMP-forming acyl-CoA ligase gene 
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cluster of A. vinosum DSM 180
T
. The 281 nt fragment of nrps from MT86 showed 85% similarity (90% 
query cover) to a glutamate-1-semialdehyde-2,1-aminomutase gene cluster of A. vinosum DSM 180
T
; 
82% similarity (51% query cover) to a propionate-CoA ligase gene cluster of Thioalkalivibrio 
sulfidophilus HL-EbGr7; 79% (57% query cover) similarity to a feature of acyl-CoA synthase gene 
cluster of Leisingera methylohalidivorans DSM 14336 strain MB2; and 79% (54% query cover) 
similarity to an acetyl-CoA synthase gene cluster of Azotobacter vinelandii CA6. Another shorter 191 
nt fragment, which was 95% similar (96% query cover) to an acetate/CoA ligase gene cluster of A. 
vinosum DSM 180
T
, was amplified and assembled successfully from MT86. 
The positive control for phzE amplification was the anthralinate synthase gene of Psedomonas sp. 
DSM50117 (425 nt). The phzE gene sequence from Pseudomonas sp. DSM50117, according to 
BLASTn analysis, was 95-97% similar (99% query cover) to this gene from P. chlororaphis subsp. 
aurantiaca strain JD37; P. chlororaphis subsp. aurantiaca StFRB508; P. chlororaphis strain GP72; 97% 
similar (88% query cover) to a partial phzE sequence of P. chlororaphis Toza7 isolate; 89% similar 
(99% query cover) to a phzE gene cluster of P. fluorescens strain LBUM223.  
The lengths of phzE fragments from eight strains were between 414 and 430 nt, and showed almost the 
same results of BLASTn analyses and indicated features as the positive control. Two strains gave 
negative results: Chlorobium phaeobacteroides strain 2360 yielded no phzE amplification product and 
Rubrivivax gelatinosus strain 151 yielded a 215 nt fragment but did not give positive results with 
BLASTn analysis. The used phzE amplification primers, PCR system and program were useful in 
phzE gene screening and allowed identification of putative PhzE synthases in eight strains (including A. 
vinosum strain MT86) of the studied phototrophic bacteria.  
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Table 3-31. Summary of gene screening of representative phototrophic bacteria. 
Strain 
No. 
pks I pks II nrps phzE 
Length Features Length Features Length Features Length Features 
Pos. 
1302 
nt 
concanamycin A; 
short-chain 
dehydrogenase; 
Acyl transferase,  
β-ketoacyl synthase,  
type I modular polyketide 
synthase 
614 nt  β-ACP synthase 218 nt Adenylation domain 425 nt 
anthranilate; 
biosynthesis protein 
PhzE (2-amino-2-deoxy-
isochrimate synthase 
5212 520 nt diguanylate cyclase × × 
328 nt  (NB) 
418 nt 
anthranilate; 
biosynthesis protein 
PhzE  
155 nt  (NB) 
5110 ND - 351 nt 
acriflavin resistance 
protein; 
putative multidrug efflux 
transporter, 
AcrB/AcrD/AcrF family 
 
241 nt 
glutamate-1-semialdehyde-2,1-
aminomutase 
418 nt 
anthranilate; 
biosynthesis protein 
PhzE  
244 nt 
acyl-CoA ligase (AMP-forming), 
exosortase system type 1 
associated 
135 nt Di-heme cytochrome c peroxidase 
5410 760 nt 
signal transduction 
histidine kinase 
ND - 
261 nt  NB 
425 nt 
anthranilate; 
biosynthesis protein 
PhzE  
157 nt  NB 
2310 647 nt  NF 
437 nt 
Putative Branched-chain 
amino acid ABC 
transporter (permease 
protein) 
190 nt 
AMP-dependent synthetase and 
ligase 
414 nt 
anthranilate; 
biosynthesis protein 
PhzE  
146 nt  NB 140 nt 
urea ABC transporter, permease 
protein UrtC 
2360 ND - ND - 559 nt 
conserved hypothetical protein, 
protein of unknown function 
DUF1568 
× - 
2410 616 nt  NF 518 nt  NB ND - 421 nt 
anthranilate; 
biosynthesis protein 
PhzE  
120/1 674 nt  NF 575 nt diguanylate cyclase/ 290 nt AMP-dependent synthetase and 425 nt anthranilate; 
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phosphodiesterase  ligase biosynthesis protein 
PhzE  
496 nt 
conserved hypothetical 
protein flagellar motor 
switch protein FliM 
132 nt 
urea ABC transporter, permease 
protein UrtC 169 nt 
ABC transporter 
substrate-binding protein 
182 
703 nt 
 
conserved hypothetical 
protein; transposase, 
IS3/IS911 family 
974 nt 
 
D12 class N6 adenine-
specific DNA 
methyltransferase; 
putative transposase 
260 nt  NF 429 nt 
anthranilate; 
biosynthesis protein 
PhzE (2-amino-2-deoxy-
isochrimate synthase 
514 nt 
NAD(+) kinase 
transcriptional regulatory 
protein ZraR 
300 nt peptidase, M10 family 436 nt 
methionine synthase, A 
subunit-2 
307 nt  NB 
151 772 nt  NF 
572 nt 
 
nitrate reductase 
245 nt 
AMP-dependent synthetase and 
ligase 
215 nt  NB 148 nt 
urea ABC transporter, permease 
protein UrtC 
169 nt 
ABC transporter 
substrate-binding protein 173 nt  (NB) 
MT86 × × 
366 nt 
 
Glucose-1-phosphate 
adenylyl transferase 281 nt 
glutamate-1-semialdehyde-2,1-
aminomutase; 
 propionate--CoA ligase; acyl-CoA 
synthetase;  
acetyl-CoA synthetase 424 nt 
anthranilate; 
biosynthesis protein 
PhzE (2-amino-2-deoxy-
isochrimate synthase 
255 nt 
multi-sensor signal 
transduction histidine 
kinase 
191 nt 
acetate/CoA ligase=acetyl-CoA 
synthase 
149 nt  (NB) 
ND: bands existed but not detected; NF: no feature; NB: no BLASTn results; -: not available; ×: No PCR results. 
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3.7 Genome evaluation of phototrophic bacteria from databases 
Because anoxygenic phototrophic bacteria are not known as producers of secondary metabolites with 
bioactivity, a genome-based screening by using antiSMASH was applied in this study to predetermine 
the potential of bioactive compound biosynthesis of these bacteria.  
Whole genome sequences of a number of phototrophic bacteria are available from NCBI database and 
accession numbers of 32 complete genome sequences were submitted to online antiSMASH and 
functional annotated for detection of biosynthetic clusters of secondary metabolites. Table 3-32 shows 
the results of the antiSMASH search of the type strains or the next related strains of the ten 
phototrophic bacteria of this study. The complete genome sequences are available and the analysis 
showed that all ten genome sequences predicted at least one terpene biosynthetic gene cluster. 
Especially Rubrivivax gelatinosus IL144 (related to strain 151) showed two terpene clusters and R: 
palustris CGA009 (related to strain 120/1) showed three terpene clusters (one of them showed very 
poor similarity to the malleobactin biosynthetic cluster).  
Marichromatium purpuratum 984 (complete genome available in the genus Marichromatium related 
to Marichromatium gracile strain 5212) showed two nrps biosynthesis gene clusters, Chlorobium 
phaeobacteroides DSM 266
T
 (complete genome available of Chlorobium phaeobacteroides strain 
2360 = DSM 266) showed one nrps biosynthesis gene cluster, Rhodopseudomonas palustris CGA009 
(complete genome available in the genus Rhodopseudomonas related to Rhodopseudomomnas 
palustris strain 120/1) showed one nrps-T1pks biosynthesis gene cluster, and Rubrivivax gelatinosus 
IL144 (next related to Rubrivivax gelatinosus strain 151) showed one T1pks-other biosynthesis gene 
cluster which was only 4% similar to the azinomycin B biosynthesis gene.  
Rubrivivax gelatinosus IL144 showed one lassopeptide biosynthesis gene cluster which was 80% 
similar to the most similar known biosynthetic gene cluster rubrivinodin.  
A. vinosum DSM 180
T
 (identical to strain 5110 and next related strain to MT86) showed one terpene 
cluster, which was 100% similar to a carotenoid biosynthesis cluster. 
Thiocystis violascens DSM 198 (complete genome available in the genus Thiocystis, strain should be 
identical to our strain designed 5410) showed an arylpolyene cluster that was 14% similar to a 
xanthomonadin cluster. Xanthomonadins are a class of carotenoid-like pigments produced by genus 
Xanthomonas. Xanthomonadin may serve to protect the bacterial membrane from oxidative damage 
(Rajagopal et al., 1997). Xanthomonas maltophilia produces aryl-polyene (xanthomonadin) pigments. 
Bacteriocin clusters account for 7 out of 39 in the strains of Marichromatium purpuratum 984, 
Chlorobium phaeobacteroides DSM 266, Chlorobium limicola DSM 245
T
 (strain identical to strain 
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2310), Prosthecochloris aestuarii DSM 271
T
 (strain identical to strain 2410) (three bacteriocin 
clusters), and Rubrivivax gelatinosus IL144.  
There are six homoserine lactone clusters (abbreviation: hserlactone cluster) account from strain 
Allochromatium vinosum DSM 180
T
, Thiocystis violascens DSM 198 (2 clusters), Rhodopseudomonas 
palustris CGA009, and Rhodobacter capsulatus SB1003 (complete genome available in the genus 
Rhodobacter related to Rhodobacter capsulatus strain 182) (2 clusters). Three nrps clusters exist in 
Marichromatium purpuratum 984 (2 nrps clusters) and Chlorobium phaeobacteroides DSM 266. 
Rubrivivax gelatinosus IL144 owns the only two peptide clusters, namely lantipeptide cluster and 
lassopeptide cluster. Rhodopseudomonas palustris CGA009 contains the only Nrps-T1pks cluster and 
one siderophore cluster. 
.  
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Table 3-32. AntiSMASH results of the whole genome sequences of the strains from database related to the 10 strains in this study. 
Strains Submitter BioProject 
Length 
(Mb) 
GC% 
NCBI 
Reference 
Sequence 
AntiSMASH 
Cluster 
Most similar known 
biosynthetic gene 
cluster and genes 
similarity 
MIBiG BGC-ID 
*Marichromatium 
purpuratum 984 
JGI 
PRJNA72575 
PRJNA224116 
PRJNA62513 
3.78 
 
67.9 
NZ_CP007031
.1 
Cluster 1=Nrps - - 
Cluster 2=Nrps - - 
Cluster 3=Other - - 
Cluster 4=Bacteriocin - - 
Cluster 5=Terpene - - 
Allochromatium 
vinosum DSM 
180
T
 = 5110 (next 
related to MT86) 
JGI PRJNA46083 
3.53 
64.4 NC_013851.1 
Cluster 1=Hserlactone - - 
Cluster 2=Other - - 
Cluster 3=Terpene Carotenoid (100%) BGC0000647_c1 
*Thiocystis 
violascens DSM 
198 = 5410 
JGI 
PRJNA74025 
PRJNA60641 
5.02 62.6 NC_018012.1 
Cluster 1=Other - - 
Cluster 2=Terpene - - 
Cluster 3=Arylpolyene Xanthomonadin (14%) BGC0000840_c1 
Cluster 4=Hserlactone - - 
Cluster 5=Hserlactone - - 
*Chlorobium 
phaeobacteroides 
DSM 266 = 2360 
JGI 
PRJNA58133 
PRJNA12609 
3.13 48.4 NC_008639.1 
Cluster 1=Bacteriocin - - 
Cluster 2=Nrps - - 
Cluster 3=Terpene - - 
Cluster 4=Butyrolactone - - 
Chlorobium 
limicola DSM 
245
T 
JGI 
PRJNA12606, 
58127 
2.76 
51.3 
NC_010803.1 
Cluster 1=Butyrolactone - - 
Cluster 2=Terpene - - 
Cluster 3=Bacteriocin - - 
Prosthecochloris 
aestuarii DSM 
271
T
 = 2410 
JGI 
 
PRJNA12749, 
58151 
 
2.51 50.1 NC_011059.1 
Cluster 1= Bacteriocin - - 
Cluster 2= Bacteriocin - - 
Cluster 3= Bacteriocin - - 
Cluster 4= Terpene - - 
*Rhodopseudo-
monas palustris 
JGI 
PRJNA62901 
PRJNA57 
5.46 65.0 NC_005296.1 
Cluster 1=Hserlactone - - 
Cluster 2=Terpene - - 
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CGA009 = 120/1 Cluster 3=Siderophore - - 
Cluster 4=Terpene - - 
Cluster 5=Nrps-T1pks - - 
Cluster 6=Terpene Malleobactin (7%) BGC0000386_c1 
Rhodobacter 
capsulatus SB1003 
= 182 
Univ. 
Chicago 
PRJNA47509P
RJNA55 
3.74 66.6 NC_014034.1 
Cluster 1=Hserlactone - - 
Cluster 2=Terpene - - 
Cluster 3=Hserlactone - - 
Rubrivivax 
gelatinosus IL144 
= 151 
National 
Institute of 
Technolog
y and 
Evaluation 
NBRC 
100245 
PRJNA158163P
RJNA62703 
5.04 
71.2 
NC_017075.1 
Cluster 1=Lassopeptide Rubrivinodin (80%) BGC0000576_c1 
Cluster 2=Lantipeptide - - 
Cluster 3=Terpene - - 
Cluster 4=T1pks-other Azinomycin B (4%) BGC0000960_c1 
Cluster 5=Terpene - - 
Cluster 6=Bacterioncin - - 
JGI = US DOE Joint Genome Institute; t1pks = Type I PKS cluster; arylpolyene = Aryl polyene cluster; nrps = Nonribosomal peptide synthetase cluster; terpen e= Terpene cluster; 
lantipeptide = Lanthipeptide cluster; bacteriocin = Bacteriocin or other unspecified ribosomally synthesized and post-translationally modified peptide product (RiPP) cluster; lassopeptide 
= Lassopeptide cluster; bottromycin = Bottromycin cluster; siderophore=Siderophore cluster; ectoine=Ectoine cluster; butyrolactone=Butyrolactone cluster; indole=Indole cluster; 
oligosaccharide=Oligosaccharide cluster; hserlactone=Homoserine lactone cluster; phosphonate=Phosphonate cluster; other=Cluster containing a secondary metabolite-related protein that 
does not fit into any other category 
-: no results; 
*: not the next related strain; they are the strains with complete genome sequence available in the Genus. 
**: not the next related strain; it is the original classification from our database.  
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Secondary metabolite biosynthetic gene clusters were identified from a total 32 genome sequences 
available strains from NCBI database by the online antiSMASH tool. The detailed information is seen 
in Table 8-1 in Appendix.  
 
T1pks-Other = Type I PKS and other cluster (mixed); Other-T1pks-Oligosaccaride = other, Type I PKS and 
oligosaccharide cluster; T3pks = Type III PKS cluster; Terpene-T3pks = terpene and Type III pks cluster; Nrps = 
Nonribosomal peptide synthetase cluster; Hserlactone-Nrps = homoserine lactone and nonribosomal peptide synthetase 
cluster; Nrps-T1pks = nonribosimal peptide synthetase and Type I PKS cluster; Arylpolyene = Aryl polyene cluster; 
Bacteriocin = Bacteriocin or other unspecified ribosomally synthesized and post-translationally modified peptide product 
(RiPP) cluster; Butyrolactone = Butyrolactone cluster; Ectoine = Ectoine cluster; Hserlactone = Homoserine lactone 
cluster; Lantipeptide = Lanthipeptide cluster; Lassopeptide = Lassopeptide cluster; Other = Cluster containing a secondary 
metabolite-related protein that does not fit into any other category; Phosphonate = Phosphonate cluster; Siderophore = 
Siderophore cluster; Terpene = Terpene cluster 
Figure 3-49. The numbers of gene clusters obtained from online antiSMASH tool. 
  
Based on the analysis of the antiSMASH program, 169 gene clusters (Figure 3-49) were found to 
match to one of the indicated functions of secondary metabolites biosynthesis among 31 species of 
anoxygenic phototrophic bacteria (Rhodobacter sphaeroides KD131 showed no matching cluster in 
the whole genome). There are 1 mixed T1pks-other, 1 mixed other-T1pks-oligosaccaride, 4 T3pks, 1 
mixed terpene-T3pks, 5 NRPS, 1 mixed homoserine lactone-NRPS, 5 mixed NRPS-T1pks, 1 aryl 
polyene, 21 bacteriocins, 5 butyrolactones, 1 ectoine, 25 homoserine lactones, 1 lanthipeptide, 10 
lassopeptides, 1 phosphonate, 4 siderophores, 75 terpenes, and 7 other clusters containing a secondary 
metabolite-related gene that does not fit into any other category. 
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Terpene = Terpene cluster; Hserlactone = Homoserine lactone cluster; Bacteriocin = Bacteriocin or other unspecified 
ribosomally synthesized and post-translationally modified peptide product (RiPP) cluster; Peptide = Lanthipeptide cluster 
(lantipeptide) and Lassopeptide cluster (Lassopeptide); Butyrolactone = Butyrolactone cluster; Siderophore = Siderophore 
cluster; Other = Cluster containing a secondary metabolite-related protein that does not fit into any other category; T1pks-
mixed: Type I PKS and other cluster (T1pks-Other), other, Type I PKS and oligosaccharide cluster (Other-T1pks-
Oligosaccaride); T3pks & T3pks-mixed = Type III PKS cluster, terpene and Type III PKS cluster (Terpene-T3pks); Nrps & 
Nrps-mixed: Nonribosomal peptide synthetase cluster, homoserine lactone and nonribosomal peptide synthetase cluster 
(Hserlactone-Nrps); Nrps-T1pks = nonribosimal peptide synthetase and Type I PKS cluster 
Figure 3-50. Pie chart of the distribution of biosynthesis gene clusters of anoxygenic phototrophic bacteria. 
 
All types of gene clusters can be categorized to eight different groups and the relative contribution of 
the different functional gene groups is depicted in Figure 3-50 and Table 3-33, namely terpenes 
(44.38%), hserlactones (homoserine lactone cluster) (14.79%), bacteriocins (12.43%), peptides 
(lassopeptide and lantipeptide, 6.51%), siderophores (2.37%), butyrolactones (2.96%), 
PKS/NRPS/mixed clusters (11%), and others (5.92%).  
The most frequently seen biosynthesis gene cluster is the terpene cluster that accounts for 44.38% (75 
of 169) of the identified genes. Among them, a total of 12 terpene clusters are related to the 
biosynthesis of carotenoids (3 clusters, 66%-100% similarity), malleobactin (5 clusters, 7%-11% 
similarity), and hopenes (4 clusters, 15% similarity). 
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Table 3-33. Summary of the secondary metabolite clusters and the most similar compounds. 
Name of cluster 
from 
antiSMASH 
No. of 
cluster 
No. of most 
similar 
compound 
Strains 
Cluster 
position 
Most similar 
compounds 
% 
Arylpolyene 1 1 
Thiocystis violascens 
DSM 198 
Cluster 3 Xanthomonadin  14%   
Bacteriocin 21 - - - - - 
Butyrolactone 5 - - - - - 
Ectoine 1 1 
Halorhodospira 
halophila SL1 
Cluster 4 Ectoine  66%   
Hserlactone 25 4 
Rhodobacter sphaeroides 
2.4.1     
Cluster 3  Streptomycin  2%   
Rhodobacter sphaeroides 
ATCC 17029     
Cluster 3  Streptomycin  2%   
Rhodopseudomonas 
palustris DX-1 
Cluster 1  Bottromycin A2  6%   
Cluster 5  Lipopolysaccharide  16%   
Hserlactone-Nrps 1 - - - - - 
Lantipeptide 1 - - - - - 
Lassopeptide 10 1 
Rubrivivax gelatinosus 
IL144 
Cluster 1 Rubrivinodin  80%   
Phosphonate 1 - - - - - 
Siderophore 4 - - - - - 
Nrps 5 - - - - - 
Nrps-T1pks 5 1 
Rhodopseudomonas 
palustris BisB18 
Cluster 6 Pyoluteorin  15%   
T1pks-Other 1 1 
Rubrivivax gelatinosus 
IL144 
Cluster 4 Azinomycin B  4%   
Other-T1pks-
Oligosaccaride 
1 - - - - - 
T3pks 4 - - - - - 
Terpene-T3pks 1 1 
Rhodomicrobium 
vannielii ATCC 17100 
Cluster 1 Carotenoid  66%   
Terpene 75 12 
Allochromatium vinosum 
DSM 180
T
 
Cluster 3    Carotenoid  
100
%   
Thioflavicocus mobilis 
8321 
Cluster 5    Carotenoid  
100
%     
Rhodospirillum rubrum 
ATCC 11170 
Cluster 1    Malleobactin  1%    
Rhodospirillum 
photometricum DSM 122 
Cluster 2    Carotenoid  
100
%   
Rhodomicrobium 
vannielii ATCC 17100 
Cluster 5    Malleobactin  7%   
Rhodopseudomonas 
palustris CGA009 
Cluster 6    Malleobactin 7%   
Rhodopseudomonas 
palustris DX-1 
Cluster 3    Hopene  5%   
Rhodopseudomonas 
palustris HaA2 
Cluster 2    Hopene  5%   
Rhodopseudomonas 
palustris BisB5 
Cluster 3    Malleobactin  7%   
Rhodopseudomonas 
palustris BisB18 
Cluster 3    Hopene  5%   
Rhodopseudomonas 
palustris BisA53 
Cluster 2    Hopene  5%   
Rhodopseudomonas 
palustris TIE-1 
Cluster 7    Malleobactin  7%   
Other 7 - - - - - 
Sum 169 22 
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The PKS/NRPS/mixed group is the combination of four parts (accounts together for 17%), namely 
T1pks-mixed (1.18%), T3pks & T3pks-mixed (2.96%), Nrps-T1pks (2.96%), and Nrps & Nrps-mixed 
(3.55%). 
①  The T1pks-mixed part contains 1 T1pks-other cluster (only 4% similar to azinomycin B in 
Rubrivivax gelatinosus IL144) and 1 other-T1pks-oligosaccaride cluster in Thioflavicoccus mobilis 
8321. 
Azinomycin B (C31H33N3O11) produced by Streptomyces griseofuscus S42227 (FERM P-8443) is 
active against Gram-positive bacteria, Gram-negative bacteria and L5178Y cells in tissue culture 
(Nagaoka et al., 1986). The cloning and sequence analysis of azi gene cluster revealed a type I 
polyketide synthase (PKS)/nonribosomal peptide synthetase (NRPS) hybrid system for the 
azinomycin B production (Zhao et al., 2008). It is an effective antitumor compound active against 
the intraperitoneally inoculated tumors such as P388 leukemia, B-16 melanoma and Ehrlich 
carcinoma (Ishizeki et al., 1987).  
② The T3pks & T3pks-mixed part contains one terpene-T3pks cluster which is 66% similar to a 
carotenoid cluster in Rhodomicrobium vannielii ATCC 17100, and four T3pks clusters in 
Rhodospirillum centenum SW, Rhodobacter capsulatus SB1003, Rhodobacter sphaeroides ATCC 
17029, and Heliobacterium modesticaldum Ice1. 
Carotenoids are organic pigments that are found in plants and some other photosynthetic 
organisms (bacteria and fungi). In plants and algae, carotenoids serve in photosynthesis (light 
absorption for use), and protection of chlorophyll from photodamage (Armstrong and Hearst, 
1996). Carotenoids produced by bacteria protect themselves from oxidative attack (Liu et al., 
2005).  
③  The Nrps-T1pks part contains 5 hybrid Nrps-T1pks clusters in four strains belonging to 
Rhodopseudomonas palustris, namely R. palustris CGA009, R. palustris DX-1, R. palustris BiB18, 
and R. palustris TIE-1. There are two Nrps-T1pks clusters in R. palustris BiB18, and one of them is 
annotated 15% similar to a pyoluteorin biosynthesis gene cluster. 
Pyoluteorin (4,5-dichloro-1H-pyrrol-2-yl-2,6-dihydroxyphenyl ketone) is an antifungal compound 
composed of a bichlorinated pyrrole linked to a resorcinol moiety (Howell and Stipanovic, 1980; 
Nowak-Thompson et al., 1999). Pyoluteorin is composed of a resorcinol ring, derived via 
polyketide biosynthesis (Cuppels et al., 1986; Nowak-Thompson et al., 1997). 
④ The Nrps & Nrps-mixed part includes 1 hserlactone-Nrps cluster in R. palustris BisB18 and 5 Nrps 
clusters in the purple sulfur bacterium Marichromatium purpuratum (2 clusters), the purple nonsulfur 
bacteria Rhodospirillum rubrum ATCC11170 and F11, and the green sulfur bacterium Chlorobium 
phaeobacteroides. 
The other groups are mostly ribosomal peptide products. 25 hserlactone (homoserine lactone) cluster 
accounts for 14.79% and 4 clusters of them are predicted to the biosynthesis of two streptomycins 
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(only 2% similarity) in Rhodobacter sphaeroides 2.4.1 and Rhodobacter sphaeroides ATCC17029 
(see Appendix, Table 8-1), one bottromycin A2 (only 6% similarity) and one lipopolysaccharide (only 
16% similarity) in Rhodopseudomonas palustris DX-1. 
Streptomycin is a useful broad-spectrum antibiotic drug derived from Streptomyces griseus, and it 
was used for the first effective treatment for tuberculosis (Schatz et al., 1944).  
Ribosomal bottromycins represent a promising class of peptides binding to the therapeutically 
unexploited aminoacyl-tRNA binding site (A site) on the 50S ribosome of the bacterial ribosome 
(Otaka and Kaji, 1976). Bottromycin A2 inhibited MS2 phage RNA-dependent protein synthesis 
and was discovered from the fermentation broth of Streptomyces bottropensis as antibacterial 
with promising activity against Gram-positive bacteria and mycoplasma (Waisvisz et al., 1957; 
Tanaka et al., 1968). 
Lipopolysaccharides (LPS) typically consist of a lipid A (or endotoxin), an oligosaccharide, and 
an O-antigen (Raetz and Whitfield, 2002). They are found in the outer membrane of Gram-
negative bacteria and elicit immune responses in animals (Schumann et al., 1990). LPS-activated 
CD4
+
CD25
+
 T regulatory (Treg) cells inhibit neutrophil function and promote their apoptosis and 
death (Lewkowicz et al., 2006).  
1 lanthipeptide and 10 lassopeptide clusters account for 6.51%. There is only one lasso pepetide 
cluster with 80% similarity to a rubrivinodin biosynthesis gene cluster in Rubrivivax gelatinosus IL144. 
Bioactive peptides, which are driven by ribosome-independent processes, are called NRP (assembled 
by NRPS). However, lanthipeptides (Zhang et al., 2012) and lassopeptides belong to a superfamily of 
ribosomally-synthesized and post-translationally modified natural products (peptides) with diverse 
bioactivities. This strategy seems to be widely distributed in all kingdoms of life. Lassopeptides 
produced from bacteria were first described in 1991, and showed an array of potential therapeutic 
functions as general receptor antagonists, enzyme inhibitors and antibacterial or antiviral (anti-HIV) 
agents (Li et al., 2015; Maksimov et al., 2012). Rubrivinodin is a lassopeptide and was detected by 
Hegemann et al. (2013). 
Bacteriocin, butyrolactone, and siderophore gene clusters occupy 21 (12.43%), 5 (2.96%) and 4 
clusters (2.37%), respectively. However, there is no predicted compounds of this type gene clusters.  
Bacteriocins are ribosomally assembled and post-translationally modified peptides (RiPPs). They 
are antimicrobial peptides produced by certain bacteria, and exhibit significant potency against 
other bacteria with a stable property and can have narrow or broad activity spectra (Cotter et al., 
2013). 
Gamma-butyrolactones and acyl homoserine lactones (AHLs or N/AHLs) are signalling 
molecules which regulate antibiotic production and morphological differentiation, and many 
physiological aspects like biofilm formation, respectively (Horinouchi, 2002). They have been 
shown to be important mainly in Streptomyces species (Hughes and Sperandio, 2008). Takano et 
al. (2005) showed that a gamma-butyrolactone-binding protein directly regulates a secondary 
metabolite pathway-specific regulatory gene in Streptomyces. AHLs are involved in prokaryotic 
function of virulence, T3SS regulation, biofilm formation, motility, antibiotic production and in 
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eukaryotic function of immunomodulation, intracellular calcium signalling and apoptosis (Hughes 
and Sperandio, 2008). 
A siderophore is a natural compound with a high affinity to ferric ion which is secreted by 
microorganisms (Reid et al., 1993). Siderophores are applicated as antibiotics in the treatment of 
iron diseases (Hider and Kong, 2010) as response to iron deficienty. 
The group named “other” (5.92%) includes arylpolyene (1 cluster, 14% similarity to xanthomonadin in 
Thiocystics violascens DSM198), ectoine (1 cluster, 66% similarity to ectoine in Halorhodospira 
halophila SL1), phosphonate (1 cluster), and other clusters (7 clusters, secondary metabolite-related 
proteins that do not fit into any other category).  
The yellow pigments (xanthomonadins) produced by the phytopathogenic bacterium 
Xanthomonas are unimportant during pathogenesis but may be important for protection against 
photobiological damage (Poplawsky et al., 2000). 
Ectoine (1,4,5,6-tetrahydro-2-methyl-4-pyrimidine carboxylic acid) is a natural product found in 
some bacteria. It serves as an osmolyte and thus helps organisms to survive extreme osmotic 
stress. Ectoine is found in high concentrations in halophilic microorganisms and confers 
resistance towards salt and temperature stress. it was first identified in the phototrophic purple 
sulfur bacteria (PSB) Halorhodospira halochloris (previously known as Ectothiorhodospira 
halophila) (Peters et al., 1990). 
Phosphonates are organophosphorus compounds and are commonly used as inhibitors of enzymes 
which utilize phosphates as substrates in medicine (Wiemer et al., 2009).  
There are no Type II PKS (T2pks) and phenazine related clusters detected in any of the 32 anoxygenic 
phototrophic bacteria by antiSMASH. 
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4 DISCUSSION 
Drug discovery from marine sources becomes more and more significant because the huge potential of 
new chemical structures isolated from the ocean. Hundreds to thousands of new compounds are 
reported every year (Molinski et al., 2009; Blunt et al., 2014). However, as far as we know, 
anoxygenic phototrophic bacteria were never screened for the secondary metabolites. From the work 
of Dr. Marcus Tank, strain MT86 was similar to the type strain of Allochromatium vinosum DSM180
T
. 
In this present thesis, the 16S rRNA gene sequence of strain MT86 was confirmed to be 99.73% and 
99.72% similar to A. vinosum DSM180
T
 and A. vinosum 5110
T 
and thereby identified as a strain of this 
species.  
4.1 Metabolite profiles of A. vinosum strain MT86 
One main aim of the present Ph.D. thesis was to screen for the secondary metabolites of A. vinosum 
MT86. For this purpose, different approaches approved for natural product discovery were used 
(variation of culture conditions for growth, salt stress and stimulating effects by salts). In addition, the 
genetic potential according to pks I, pks II, nrps, and phzE gene sequences was analyzed.  
Cultivation of A. vinosum MT86 under different conditions and fractionation of the supernatant extract 
of MT86 was performed to get the first insights into the production of bioactive compounds.  
It is known that thiosulfate acts as electron donor in the photolithoautotrophic growth of A. vinosum 
DSM180
T
, and acetate is a carbon source of photolithoheterotrophic growth (Weissgerber et al., 2011). 
In consideration of the utilisation of thiosulfate and acetate, Pfennigs medium with MgCl2, 
supplemented with thiosulfate and acetate was experimentally supported to be the optimal cultivation 
condition for growth of A. vinosum MT86. This also made the cultivation much easier because 
addition of sulfide solution every two days was not necessary.  
Compound F13 was considered as the most interesting one for further studies and was produced under 
various culture conditions by strain MT86 (Table 4-1). In the first chromatograms it was designated as 
P10, which was shown to be identical to F13 of the later HPLC separations, according to NMR spectra. 
A. vinosum DSM180
T
 does not require salts but can tolerate low concentrations (Weissgerber et al., 
2011). Comparison of cultures of A. vinosum MT86 grown at different salt concentrations revealed 
that the strain could tolerant up to 3.33% salts. This result is in accord with those from Weissgerber et 
al. (2011). The preferred cultivation conditions were 0.67% salts for 10 days and 2.5% salts for 15 
days. The production of compound F13 was reproducible under the different conditions and showed 
some antimicrobial properties.  
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Table 4-1. Comparison of F13 produced in different cultivation. 
 
20 L 36L 50 L (45 L) 50 L (50 L) 
Salt concentration  0% 0% 0.67% 2.5% 
 
Thiosulfate and acetate - 1% 1% 1% 
 
Mg
2+
 MgSO4·7H2O MgCl2·6H2O MgCl2·6H2O MgCl2·6H2O 
 
Trace element solution SL-12 SLA SLA SLA 
Adding sulfide solution 1%, every 2 days - - - 
Incubationn time 
in twice 
16 d + 17 d 
11 d 10 d 15 d 
Light intensity (lux) 1000 1000 1000 1000 
Temperature (°C) 28-30 28-30 28-30 28-30 
Dried weight of  
supernatant crude extract 
82.7 mg 283 mg * 318 mg 570 mg 
Fractionations Peak 1-10 F1-F18 F1-F18 
P1-P18 (Polar column) 
C1-C18 (C18 column) 
F13 exist or not + (P10) + (F13) + (F13) + (P13=C13) 
Summary F13 = P10 = P13 = F13 
+: existed; -: no adding sulfide solution; *: oil-gel liked 
 
4.2 Metabolite profiles of other anoxygenic phototrophic bacteria 
Metabolite production of Rhodopseudomonas palustris strain120/1, Rhodobacter capsulatus strain 182, 
and Rubrivivax gelatinosus strain 151 were studied. These bacteria were the most interesting regarding 
potential secondary metabolite production. With all strains, the metabolite profiles according to the 
HPLC-DAD/MS chromatograms, indicated increased metabolite production at prolonged cultivation 
for 10 (instead of 7) days.  
The antiSMASH search of the genome of Rubrivivax gelatinosus IL144 revealed the potential for 
biosynthesis of terpenes and also a T1pks-other gene cluster was identified, although the later showed 
only 4% similarity to the gene for biosynthesis of zainomycin. 
Rubrivivax gelatinosus strain 151 was an interesting bacterium because of its bioactivity and the 
metabolite profile revealed by HPLC analysis. Extracts of strain 151 showed good inhibition of 
Staphylococcus lentus and Septoria tritici (82% and 80% inhibition). In the HPLC chromatograms 
several well separated peaks appeared, which indicated that they could probably be easily purified. In 
conclusion, Rubrivivax gelatinosus strain 151 is a candidate for further studies on secondary 
metabolites. 
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4.3 Classification and identification of strains 
16S rRNA alignment results showed that strain 5410 used in this study was next related to an 
uncultured bacterium clone EMIRGE OUT s7t4e 93. This is different classification from the original 
strain offered at the beginning. However, the pks I result of strain 5410 showed a 760 nt fragment that 
was 99% similar to a signal transduction histidine kinase gene cluster of Thiocystis violascens DSM 
198 (which should be identical to strain 5410). 
Strain MT86 showed 99.73% and 99.72% similarity to Allochromatium vinosum DSM180
T
 and A. 
vinosum strain 5110
T
, respectively. Strain 5110 in this study is 99% similar to A. vinosum DSM180
T
. 
In conclusion, stain MT86 should belong to the same species as a new strain of A. vinosum. 
4.4 PCR amplification of strains and sequences BLASTn analysis  
BLASTn results of pks I, pks II, nrps, and phzE sequences from control strains demonstrated that the 
primers, PCR systems and programs amplification were well functioning. The results of the sequences 
of pks I and pks II fragments of all ten strains revealed similar features to deposited sequences of 
NCBI database. However, relatedness was obtained to several other functional genes, but not to the 
polyketide synthase systems. There was no indication of a type II pks gene in any of the bacteria 
analysed in present study. 
The nrps amplification and BLASTn results showed an adenylation (A) domain could be found in 
positive control strain. “A domain” is capable of substrate recognition and formation of the 
corresponding acyl-adenylate-monophosphate by consumption of ATP to PCP. It is an important 
domain in the modules of NRPS systems. Acyl-CoA synthases (synonymous name is acetate-CoA 
ligases, EC 6.2.1.1) played important functional roles in coenzymes formation, such as active in 
acetyl-CoA biosynthetic process from acetate (ATP + acetate + CoA = AMP + diphosphate + acetyl-
CoA). From Weissgerber et al. (2011), acetate is utilized by A. vinosum DSM180
T
 by converting to 
acetyl-CoA via acetate-CoA-ligase or the successive reactions of acetate kinase and phosphate 
acetyltransferase. In addition, the CoAs are the basic units for chain elongation, and CoA-ligase is 
necessary in PKS, NRPS-PKS and also in fatty acid synthases. In conclusion, there is no direct 
relationship to the NRPS-PKSs in A. vinosum MT86 and all other tested strains.  
The phzE amplification and BLASTn results showed an anthranilate synthase gene of positive control 
Pseudomonas sp. DSM50117 (425 nt) and also in eight strains (with exception of strains 2360, 414 nt 
and 151, 430 nt). Anthranilate synthase (ID GO: 0004049 = EC 4.1.3.27) belongs to the enzymes of 
phenazine biosynthesis. PhzE (synonymous name is 2-amino-2-deoxy-isochorismate synthase, EC 
4.1.3.-) is a phenazine biosynthesis specific protein (from databases of ExPASy and UniProtKB). It 
catalyses the reaction chorismate + L-glutamine = anthranilate + pyruvate + L-glutamate, or 
chorismate + L-glutamine = 2-amino-4-deoxyisochorismate + L-glutamate (see in Figure 4-1).  
DISCUSSION 
 
 
 
136 
 
Figure cited from: 
http://www.pseudomonas.com:1555/PSEUDO/NEW-IMAGE?type=REACTION&object=RXNB-5661 
Figure 4-1. A PhzE pathway for Pseudomonas aeruginosa PAO1. 
 
In conclusion, from the results of PCR amplification of pks I, pks II, nrps, and phzE fragments of ten 
phototrophic bacteria, type I and type II pks could not be amplified in these bacteria by the methods 
used in this study. Moreover, with the exception of C. phaeobacteroides strain 2360 (no phzE 
amplification product) and Rubrivivax gelatinosus strain 151 (a 215 nt fragment without BLASTn 
result), the lengths of all phzE fragments from eight strains are between 414 and 430 nt, which are 
similar to the size of the positive control. The phzE amplification system and PCR program were 
useful in phzE gene screening of those ten phototrophic bacteria. In addition, eight strains including 
strain MT86, showed the possibility of phenazine biosynthesis. 
4.5 Genome evaluation of phototrophic bacteria from database 
Genome mining of gene clusters encoding the biosynthetic pathways for these metabolites has become 
a significant methodology for novel compound discovery. Since 2008, genome mining approaches 
allowed the targeted isolation and characterization of such molecules and helped to better understand 
these compounds classes and their biosyntheses (Hegemann et al., 2015). AntiSMASH is a 
comprehensive resource for the genome mining of biosynthetic gene clusters (Weber et al., 2015). By 
comparison of BLASTn results with PCR amplificates and the antiSMASH-based analyses (see Figure 
3-49, Figure 3-50 and Table 3-33) of the results, some interesting conclusions can be obtained. 
In genome sequences available anoxygenic phototrophic bacteria, clusters of terpene biosynthesis 
occupy the most significant part of the antiSMASH results. In the genome of A. vinosum 180
T
, 
hserlactone, terpene (100% similar to carotenoid) and other clusters are the representatives of 
secondary metabolites biosynthesis genes. While terpenes are the major class of secondary metabolites 
discovered in anoxygenic phototrophic bacteria, polyketides and nonribosomal peptides are also 
identified, as were ribosomally assembled and post-translationally modified peptides (RiPPs). 
According to antiSMASH, no phenazine E gene clusters are predicted from the 32 genome sequences 
of anaerobic anoxygenic phototrophic bacteria. However, the PCR amplification and BLASTn results 
showed that except for C. phaeobacteroides stain 2360 and Rubrivivax gelatinosus strain 151, the 
lengths of phzE fragments from other eight strains were between 414 and 430 nt. When a bacterial 
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genome sequence (by accession number) is uploaded to antiSMASH, the program identifies putative 
gene clusters by comparing all predicted gene products to models that in database. It is speculated that 
the differences of results between PCR, BLASTn and antiSMASH analysis showed that not all classes 
of secondary metabolites could be predicted to gene products, and vice versa. This hypothesis is 
consilient to Zeilinger et al. (2015) that, while antiSMASH is extremely powerful, it still has some 
limitations in its ability to correctly predict genes and their encoded proteins and identify full 
biosynthetic pathways. It can easily miss some individual biosynthetic genes and the rules for defining 
the boundaries of secondary metabolic clusters are not yet entirely clear.  
Comparison of the primer sequences with whole or partial genome sequences was in consideration. 
Unfortunately, by using the Primer-BLAST, there is a limitation of the gene size of no more than 
50000 bp and the predicted genes of secondary metabolites by antiSMASH showed always more than 
this size. Therefore, the sequence matches of the primers used for amplification of the desired genes 
within strains investigated in this study could not be demonstrated. 
Genome mining has revealed the diversity, abundance and complex nature of secondary metabolite 
potential of anoxygenic phototrophic bacteria. Secondary metabolic pathways and their corresponding 
products are predicted from a genome sequence and a chemo type is linked to its biosynthetic gene 
cluster (genotype) based on information derived from the prediction (Zerikly and Challis, 2009). In 
current genome mining approaches, the “prediction step” has started to be automated by use of 
computational tools such as antiSMASH to rapidly characterize biosynthetic gene clusters in microbial 
genome sequences (Medema et al., 2011).  
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5 SUMMARY  
This thesis is the first detailed study on secondary metabolites produced by anoxygenic phototrophic 
bacteria. The main purpose of the work was the isolation of bioactive natural products from 
anoxygenic phototrophic bacteria, using cultivation-based, chemical and molecular approaches.  
Much of the work focussed on the purple sulfur bacterium Allochromatium vinosum strain MT86. This 
strain was shown previously to produce antibiotic substances. For this strain, the optimal culture 
conditions were determined to be Pfennigs medium (containing MgCl2) with the addition of thiosulfate 
and acetate. By comparison of metabolite profiles in HPLC-DAD/MS chromatograms of extracts from 
cultures grown under different conditions, it was shown that this medium well suited suitable for 
proper production of secondary metabolites by A. vinosum strain MT86. This was in particular 
the case for interesting compound F13, which was found under a variety of culture conditions. 
The structure of compound F13 was established using HPLC-DAD/MS, NMR-, IR-, and CD-
analyses. Bioactivity tests showed that F13 was inhibitory against Bacillus subtilis and 
Staphylococcus lentus (IC50 = 70.5 µM (± 2.9) and 57.0 µM (± 3.3) ).  
In addition, the production of secondary metabolites, respectively the potential thereof, was studied in 
a number of other anoxygenic phototrophic bacteria, including purple sulfur bacteria, purple nonsulfur 
bacteria and green sulfur bacteria. Among several purple nonsulfur bacteria, extracts of Rubrivivax 
gelatinosus strain 151 showed antibiotic activities against Staphylococcus lentus and Septoria tritici. 
Identification of bioactive metabolites was not possible. 
Genome-based search for genes for secondary metabolite biosynthesis revealed that Allochromatium 
vinosum MT86 has no pks I, pks II and nrps genes, but phzE gene exists. Within ten representative 
anoxygenic phototrophic bacteria (including strain MT86), type I and type II pks could not be 
identified. Moreover, there were no genes with direct relationship to nrps genes, with the exception of 
genes of CoA ligase in Allochromatium vinosum MT86 and 5110, which maybe relevant to the 
synthesis of NRPS. 
The phzE amplification system and PCR program resulted in products of the expected sequence length 
in eight from ten strains, with the exception of Chlorobium phaeobacteroides strain 2360 and 
Rubrivivax gelatinosus strain 151. These strains included Allochromatium vinosum strain MT86. The 
sequence comparison yielded a clear relationship to the relevant phzE genes.  
The complete genome-based bioinformatics screening of anoxygenic phototrophic bacteria clearly 
indicates the uncertainty in determining the potential of the synthesis of bioactive compounds by these 
bacteria. Terpene biosynthesis clusters occupied the most significant fraction in the antiSMASH 
results of 62 complete genomes of anoxygenic phototrophic bacteria. These analyses showed that 
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terpene, homoserine lactones and other synthesis gene clusters for secondary metabolites were present 
in the genome of A. vinosum 180
T
. However, the antiSMASH results showed that there was no 
phenazine gene clusters predicted from 32 whole genome sequences. The results enlighten the 
knowledge about the natural products potential of anoxygenic phototrophic bacteria.  
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6 ZUSAMMENFASSUNG  
Dies ist die erste detaillierte Untersuchung zur Sekundärmetabolitproduktion durch anoxygene 
phototrophe Bakterien. Das Hauptziel der Arbeit war die Isolierung von Wirkstoffen aus anoxygenen 
phototrophen Bakterien durch kultur-abhängige Methoden sowie chemische und molekulare Analysen. 
Ein Großteil der Arbeit konzentrierte sich auf das Schwefelpurpurbakterium Allochromatium vinosum 
Stamm MT86. Von diesem Stamm war bekannt, dass er antibiotische Substanzen produziert. Als 
optimal für die Kultur dieses Stammes erwies sich Pfennigs Medium (mit MgCl2) mit Zusatz von 
Thiosulfate und Acetat. Durch Vergleich der Metabolitprofile in HLPC-DAD/MS Chromatogrammen 
von Extrakten  aus Kulturen, die unter verschiedenen Bedingungen angezogen wurden, zeigte sich, 
dass es für die Metabolitproduktion durch A. vinosum Stamm MT86 gut geeignet war. Dies galt 
insbesondere für die interessante Verbindung F13, die unter verschiedenen Kulturbedingungen 
gebildet wurde. Die Struktur der Substanz F13 wurde aufgeklärt durch HPLC-DAD/MS-, NMR-, IR-, 
und CD-Analysen. Bioaktivitätstests mit F13 zeigten, dass sie gegen Bacillus subtilis und 
Staphylococcus lentus (IC50 = 70.5 µM (± 2.9) und 57.0 µM (± 3.3) aktiv war).  
Zusätzlich wurde die Produktion von Sekundärmetaboliten bzw. das Potential hierzu in einer Auswahl 
weiterer anoxygener phototropher Bakterien, einschließlich Schwefelpurpurbakterien, Nichtschwefel-
Purpurbakterien und grüner Schwefelbakterien, untersucht. Unter den Nicht-Schwefel Purpurbakterien 
zeigten Extrakte von Rubrivivax gelatinosus Stamm 151 antibiotische Aktivitäten gegen 
Staphylococcus lentus and Septoria tritici. Eine Identifizierung der bioaktiven Metabolite war nicht 
möglich. Genom-basierte Suche nach Genen für die Sekundärmetabolitsynthese machte deutlich, dass 
in Allochromatium vinosum MT86 pks I, pks II und nrps Gene nicht vorhanden sind, wohl aber phzE 
Gene.. Als repräsentativ für Sekundärmetabolit-Biosynthesewege wurden pks I, pks II, nrps, and phzE 
Gene durch PCR Amplifikation mittels für diese Gene spezifischer Primer  analysiert. In zehn 
repräsentativen anoxygenen phototrophen Bakterien (einschließlich Stamm MT86) konnten), Type I 
und Typ II pks nicht identifiziert werden. Zudem wurden keine Gene gefunden, die einen direkten 
Bezug zu nrps Genen haben gefunden. Eine Ausnahme machen Gene der CoA-ligase in 
Allochromatium vinosum MT86 and 5110, die in Bezug zur Bildung NRPS stehen. 
Die Amplifikation von phzE und das PCR Programm ergaben Amplifikate in der erwarteten 
Sequenzlänge in acht von zehn untersuchten Stämmen, mit Ausnahme von Chlorobium 
phaeobacteroides Stamm 2360 und Rubrivivax gelatinosus Stamm 151. Dies schließt Allochromatium 
vinosum Stamm MT86 mit ein. Ein Sequenzvergleich gibt klaren Bezug zu den relevanten phzE Genen. 
Die gesamte Information der verfügbaren Genome von anoxygenen phototrophen Bakterien zeigt die 
Unsicherheit auf, die bei der Bestimmung des Potentials zur Biosynthese von bioaktiven Substanzen 
durch diese Bakterien besteht. Biosynthesecluster für Terpene hatten den größten Teil der Ergebnisse 
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aus 62 Genomen anoxygener phototropher Bakterien unter den Ergebnissen mit antiSMASH. Es 
wurden Gene zur Biosynthese von Terpenen, Homoserinlacton und anderen Sekundärmetaboliten im 
Genom von A. vinosum 180
T 
gefunden. Allerdings wurden mittels antiSMASH keine Hinweise auf 
Phenazin-Biosynthesegene in einem der 32 untersuchten Genome gefunden.  
Die Ergebnisse beleuchten unseren Kenntnisstand zum Potential der Wirkstoffsynthese durch 
anoxygene phototrophe Bakterien. 
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8 APPENDIX 
Table 8-1. AntiSMSAH results of whole genome sequences of 62 anoxygenic phototrophic bacteria. 
Taxnomy Species Submitter BioProject 
Length 
(Mb) 
NCBI 
Reference 
Sequence 
Clusters 
Most similar known 
biosynthetic gene 
cluster and genes 
similarity 
MIBiG BGC-ID 
PSB 
Chromatiaceae  
Gamma-
proteobacteria 
Allochromatium        
A.vinosum DSM 180 JGI PRJNA46083 3.53 NC_013851.1 
Cluster 1=Hserlactone / / 
Cluster 2=Other / / 
Cluster 3=Terpene     Carotenoid (100%) BGC0000647_c1 
Marichromatium        
M. purpuratum 984 JGI 
PRJNA72575 
PRJNA224116 
PRJNA62513 
3.78 
NZ_CP007031
.1 
Cluster 1=Nrps / / 
Cluster 2=Nrps / / 
Cluster 3=Other / / 
Cluster 4=Bacteriocin / / 
Cluster 5=Terpene     / / 
Thiocystis        
T. biolascens DSM 
198 
JGI 
PRJNA74025 
PRJNA60641 
5.02 NC_018012.1 
Cluster 1=Other / / 
Cluster 2=Terpene     / / 
Cluster 3=Arylpolyene Xanthomonadin (14%) BGC0000840_c1 
Cluster 4=Hserlactone / / 
Cluster 5=Hserlactone / / 
Thioflavicoccus        
T. mobilis 8321 JGI 
PRJNA184343
PRJNA60883 
4.05 NC_019940.1 
Cluster 1=Bacteriocin / / 
Cluster 2=Other-T1pks-
Oligosaccaride 
/ / 
Cluster 3=Terpene     / / 
Cluster 4=Terpene     / / 
Cluster 5=Terpene    Carotenoid (100%  ) BGC0000647_c1 
PSB 
Ectothiorhodos
piracea 
Gamma-
proteobacteria 
Halorhodospira        
H. halophile SL1 JGI 
PRJNA58473, 
PRJNA15767 
2.68 nt NC_008789.1 
Cluster 1=Other / / 
Cluster 2=Terpene     / / 
Cluster 3=Terpene     / / 
Cluster 4=Ectoine Ectoine (66%) BGC0000852_c1 
Cluster 5=Terpene     / / 
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PNSB  
Alpha-
proteobacteria 
Rhodospirillum        
R. centenum SW  TGen 
PRJNA58805 
PRJNA18307 
4.36 nt NC_011420.2 
Cluster 1=Terpene     / / 
Cluster 2=T3pks / / 
Cluster 3=Terpene     / / 
R. rubrum  
ATCC11170 
JGI 
PRJNA57655 
PRJNA58 
4.35 nt NC_007643.1 
Cluster 1=Terpene     Malleobactin (11% ) BGC0000386_c1 
Cluster 2=Terpene     / / 
Cluster 3=Lassopeptide / / 
Cluster 4=Bacteriocin / / 
Cluster 5=Terpene     / / 
Cluster 6=Lassopeptide / / 
Cluster 7=Nrps / / 
Cluster 8=Hserlactone / / 
R. rubrum F11 
Gonzaga 
University  
PRJNA162149 
PRJNA67413 
4.35 NC_017584.1 
Cluster 1=Terpene     / / 
Cluster 2=Terpene     / / 
Cluster 3=Lassopeptide / / 
Cluster 4=Lassopeptide / / 
Cluster 5=Bacteriocin / / 
Cluster 6=Lassopeptide / / 
Cluster 7=Terpene     / / 
Cluster 8=Lassopeptide / / 
Cluster 9=Nrps / / 
Cluster 10=Hserlactone / / 
R. photometricum 
DSM122 
CNRS 
PRJEA81611, 
159003 
3.88 NC_017059.1 
Cluster 1=Terpene     / / 
Cluster 2=Terpene     Carotenoid (100%) BGC0000647_c1 
Cluster 3=Hserlactone / / 
Rhodobacter        
R. capsulatus SB1003 
Univ. 
Chicago 
PRJNA47509, 
PRJNA55 
3.74 NC_014034.1 
Cluster 1=Hserlactone / / 
Cluster 2=Terpene     / / 
Cluster 3=Hserlactone / / 
R. sphaeroides 2.4.1 JGI 
PRJNA57653, 
PRJNA56 3.19 NC_007493.2 
Cluster 1=Lassopeptide / / 
Cluster 2=Terpene     / / 
Cluster 3=Hserlactone Streptomycin (2%) BGC0000717_c1 
Cluster 4=T3pks / / 
Cluster 5=Terpene     / / 
R. sphaeroides ATCC 
17025 
JGI 
PRJNA58451, 
PRJNA15755 
3.22 NC_009428.1 
Cluster 1=Terpene       
Cluster 2=Hserlactone   
Cluster 3=Hserlactone   
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Cluster 4=Lassopeptide   
Cluster 5=Terpene       
R. sphaeroides ATCC 
17029 
JGI  
PRJNA58449, 
PRJNA15754 
3.15 NC_009049.1 
Cluster 1=Lassopeptide / / 
Cluster 2=Terpene     / / 
Cluster 3=Hserlactone Streptomycin (2%) BGC0000717_c1 
Cluster 4=T3pks / / 
Cluster 5=Terpene     / / 
R. sphaeroides KD131 
GenoTech 
corp. 
PRJNA59277, 
PRJNA31111 
4.71 NC_011960.1 No / / 
Rhodomicrobium        
R. vannielii ATCC 
17100 
JGI 
 
PRJNA38253, 
43247 
 
4.01 NC_014664.1 
Cluster 1=Terpene  -
T3pks 
Carotenoid (66%) BGC0000641_c1 
Cluster 2=Bacteriocin / / 
Cluster 3=Terpene     / / 
Cluster 4=Hserlactone / / 
Cluster 5=Terpene     Malleobactin (7%) BGC0000386_c1 
Cluster 6=Other / / 
Rhodopseudomonas        
R. palustris CGA009 JGI 
PRJNA62901 
PRJNA57 
5.46 NC_005296.1 
Cluster 1=Hserlactone / / 
Cluster 2=Terpene     / / 
Cluster 3=Siderophore / / 
Cluster 4=Terpene     / / 
Cluster 5=Nrps-T1pks / / 
Cluster 6=Terpene     Malleobactin (7%) BGC0000386_c1 
R. palustris DX-1 JGI 
PRJNA43327, 
PRJNA38503 
5.40 NC_014834.1 
Cluster 1=Hserlactone Bottromycin A2 (6%) BGC0000469_c1 
Cluster 2=Hserlactone / / 
Cluster 3=Terpene     Hopene (15%) BGC0000663_c1 
Cluster 4=Nrps-T1pks / / 
Cluster 5=Hserlactone 
Lipopolysaccharide 
(16%) 
BGC0000772_c1 
Cluster 6=Terpene     / / 
Cluster 7=Siderophore / / 
Cluster 8=Terpene     / / 
R. palustris HaA2 JGI 
PRJNA58439, 
PRJNA15747 
5.33 NC_007778.1 
Cluster 1=Hserlactone / / 
Cluster 2=Terpene     Hopene (15%) BGC0000663_c1 
Cluster 3=Terpene     / / 
Cluster 4=Hserlactone / / 
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Cluster 5=Terpene     / / 
Cluster 6=Siderophore / / 
R. palustris BisB5 JGI 
PRJNA58441, 
PRJNA15749 
4.89 NC_007958.1 
Cluster 1=Hserlactone / / 
Cluster 2=Hserlactone / / 
Cluster 3=Terpene     Malleobactin (7%) BGC0000386_c1 
Cluster 4=Terpene     / / 
Cluster 5=Terpene     / / 
R. palustris BisB18 JGI 
PRJNA58443, 
PRJNA15750 
5.51 NC_007925.1 
Cluster 1=Hserlactone / / 
Cluster 2=Terpene     / / 
Cluster 3=Terpene     Hopene (15%) BGC0000663_c1 
Cluster 4=Hserlactone-
Nrps 
/ / 
Cluster 5=Terpene     / / 
Cluster 6=Nrps-T1pks Pyoluteorin (15%) BGC0000128_c1 
Cluster 7=Nrps-T1pks / / 
Cluster 8=Phosphonate / / 
R. palustris BisA53 JGI.  
PRJNA58445, 
PRJNA15751 
5.51 NC_008435.1 
Cluster 1=Terpene     / / 
Cluster 2=Terpene     Hopene (15%) BGC0000663_c1 
Cluster 3=Bacteriocin / / 
Cluster 4=Hserlactone / / 
Cluster 5=Terpene     / / 
Cluster 6=Terpene     / / 
R. palustris TIE-1 JGI  
PRJNA58995, 
PRJNA20167 
5.74 NC_011004.1 
Cluster 1=Hserlactone / / 
Cluster 2=Terpene     / / 
Cluster 3=Hserlactone / / 
Cluster 4=Siderophore / / 
Cluster 5=Terpene    / / 
Cluster 6=Nrps-T1pks / / 
Cluster 7=Terpene     Malleobactin (7%) BGC0000386_c1 
PNSB  
Beta-
proteobacteria 
Rubrivivax        
R. gelatinosus IL144 
National 
Institute of 
Technology 
and 
Evaluation 
NBRC 
100245 
PRJNA158163
, PRJNA62703 
5.04 NC_017075.1 
Cluster 1=Lassopeptide Rubrivinodin (80%) BGC0000576_c1 
Cluster 2=Lantipeptide / / 
Cluster 3=Terpene     / / 
Cluster 4=T1pks-Other Azinomycin B (4%) BGC0000960_c1 
Cluster 5=Terpene     / / 
Cluster 6=Bacteriocin / / 
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GSB 
Chlorobiaceae 
Chlorobium        
C. phaeovibrioides 
DSM 265 
JGI 
PRJNA12607 
PRJNA58129 
1.97 NC_009337.1 Cluster 1=Terpene     / / 
C. phaeobacteroides 
DSM 266 
JGI 
PRJNA58133, 
PRJNA12609 
3.13 NC_008639.1 
Cluster 1=Bacteriocin / / 
Cluster 2=Nrps / / 
Cluster 3=Terpene     / / 
Cluster 4=Butyrolactone / / 
C. limicola DSM 245 JGI 
PRJNA12606, 
58127 
2.76 NC_010803.1 
Cluster 1=Butyrolactone / / 
Cluster 2=Terpene     / / 
Cluster 3=Bacteriocin / / 
C. tepidum TLS TIGR 
PRJNA57897, 
PRJNA302 
2.15 NC_002932.3 
Cluster 1=Butyrolactone / / 
Cluster 2=Terpene     / / 
C. chlorochromatii 
CaD3 
JGI 
PRJNA13921, 
58375 
2.57 NC_007514.1 Cluster 1=Terpene     / / 
C. luteolum DSM 273 JGI 
PRJNA13012, 
58175 
2.36 NC_007512.1 
Cluster 1=Bacteriocin / / 
Cluster 2 =Terpene    / / 
C. phaeobacteroides 
BS1 
JGI 
PRJNA58131, 
PRJNA12608 
2.74 NC_010831.1 
Cluster 1=Bacteriocin / / 
Cluster 2=Bacteriocin / / 
Cluster 3=Bacteriocin / / 
Cluster 4=Butyrolactone / / 
Cluster 5=Terpene     / / 
Cluster 6=Bacteriocin / / 
Cluster 7=Bacteriocin / / 
Chloroherpeton        
C. thalassium 
ATCC35110 
JGI 
PRJNA29215, 
59187 
3.29 NC_011026.1 
Cluster 1=Terpene     / / 
Cluster 2=Bacteriocin / / 
Pelodictyon**          
P. phaeoclathratiforme 
BU-1 
JGI 
PRJNA13011, 
58173 3.02 NC_011060.1 
Cluster 1=Terpene     / / 
Cluster 2=Bacteriocin / / 
Prosthecochloris        
P.  aestuarii DSM 271 JGI 
PRJNA12749, 
58151 2.51 NC_011059.1 
Cluster 1=Bacteriocin / / 
Cluster 2=Bacteriocin / / 
Cluster 3=Bacteriocin / / 
Cluster 4 =Terpene    / / 
Chlorobaculum ***        
C. parvum NCIB 8327 JGI  PRJNA29213, 2.29 NC_011027.1 Cluster 1=Terpene     / / 
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JGI= US DOE Joint Genome Institute; t1pks=Type I PKS cluster; t2pks=Type II PKS cluster; t3pks=Type III PKS cluster; otherks=Other types of PKS cluster; arylpolyene=Aryl polyene 
cluster; resorcinol=Resorcinol cluster; ladderane=Ladderane cluster; PUFA=Polyunsaturated fatty acid cluster; nrps=Nonribosomal peptide synthetase cluster; terpene=Terpenecluster; 
lantipeptide=Lanthipeptide cluster; bacteriocin=Bacteriocin or other unspecified ribosomally synthesized and post-translationally modified peptide product (RiPP) cluster; 
lassopeptide=Lassopeptide cluster; bottromycin=Bottromycin cluster; siderophore=Siderophore cluster; ectoine=Ectoine cluster; butyrolactone=Butyrolactone cluster; indole=Indole cluster; 
oligosaccharide=Oligosaccharide cluster; hserlactone=Homoserine lactone cluster; phosphonate=Phosphonate cluster; other=Cluster containing a secondary metabolite-related protein that 
does not fit into any other category 
59185 Cluster 2=Butyrolactone / / 
Cluster 3=Bacteriocin / / 
Chloroflexus        
C.aggregans DSM 
9485 
JGI 
PRJNA16708, 
58621 
4.68 NC_011831.1 
Cluster 1=Terpene     / / 
Cluster 2=Terpene     / / 
Chloroflexus. sp. Y-
400-fl 
JGI 
PRJNA59085, 
PRJNA21119 
5.27 NC_012032.1 
Cluster 1=Terpene     / / 
Cluster 2=Terpene     / / 
C. aurantiacus J-10-f1 JGI 
PRJNA57657 
PRJNA59 
5.26 NC_010175.1 
Cluster 1=Terpene     / / 
Cluster 2=Terpene    / / 
GNSB 
Chloro-
flexaceae 
Roseiflexus*        
R. castenholzii DSM 
13941  
JGI  
PRJNA13462, 
58287 
5.72 NC_009767.1 
Cluster 1=Terpene     / / 
Cluster 2=Terpene     / / 
Cluster 3=Terpene     / / 
Cluster 4=Other / / 
Roseiflexus RS-1  JGI 
PRJNA58523, 
PRJNA16190 
5.80 NC_009523.1 
Cluster 1=Terpene     / / 
Cluster 2=Terpene     / / 
Cluster 3=Other / / 
Cluster 4=Terpene     / / 
Helio-
bacteria 
 
Heliobacterium        
H. modesticaldum Ice1 
Arizona 
State 
University 
PRJNA13427, 
58279 3.08 
NC_010337.2 Cluster 1=T3pks / / 
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Background 
In certain aquatic environments, anoxygenic phototrophic bacteria are important primary 
producers. Strain MT86 was isolated from coastal sediments of the Indian Ocean. 
Phylogenetic analyses revealed the type strain Allochromatium vinosum DSM 180T to be the 
closest relative. Allochromatium vinosum MT86 is an anoxygenic phototrophic sulfur 
bacterium. As far as known this is the first report on the production of bioactive compounds 
by purple sulfur bacteria. 
Methods 
45 L of modified Pfennig medium with 0.67% salts was prepared and strain MT86 was 
incubated for 10 days at 28°C and 1000 lux. After centrifugation, the supernatant of the 
culture broth was extracted by ethyl acetate (1:1). HPLC-DAD/MS, semi-preparative HPLC, 
and NMR analyses were used for fractionation and compound identification, respectively. 
Antibiotic activities were determined with the crude extract, the fractions, and isolated 
compounds.  
Results & Discussion 
In this study, we discovered the new bioactive compound F13 from A. vinosum MT86. 5.2 mg 
of pure compound was obtained. The m/z of F13 is 300 corresponds to the molecular formula 
C20H28O2. From the NMR chromatography, the structure was obtained. IC50 values for F13 
against Bacillus subtilis, and Staphylococcus lentus were 70.5 µM (± 2.9) and 57.0 µM (± 3.3), 
respectively. Compound F13 is the first antibiotic substance isolated from phototrophic 
bacteria. Chemical structure and biological activities are presented.  
Reference 
Imhoff J.F., Hiraishi A., and Süling J. (2005). Anoxygenic Phototrophic Purple Bacteria. Bergey's 
Manual of Systematic Bacteriology (2
nd
 Edition), Vol. 2 (Part 2): pp. 119-132. 
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